0001903596-23-000455.txt : 20230522 0001903596-23-000455.hdr.sgml : 20230522 20230522164611 ACCESSION NUMBER: 0001903596-23-000455 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230522 DATE AS OF CHANGE: 20230522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ETHEMA HEALTH Corp CENTRAL INDEX KEY: 0000792935 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 841227328 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-15078 FILM NUMBER: 23945202 BUSINESS ADDRESS: STREET 1: 950 EVERNIA STREET CITY: WEST PALM BEACH STATE: FL ZIP: 33401 BUSINESS PHONE: 561-593-8365 MAIL ADDRESS: STREET 1: 950 EVERNIA STREET CITY: WEST PALM BEACH STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: GREENESTONE HEALTHCARE CORP DATE OF NAME CHANGE: 20120815 FORMER COMPANY: FORMER CONFORMED NAME: NOVA NATURAL RESOURCES CORP DATE OF NAME CHANGE: 19920703 10-Q 1 grst_10q.htm
0000792935 false Q1 2023 --12-31 0000792935 2023-01-01 2023-03-31 0000792935 2023-05-19 0000792935 2023-03-31 0000792935 2022-12-31 0000792935 grst:RedeemableBPreferredStockMember 2023-03-31 0000792935 grst:RedeemableBPreferredStockMember 2022-12-31 0000792935 us-gaap:RedeemablePreferredStockMember 2023-03-31 0000792935 us-gaap:RedeemablePreferredStockMember 2022-12-31 0000792935 grst:RedeemableAPreferredStockMember 2023-03-31 0000792935 grst:RedeemableAPreferredStockMember 2022-12-31 0000792935 2022-01-01 2022-03-31 0000792935 us-gaap:PreferredClassAMember 2022-12-31 0000792935 us-gaap:CommonStockMember 2022-12-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000792935 grst:DiscountInParValueMember 2022-12-31 0000792935 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000792935 us-gaap:RetainedEarningsMember 2022-12-31 0000792935 us-gaap:NoncontrollingInterestMember 2022-12-31 0000792935 us-gaap:PreferredClassAMember 2021-12-31 0000792935 us-gaap:CommonStockMember 2021-12-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000792935 grst:DiscountInParValueMember 2021-12-31 0000792935 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000792935 us-gaap:RetainedEarningsMember 2021-12-31 0000792935 us-gaap:NoncontrollingInterestMember 2021-12-31 0000792935 2021-12-31 0000792935 us-gaap:PreferredClassAMember 2023-01-01 2023-03-31 0000792935 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000792935 grst:DiscountInParValueMember 2023-01-01 2023-03-31 0000792935 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000792935 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000792935 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000792935 us-gaap:PreferredClassAMember 2022-01-01 2022-03-31 0000792935 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000792935 grst:DiscountInParValueMember 2022-01-01 2022-03-31 0000792935 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000792935 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000792935 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000792935 us-gaap:PreferredClassAMember 2023-03-31 0000792935 us-gaap:CommonStockMember 2023-03-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000792935 grst:DiscountInParValueMember 2023-03-31 0000792935 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000792935 us-gaap:RetainedEarningsMember 2023-03-31 0000792935 us-gaap:NoncontrollingInterestMember 2023-03-31 0000792935 us-gaap:PreferredClassAMember 2022-03-31 0000792935 us-gaap:CommonStockMember 2022-03-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000792935 grst:DiscountInParValueMember 2022-03-31 0000792935 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000792935 us-gaap:RetainedEarningsMember 2022-03-31 0000792935 us-gaap:NoncontrollingInterestMember 2022-03-31 0000792935 2022-03-31 0000792935 us-gaap:LandMember 2023-03-31 0000792935 us-gaap:LandMember 2022-12-31 0000792935 us-gaap:PropertyPlantAndEquipmentMember 2023-03-31 0000792935 us-gaap:PropertyPlantAndEquipmentMember 2022-12-31 0000792935 us-gaap:LeaseholdImprovementsMember 2023-03-31 0000792935 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000792935 us-gaap:FurnitureAndFixturesMember 2023-03-31 0000792935 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000792935 us-gaap:VehiclesMember 2023-03-31 0000792935 us-gaap:VehiclesMember 2022-12-31 0000792935 us-gaap:ComputerEquipmentMember 2023-03-31 0000792935 us-gaap:ComputerEquipmentMember 2022-12-31 0000792935 grst:LeoniteCapitalLLCMember 2023-01-01 2023-03-31 0000792935 grst:LeoniteCapitalLLCMember 2022-01-01 2022-12-31 0000792935 grst:LeoniteFundILPMember 2023-01-01 2023-03-31 0000792935 grst:LeoniteFundILPMember 2022-01-01 2022-12-31 0000792935 grst:AuctusFundLLCMember 2023-01-01 2023-03-31 0000792935 grst:AuctusFundLLCMember 2022-01-01 2022-12-31 0000792935 grst:LabrysFundLPMember 2023-01-01 2023-03-31 0000792935 grst:LabrysFundLPMember 2022-01-01 2022-12-31 0000792935 grst:EdBlasiakMember 2023-01-01 2023-03-31 0000792935 grst:EdBlasiakMember 2022-01-01 2022-12-31 0000792935 grst:JoshuaBaumanMember 2023-01-01 2023-03-31 0000792935 grst:JoshuaBaumanMember 2022-01-01 2022-12-31 0000792935 grst:SeriesNConvertibleNotesMember 2023-01-01 2023-03-31 0000792935 grst:SeriesNConvertibleMember 2023-01-01 2023-03-31 0000792935 grst:SeriesNConvertibleNotesMember 2022-01-01 2022-12-31 0000792935 2022-01-01 2022-12-31 0000792935 grst:CranberryCoveHoldingsLtdMember 2023-03-31 0000792935 grst:CranberryCoveHoldingsLtdMember 2022-12-31 0000792935 grst:Excercise1Member 2023-01-01 2023-03-31 0000792935 grst:Excercise2Member 2023-01-01 2023-03-31 0000792935 grst:Excercise2Member 2023-01-01 2023-03-31 0000792935 grst:InPatientServicesMember 2023-01-01 2023-03-31 0000792935 grst:TotalMember 2023-01-01 2023-03-31 0000792935 grst:RentalOperationsMember 2023-03-31 0000792935 grst:InPatientServicesMember 2023-03-31 0000792935 grst:RentalOperationsMember 2022-01-01 2022-03-31 0000792935 grst:InPatientServicesMember 2022-01-01 2022-03-31 0000792935 grst:TotalMember 2022-01-01 2022-03-31 0000792935 grst:RentalOperationsMember 2022-03-31 0000792935 grst:InPatientServicesMember 2022-03-31 0000792935 grst:TotalMember 2022-03-31 0000792935 grst:WarrantsMember 2023-01-01 2023-03-31 0000792935 grst:WarrantsMember 2022-01-01 2022-03-31 0000792935 grst:ConvertibleNoteMember 2023-01-01 2023-03-31 0000792935 grst:ConvertibleNoteMember 2022-01-01 2022-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023

 

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

 

Commission File Number 000-54748

 

ETHEMA HEALTH CORPORATION.

(Exact Name of Registrant as Specified in its Charter)

 

Colorado   84-1227328
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. employer
Identification No.)
     

950 Evernia Street

West Palm Beach, Florida

   33401
Address of Principal Executive Offices   Zip Code

 

(416) 500-0020

Registrant’s Telephone Number, Including Area Code

 

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒  Smaller reporting company ☒
  Emerging growth company ☐  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered

 

Common shares    GRST   OTC Pink

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: Number of shares of common stock outstanding as of May 19, 2023 was 3,729,053,805.

 

 

  

 

NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In particular, statements contained in this Quarterly Report on Form 10-Q, including but not limited to, statements regarding the sufficiency of our cash, our ability to finance our operations and business initiatives and obtain funding for such activities; our future results of operations and financial position, business strategy and plan prospects, or costs and objectives of management for future acquisitions, are forward looking statements. These forward-looking statements relate to our future plans, objectives, expectations and intentions and may be identified by words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “seeks,” “goals,” “estimates,” “predicts,” “potential” and “continue” or similar words. Readers are cautioned that these forward-looking statements are based on our current beliefs, expectations and assumptions and are subject to risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed, projected or implied in any forward-looking statements. We undertake no obligation to revise or update any forward-looking statements for any reason.

 

NOTE REGARDING COMPANY REFERENCES

 

Throughout this Quarterly Report on Form 10-Q, “Ethema,” the “Company,” “we,” “us” and “our” refer to Ethema Health Corporation.

 

 

 

 

FORM 10-Q

ETHEMA HEALTH CORPORATION

TABLE OF CONTENTS

 

    Page
  PART I - FINANCIAL INFORMATION  
Item l. Financial Statements 1
  Condensed Consolidated Balance Sheets as of March 31, 2023 (Unaudited) and December 31, 2022 1
  Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022 2
  Unaudited Condensed Consolidated Statements of Stockholders’ Deficit for the three months ended March 31, 2023 and 2022 3
  Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March  31, 2023 and 2022 4
  Notes to the Unaudited Condensed Consolidated Financial Statements 5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 24
Item 3. Quantitative and Qualitative Disclosures About Market Risk 27
Item 4. Controls and Procedures 27
     
  PART II - OTHER INFORMATION  
Item 1. Legal Proceedings 28
Item 1A. Risk Factors 28
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28
Item 3. Defaults Upon Senior Securities 28
Item 4. Mine Safety Disclosures 28
Item 5. Other Information 28
Item 6. Exhibits 29
SIGNATURES 30

 

 

 

ETHEMA HEALTH CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

       
  

March 31,

2023

  December 31, 2022
ASSETS   (Unaudited)      
           
Current assets          
Cash  $27,580   $140,757 
Accounts receivable, net   543,119    337,074 
Prepaid expenses   34,142    44,718 
Other current assets   84,823    20,347 
Total current assets   689,664    542,896 
Non-current assets          
Property and equipment   2,979,853    2,974,395 
Intangible assets, net   1,163,437    1,252,932 
Right of use assets   1,322,851    1,393,071 
Deposits paid   450,000    400,000 
Total non-current assets   5,916,141    6,020,398 
Total assets  $6,605,805   $6,563,294 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
Current liabilities          
Accounts payable and accrued liabilities  $372,830   $170,934 
Taxes payable   282,878    248,644 
Convertible notes, net of discounts   5,351,270    5,269,250 
Short-term notes   496,923    460,534 
Mortgage loans   3,478,130    3,504,605 
Receivables funding   443,459    416,731 
Government assistance loans   61,473    14,818 
Operating lease liability   299,027    287,017 
Finance lease liability   8,017    7,891 
Redeemable Preferred stock - Series B; $1.00 par value, 10,000,000 shares authorized; 400,000 shares outstanding as of March 31, 2023   400,000    — 
Accrued dividends   218,357    194,829 
Related party payables   2,655,976    2,713,878 
Total current liabilities   14,068,340    13,289,131 
Non-current liabilities          
Government assistance loans   29,484    79,555 
Deferred taxation   201,919    217,451 
Third party loans   590,372    578,335 
Operating lease liability   1,125,990    1,206,413 
Finance lease liability   22,883    24,952 
Total non-current liabilities   1,970,648    2,106,706 
Total liabilities   16,038,988    15,395,837 
           
Redeemable Preferred stock - Series B; $1.00 par value, 10,000,000 shares authorized; 400,000 shares outstanding as of December 31, 2022.   —    400,000 
           
Stockholders’ deficit          
Preferred stock - Series A; $0.01 par value, 10,000,000 shares authorized;
4,000,000 shares outstanding as of March 31, 2023 and December 31, 2022.		   40,000    40,000 
Common stock - $0.01 par value, 10,000,000,000 shares authorized; 
3,729,053,805 shares issued and outstanding as of March 31, 2023 and December 31, 2022.		   37,290,539    37,290,539 
Additional paid-in capital   23,419,917    23,419,917 
Discount for shares issued below par value   (27,363,367)   (27,363,367)
Accumulated other comprehensive loss   (6,569)   (5,065)
Accumulated deficit   (43,686,855)   (43,484,751)
Stockholders’ deficit attributable to Ethema Health Corporation stockholders’   (10,306,335)   (10,102,727)
Non-controlling interest   873,152    870,184 
Total stockholders’ deficit   (9,433,183)   (9,232,543)
Total liabilities and stockholders’ deficit  $6,605,805   $6,563,294 

 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements

 1

 

  

ETHEMA HEALTH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 

AND COMPREHENSIVE INCOME (LOSS)

 

       
   Three months ended
March 31, 2023		  Three months ended
March 31, 2022
       
Revenues  $1,300,046   $1,023,315 
           
Operating expenses          
General and administrative   241,237    209,932 
Rent expense   114,564    90,031 
Management fees   27,500    30,000 
Professional fees   111,204    49,587 
Salaries and wages   592,036    436,825 
Depreciation expense   138,479    132,000 
Total operating expenses   1,225,020    948,375 
           
Operating Income   75,026    74,940 
           
Other (expense) income          
Other income   —      10,018 
Interest expense   (157,096)   (80,768)
Amortization of debt discount   (76,921)   (252,832)
Derivative liability movement   —      197,476 
Foreign exchange movements   (2,955)   (95,556)
Loss before taxation   (161,946)   (146,722)
Taxation   (13,771)   (18,263)
Consolidated Net loss   (175,717)   (164,985)
Net income attributable to non-controlling interest   (2,968)   (9,462)
Net loss attributable to Ethema Health Corporation Stockholders’   (178,685)   (174,447)
Preferred stock dividend   (23,419)   (24,613)
Net loss available to common shareholders of Ethema Health Corporation   (202,104)   (199,060)
Accumulated other comprehensive (loss) income          
Foreign currency translation adjustment   (1,504)   34,517 
           
Total comprehensive loss  $(203,608)  $(164,543)
           
Basic and diluted loss per common share  $(0.00)  $(0.00)
Weighted average common shares outstanding – Basic and diluted   3,729,053,805    3,630,720,472 

 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements 

 

 2

 

ETHEMA HEALTH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

 

  

                                                                
   Series A Preferred  Common   
   Shares  Amount  Shares  Amount  Additional Paid-in Capital  Discount to par value  Accumulated Other Comprehensive Income (Loss)  Accumulated Deficit  Non-controlling shareholders interest  Total
Balance as of December 31, 2022   4,000,000   $40,000    3,729,053,805   $37,290,539   $23,419,917   $(27,363,367)  $(5,065)  $(43,484,751)  $870,184   $(9,232,543)
Foreign currency translation   —      —      —      —      —      —      (1,504)   —      —      (1,504)
Net loss   —      —      —      —      —           —      (178,685)   2,968    (175,717)
Dividends accrued   —      —      —      —      —      —      —      (23,419)   —      (23,419)
Balance as of March 31, 2023   4,000,000   $40,000    3,729,053,805   $37,290,539   $234,199,117   $(27,363,367)  $(6,569)  $(43,686,855)  $873,152   $(9,433,183)

  

 

   Series A Preferred  Common   
   Shares  Amount  Shares  Amount  Additional Paid-in Capital  Discount to par value  Accumulated Other Comprehensive Income (Loss)  Accumulated Deficit  Non-controlling shareholders interest  Total
Balance as of December 31, 2021   4,000,000   $40,000    3,579,053,805   $35,70,539   $22,791,350   $(26,013,367)  $816,532   $(44,103,311)  $822,876   $(9,855,381)
Conversion of convertible notes   —      —      150,000,000    1,500,000    —      (1,350,000)   —      —      —      150,000 
Foreign currency translation   —      —      —      —      —      —      34,517    —      —      34,517 
Net loss   —      —      —      —      —           —      (174,447)   9,462    (164,985)
Dividends accrued   —      —      —      —      —      —      —      (24,613)   —      (24,613)
Balance as of March 31, 2022   4,000,000   $40,000    3,729,053,805   $37,290,539   $22,791,350   $(27,363,367)  $851,049   $(44,302,371)  $832,338   $(9,860,462)

   

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements

 

 

 3

 

ETHEMA HEALTH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

 

       
   Three months ended
March 31,
2023		  Three months ended
March 31,
2022
Operating activities          
Consolidated net loss  $(175,717)  $(164,985)
Adjustment to reconcile consolidated net loss to net cash provided by (used in) operating activities:          
Depreciation and amortization expense   138,479    132,000 
Amortization of debt discount   76,921    252,832 
Derivative liability movements   —      (197,476)
Amortization of right of use asset   70,219    63,064 
Deferred taxation movement   (15,532)   (18,794)
Changes in operating assets and liabilities          
Accounts receivable   (151,744)   (115,000)
Prepaid expenses   10,576    10,456 
Other current assets   (64,476)   (1,171)
Accounts payable and accrued liabilities   251,384    (22,013)
Operating lease liabilities   (68,413)   (57,156)
Taxes payable   34,177    49,169 
Net cash provided by (used in) operating activities   105,874    (69,074)
           
Investing activities          
Deposits paid   (50,000)   —   
Purchase of property and equipment   (52,418)   (72,858)
Net cash used in investing activities   (102,418)   (72,858)
           
Financing activities          
Repayment of mortgage   (29,300)   (29,850)
Proceeds from receivables funding   190,000    —   
Repayment of receivables funding   (204,133)   —   
Repayment of convertible notes   (10,000)   (201,733)
Proceeds from promissory notes   —      100,000 
Repayment of government assistance loans   (3,449)   —   
Repayment of third party loans   —      (78,977)
Repayment of finance leases   (1,944)   (1,822)
Proceeds from related party notes   —      259,228 
Repayment of related party notes   (58,917)   —   
Net cash (used in) provided by financing activities   (117,743)   46,846 
           
Effect of exchange rate on cash   1,110    73,288 
           
Net change in cash   (113,177)   (21,798)
Beginning cash balance   140,757    48,822 
Ending cash balance  $27,580   $27,024 
           
Supplemental cash flow information          
Cash paid for interest  $53,310   $43,304 
Cash paid for income taxes  $—     $—   
           
Non-cash investing and financing activities          
Conversion of convertible notes  $—     $150,000 

 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements

 

 4

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

1. Nature of business

 

Since 2010, the Company has operated addiction treatment centers. Initially the Company operated an addiction treatment center in Ontario Canada under its Greenestone Muskoka clinic, which was sold on February 14, 2017. Simultaneously with this sale the Company purchased buildings and operated an addiction treatment center in Delray Beach Florida under its Addiction Recovery Institute of America subsidiary with a license obtained in December 2016, initially through owned properties in Delray Beach and subsequently though leased properties in West Palm Beach, Florida. Since June 30, 2020, the Company has been actively involved in the management of a treatment center operated by Evernia in West Palm Beach, Florida. On July 1, 2021, the Company closed on the acquisition of 75% of ATHI, which owns 100% of Evernia, once the probationary approval of a license was obtained from the Department of Children and Family Services of Florida. Evernia is the only active treatment center operated by the Company.

 

The Company also owns the real estate on which its Greenstone Muskoka clinic operated. The current tenant operates an addiction treatment center on these premises. The Company collects rent on this property, which is treated as a separate business segment. 

     

2. Summary of significant accounting policies

 

 Financial Reporting

 

The (a) unaudited condensed consolidated balance sheets as of March 31, 2023, which have been derived from the unaudited condensed consolidated financial statements, and as of December 31, 2022, which have been derived from audited consolidated financial statements, and (b) the unaudited condensed consolidated statements of operations, stockholders’ deficit and cash flows of the Company, have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of results that may be expected for the year ending December 31, 2023. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023.

 

All amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.

 

a) Use of Estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

 

b) Principals of consolidation and foreign currency translation

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and all of its subsidiaries. All intercompany transactions and balances have been eliminated on consolidation.

 

Certain of the Company’s subsidiaries functional currency is the Canadian dollar, while the Company’s reporting currency is the U.S. dollar. All transactions initiated in Canadian dollars are translated into US dollars in accordance with ASC 830, “Foreign Currency Translation” as follows:

 

  ● Monetary assets and liabilities at the rate of exchange in effect at the balance sheet date.

 

  ● Certain non-monetary assets and liabilities and equity at historical rates.

 

  ● Revenue and expense items and cash flows at the average rate of exchange prevailing during the year.

 

 Adjustments arising from such translations are deferred until realization and are included as a separate component of stockholders’ deficit as a component of accumulated other comprehensive income or loss. Therefore, translation adjustments are not included in determining net income (loss) but reported as other comprehensive income (loss).

 

 5

 

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 
2. Summary of significant accounting policies (continued)

 

b) Principals of consolidation and foreign currency translation (continued)

 

For foreign currency transactions, the Company translates these amounts to the Company’s functional currency at the exchange rate effective on the invoice date. If the exchange rate changes between the time of purchase and the time actual payment is made, a foreign exchange transaction gain or loss results which is included in determining net income for the year.

 

The relevant translation rates are as follows: For the three months ended March 31, 2023, a closing rate of CDN$1 equals US$0.7389 and an average exchange rate of CDN$1 equals US$0.7394, for the year ended December 31, 2022, a closing rate of CDN$1.0000 equals US$0.7383 and an average exchange rate of CDN$1.0000 equals US$0.7686.

 

c) Business Combinations

 

The Company allocates the fair value of purchase consideration to the tangible and intangible assets acquired and liabilities assumed for business combinations with third parties based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill.

 

Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired users, acquired technology, and trade names from a market participant perspective, useful lives and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates.

 

 

d) Cash and cash equivalents

 

For purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with several financial institution in the USA and Canada. There were no cash equivalents at

March 31, 2023 and December 31, 2022.

 

The Company primarily places cash balances in the USA with high-credit quality financial institutions located in the United States which are insured by the Federal Deposit Insurance Corporation up to a limit of $250,000 per institution, in Canada which are insured by the Canadian Deposit Insurance Corporation up to a limit of CDN$100,000 per institution.

 

e) Accounts receivable

 

Accounts receivable primarily consists of amounts due from third-party payors (non-governmental) and private pay patients and is recorded net of allowances for doubtful accounts and contractual discounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s unaudited condensed consolidated financial statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimating net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies denying claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients.

 

 

 6

 

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

  
2. Summary of significant accounting policies (continued)

 

f) Allowance for Doubtful Accounts, Contractual and Other Discounts

  

The Company derives the majority of its revenues from commercial payors at in-network rates. Management estimates the allowance for contractual and other discounts based on its historical collection experience and contractual rates. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account is written off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.

 

g) Property and equipment

  

Property and equipment is recorded at cost. Depreciation is calculated on the straight line basis over the estimated life of the asset.

 

h) Intangible assets

 

Intangible assets are stated at acquisition cost less accumulated amortization, if applicable, less any adjustments for impairment losses.

 

Amortization is charged on a straight-line basis over the estimated remaining useful lives of the individual intangibles. Where intangibles are deemed to be impaired the Company recognizes an impairment loss measured as the difference between the estimated fair value of the intangible and its book value.

 

Licenses to provide substance abuse rehabilitation services are amortized over the expected life of the contract, including any anticipated renewals. The Company expects its licenses to remain in operation for a period of five years.

   

i) Leases

 

 The Company accounts for leases in terms of AC 842 whereby leases are classified as either finance or operating leases. Leases that transfer substantially all of the benefits and inherent risks of ownership of property to the Company are accounted for as finance leases. At the time a finance lease is entered into, an asset is recorded together with its related long-term obligation to reflect the acquisition and financing. Property and equipment recorded under finance leases is amortized on the same basis as described above. Operating leases are recognized on the balance sheet as a lease liability with a corresponding right of use asset for all leases with a term that is more than twelve months. Payments under operating leases are expensed as incurred.

 

j) Derivatives

 

The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. The Company previously used a Black Scholes Option Pricing model to estimate the fair value of convertible debt conversion features at the end of each applicable reporting period. Changes in the fair value of these derivatives during each reporting period were included in the statements of operations. Inputs into the Black Scholes Option Pricing model require estimates, including such items as estimated volatility of the Company’s stock, risk free interest rate and the estimated life of the financial instruments being fair valued.

 

If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion feature.

 

 

 7

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

  
2. Summary of significant accounting policies (continued)

 

k) Financial instruments

 

The Company initially measures its financial assets and liabilities at fair value. The Company subsequently measures all its financial assets and financial liabilities at amortized cost.

 

Financial assets measured at amortized cost include cash and accounts receivable.

 

Financial liabilities measured at amortized cost include bank indebtedness, accounts payable and accrued liabilities, harmonized sales tax payable, withholding taxes payable, convertible notes payable, loans payable and related party notes.

 

Financial assets measured at cost are tested for impairment when there are indicators of impairment. The amount of the write-down is recognized in net income. The previously recognized impairment loss may be reversed to the extent of the improvement, directly or by adjusting the allowance account, provided it is no greater than the amount that would have been reported at the date of the reversal had the impairment not been recognized previously. The amount of the reversal is recognized in net income. The Company recognizes its transaction costs in net income in the period incurred. However, financial instruments that will not be subsequently measured at fair value are adjusted by the transaction costs that are directly attributable to their origination, issuance or assumption.

 

FASB ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

  ● Level 1. Observable inputs such as quoted prices in active markets;
  ●  Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
  ● Level 3. Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions.

 

The Company measures its convertible debt and derivative liabilities associated therewith at fair value. These liabilities are revalued periodically and the resultant gain or loss is realized through the consolidated Statement of Operations and Comprehensive Loss.

 

l) Related parties

 

Parties are considered to be related to the Company if the parties directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged.

 

m) Revenue recognition

 

ASC 606 requires companies to exercise more judgment and recognize revenue using a five-step process.

 

The Company’s provision for doubtful accounts are recorded as a direct reduction to revenue instead of being presented as a separate line item on the consolidated statements of operations and comprehensive loss.

 

As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities.

 

 8

 

 ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

  
2. Summary of significant accounting policies (continued)

 
  m) Revenue recognition (continued)

 

The Company receives payments from the following sources for services rendered in our U.S. Facility: (i) commercial insurers; and (ii) individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and does not adjust for the effects of a significant financing component.

 

The Company derives a significant portion of its revenue from other payors that receive discounts from established billing rates. The various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.

 

Settlements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s receivables were $543,119 and $337,074 at March 31, 2023 and December 31, 2022, respectively. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount.

 

The Company’s revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those services. The Company derives its revenues from the sale of its services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its revenue transactions: 

 

  i. identify the contract with a customer;
  ii. identify the performance obligations in the contract;
  iii. determine the transaction price;
  iv. allocate the transaction price to performance obligations in the contract; and
  v. recognize revenue as the performance obligation is satisfied.

 

n) Income taxes

 

The Company accounts for income taxes under the provisions of ASC Topic 740, “Income Taxes”. Under ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes are provided using the liability method. Under this method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The tax basis of an asset or liability is the amount attributed to that asset or liability for tax purposes. The effect on deferred taxes of a change in tax rates is recognized in income in the period of change. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion of, or all of, the deferred tax assets will not be realized.

  

 9

 

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

  
2. Summary of significant accounting policies (continued)

 

n) Income taxes (continued)

 

ASC Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions taken or expected to be taken in a tax return. The first step is to determine if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company recognizes interest and penalties accrued on unrecognized tax benefits within general and administrative expense. To the extent that accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction in general and administrative expenses in the period that such determination is made. The tax returns for fiscal 2019, through 2022 are subject to audit or review by the US tax authorities, whereas fiscal 2011 through 2022 are subject to audit or review by the Canadian tax authority.

 

o) Net income (loss) per Share

 

Basic net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the year.

 

Diluted net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation.

 

Dilution is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share). 

 

p) Stock based compensation

 

Stock based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over the employee’s requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized in the consolidated statements of operations for the three months ended March 31, 2023 and 2022 is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. We have no awards with performance conditions and no awards dependent on market conditions.

 

q) Financial instruments risks

 

The Company is exposed to various risks through its financial instruments. The following analysis provides a measure of the Company’s risk exposure and concentrations at the balance sheet dates, March 31, 2023 and December 31, 2022.

 

  i. Credit risk

 

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Financial instruments that subject the Company to credit risk consist primarily of accounts receivable.

 

Credit risk associated with accounts receivable is mitigated as only a percentage of the revenue billed to health insurance companies is recognized as income until such time as the actual funds are collected. The revenue is concentrated amongst several health insurance companies located in the US.

 

 10

 

In the opinion of management, credit risk with respect to accounts receivable is assessed as low.

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

  
2. Summary of significant accounting policies (continued)

 
  q) Financial instruments Risks (continued)

 

  ii. Liquidity risk

 

Liquidity risk is the risk the Company will not be able to meet its financial obligations as they fall due. The Company is exposed to liquidity risk through its working capital deficiency of approximately $13.4 million, and an accumulated deficit of approximately $43.7 million. The Company is dependent upon the raising of additional capital in order to implement its business plan. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial condition. In the opinion of management, liquidity risk is assessed as high, material and remains unchanged from that of the prior year.

 

  iii. Market risk

 

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of three types of risk: interest rate risk, currency risk, and other price risk. The Company is exposed to interest rate risk and currency risk.

 

  a. Interest rate risk

 

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its convertible debt, mortgage loans, short term loans, third party loans and government assistance loans as of March 31, 2023. In the opinion of management, interest rate risk is assessed as moderate.

 

  b. Currency risk

 

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company is subject to currency risk as it has subsidiaries that operate in Canada and are subject to fluctuations in the Canadian dollar. A substantial portion of the Company’s financial assets and liabilities are denominated in Canadian dollars, however net earnings in foreign currency is minimal and a 5% depreciation or appreciation of the Canadian dollar against the U.S. dollar would result in an immaterial increase or decrease in the Company’s after tax net income from operations. The Company has not entered into any hedging agreements to mitigate this risk. In the opinion of management, currency risk is assessed as low, material and remains unchanged from that of the prior year.

 

  c. Other price risk

 

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. In the opinion of management, the Company is not exposed to this risk and remains unchanged from the prior year.

 

 

q) Allowance for credit losses

 

 The Company recognizes revenue based on historical collections received from healthcare providers, recognizing only a percentage of revenues actually billed. Effectively recognizing revenue net of any expected billing differentials. Based on the Company’s collection experience, the percentage of revenue recognized is adjusted on a periodic basis, thereby taking into account expected credit losses in the revenue recognition process. The revenue we recognize is already net of expected credit losses.

 

We constantly evaluate our collections experience and consider the market conditions and current economic developments facing the Company’s operations . We have not experienced significantly different collections to revenues we have recognized and we have not seen any deterioration in the payment patterns from the healthcare providers that the Company works with, we cannot predict with any certainty that the payment patterns the Company experiences may change and we may be required to adjust the percentage of revenue recognized.

 

r) Recent accounting pronouncements

 

The Financial Accounting Standards Board (“FASB”) issued additional updates during the three months ended March 31, 2023. None of these standards are either applicable to the Company or require adoption at a future date and none are expected to have a material impact on the Company’s consolidated financial statements upon adoption.

 

 11

 

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

  

3. Going concern

 

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with US GAAP applicable to a going concern, which assumes that the Company will be able to meet its obligations and continue its operations in the normal course of business. At March 31, 2023 the Company has a working capital deficiency of $13.4 million, and total liabilities in excess of assets in the amount of $9.4 million . Management believes that current available resources will not be sufficient to fund the Company’s planned expenditures over the next 12 months. These factors, individually and collectively indicate that a material uncertainty exists that raises substantial doubt about the Company's ability to continue as a going concern for one year from the date of issuance of these condensed interim consolidated financial statements. 

 

The Company will be dependent upon the raising of additional capital through placement of common shares, and/or debt financing in order to implement its business plan and generating sufficient revenue in excess of costs. If the Company raises additional capital through the issuance of equity securities or securities convertible into equity, stockholders will experience dilution, and such securities may have rights, preferences or privileges senior to those of the holders of common stock or convertible senior notes. If the Company raises additional funds by issuing debt, the Company may be subject to limitations on its operations, through debt covenants or other restrictions. If the Company obtains additional funds through arrangements with collaborators or strategic partners, the Company may be required to relinquish its rights to certain geographical areas, or techniques that it might otherwise seek to retain. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial condition. These unaudited condensed consolidated financial statements do not include any adjustments to the amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

  

4. Property and equipment

  

Property and equipment consists of the following:  

  

      March 31,
2023		   December 31, 2022
 

Useful

lives

   Cost   Accumulated depreciation   Net book value   Net book value
Land Indefinite   $ 158,871     $ —       $ 158,871     $ 158,742  
Property 25 years     3,005,354       (723,081 )     2,282,273       2,310,448  
Leasehold improvements Life of lease     446,065       (54,164 )     391,901       373,320  
Furniture and fittings 6 years     139,889       (29,106 )     110,783       92,941  
Vehicles 5 years     55,949       (20,668 )     35,281       38,079  
Computer equipment 3 years     1,450       (706 )     744       865  
      $ 3,807,578     $ (827,725 )   $ 2,979,853     $ 2,974,395  

 

Depreciation expense for the three months ended March 31, 2023 and 2022 was $48,494 and $42,505, respectively.

   

5. Intangibles

 

Intangible assets consist of the following:

 

   Useful
lives		  March 31,
2023		  December 31, 2022
      Cost  Accumulated amortization  Net book value  Net book value
Health care Provider license  5 years  $1,789,903   $(626,466)  $1,163,437   $1,252,932 
                        

 

The Company evaluates intangible assets for impairment on an annual basis during the last month of each year and at an interim date if indications of impairment exist. Intangible asset impairment is determined by comparing the fair value of the asset to its carrying amount with an impairment being recognized only when the fair value is less than carrying value and the impairment is deemed to be permanent in nature.

 

The Company recorded $89,495 in amortization expense for finite-lived assets for each of the three months ended March 31, 2023 and 2022.

 12

 

 

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

  

6. Leases

 

Right of use assets are included in the consolidated balance sheet are as follows:

   March 31,
2023		  December 31,
2022
Non-current assets          
Right-of-use assets – finance leases, net of depreciation, included in Property and equipment  $35,281   $38,079 
Right-of-use assets - operating leases, net of amortization  $1,322,851   $1,393,071 

  

Lease costs consists of the following: 

 

              
   Three  months ended March 31,
   2023  2022
 Finance lease cost:          
Amortization of right-of-use assets  $2,797   $2,797 
Interest expense on finance lease liabilities   526    648 
    3,323    3,445 
           
Operating lease cost  $86,127   $63,064 
Lease cost  $89,450   $186,727 

 

Other lease information: 

   Three months ended March 31,
   2023  2022
Cash paid for amounts included in the measurement of lease liabilities      
Operating cash flows from finance leases  $(526)  $(648)
Operating cash flows from operating leases   (86,127)   (63,064)
Financing cash flows from finance leases   (1,944)   (1,809)
Cash paid for amounts included in the measurement of lease liabilities  $(88,597)  $(65,521)
           
Weighted average lease term – finance leases   3 years and seven months    4 years and seven months 
Weighted average remaining lease term – operating leases   3 years and 10 months    4 years and 10 months 
           
Discount rate – finance leases   6.60%   6.61%
Discount rate – operating leases   4.64%   4.64%

 

Maturity of Leases

 

Finance lease liability

 

The amount of future minimum lease payments under finance leases as of March 31, 2023 is as follows:

 

 

   Amount
Remainder of 2023  $7,372 
2024   9,829 
2025   9,829 
2026   6,195 
2027   1,707 
    34,932 
Imputed interest   (4,032)
Total finance lease liability  $30,900 
Disclosed as:     
Current portion  $8,017 
Non-Current portion   22,883 
Lease liability  $30,900 

 

 13

 

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

  
6. Leases (continued)

 

Operating lease liability

 

The amount of future minimum lease payments under operating leases are as follows:

 Schedule of Operating lease liability

   Amount
    
Remainder of 2023  $262,549 
2024   366,110 
2025   384,416 
2026   403,637 
2027   33,771 
Total undiscounted minimum future lease payments   1,450,483 
Imputed interest   (25,465)
Total operating lease liability  $1,425,017 
      
Disclosed as:     
Current portion  $299,027 
Non-Current portion   1,125,990 
 Lease liability  $1,425,017 

    

Lessor Property

 

The Company’s wholly owned subsidiary CCH owns a property located at 3571 Muskoka Road, #169, Bala, on which the operations of the Canadian Rehab Clinic were located prior to disposal on February 14, 2017, The property is leased to the purchasers of the business of the Canadian Rehab Clinic, initially for a period of 5 years, which was renewed for an additional 5 years, with a further two 5 year renewal periods available to the lessee. The lessee has an option to acquire the property for CDN$10 million. The Company considers the likelihood of the option being exercised as remote at this time.

 

The Lease was considered in terms of ASC 842, Leases and determined to be an operating lease as the criteria for the lease to be a sales-type lease or a direct financing lease were not met, including the possibility of the lessee exercising the option to purchase the property being considered as remote.

 

The Company derived rental income of CDN$126 942 ($89,419) for the three months ended March 31, 2023.

 

7. Short-term Convertible Notes

 

The short-term convertible notes consist of the following:

  

    Interest rate   Maturity Date   Principal   Interest   March 31, 2023   December 31, 2022
Leonite Capital, LLC     12.0 %   On Demand    $ 129,379      $ 59,198      $ 188,577      $ 184,749  
Leonite Fund I, LP     Variable     March 1, 2023     745,375       19,738       765,113       720,830  
                                             
Auctus Fund, LLC     0.0 %   On Demand     70,000       —         70,000       80,000  
                                             
Labrys Fund, LP     12.0 %   On Demand     —         —         —         8,826  
                                             
Ed Blasiak     6.5 %   On Demand     55,000       9,216       64,216       63,322  
                                             
Joshua Bauman     11.0 %   October 21, 2022     150,000       23,778       173,778       169,710  
                                             
Series N convertible notes     6.0 %   On Demand     3,229,000       860,586       4,089,586       4,041,813  
                                             
                 $ 4,378,754      $ 972,516     $ 5,351,270     $ 5,269,250  

    

 14

 

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

7. Short-term Convertible Notes (continued)

 

Leonite Capital, LLC

 

On July 12, 2020, the Company entered into a Senior Secured Convertible Note agreement with Leonite for $440,000 with an original issue discount of $40,000 for gross proceeds of $400,000, the initial tranche advanced will be for cash of $200,000 plus the OID of $20,000, the remaining advances will be at the discretion of the Leonite. The loan bears interest at 6.5% per annum and matures on June 12, 2021. The Company is required to make monthly payments of the accrued interest on the advances made. The note is convertible into common shares at the option of the holder at $0.10 per share, or 80% multiplied by the price per share paid in subsequent financings or after a six month period from the effective date at 60% of the lowest trading price during the preceding 21 consecutive trading days. The note has both conversion price protection and anti-dilution protection provisions.

 

On February 28, 2022, in terms of a conversion notice, Leonite converted the principal sum of $149,250 of the Leonite Note into 150,000,000 shares of common stock at a conversion price of $0.0010 per share.

 

On March 1, 2023, the Company entered into a forbearance agreement with Leonite whereby the parties agreed to extend the maturity date of the note to June 8, 2023, the Company will continue to pay interest on the note, until repaid. The note has not been repaid as yet and the Company in continuing to negotiate the resolution of the note. 

 

Leonite Fund I, LP

 

Effective June 1, 2022, The Company entered into a Note Exchange Agreement whereby the convertible promissory notes entered into with Labrys Fund LP on May 7, 2021, with. A principal outstanding of $341,000, and on June 2, 2021 with a principal outstanding of $230,000 and accrued interest thereon of $25,300, were exchanged for a new Senior Secured Convertible Promissory note in the principal amount of $745,375, including an OID of $149,075. The Note matured on March 1, 2023, and bore interest at the minimum of 10% per annum or the Wall Street Journal quoted prime rate plus 5.75%. The note is currently in default, although no default has been declared and management is negotiating with Leonite on a resolution.

 

Interest is payable monthly and the note may be prepaid with a prepayment penalty of 10%. The note is convertible into common stock at a fixed conversion price of $0.01 per share, subject to anti-dilution adjustments and a fundamental transaction clause allowing the note holder to receive the same consideration as common stockholders would receive.

 

The convertible note is secured by all of the assets of Ethema Health Corporation and Addiction Recovery Institute of America, LLC.

 

On March 1, 2023, the Company entered into a forbearance agreement with Leonite whereby the parties agreed to extend the maturity date of the note to June 8, 2023, the Company will continue to pay interest on the note, until repaid. The note has not been repaid as yet and the Company in continuing to negotiate the resolution of the note. 

 

Auctus Fund, LLC

 

On August 7, 2019, the Company, entered into a Securities Purchase Agreement with Auctus Fund, LLC, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $225,000. The Note had a maturity date of May 7, 2020 and bore interest at the rate of ten percent per annum from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company had the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note is convertible at any time and from time to time at the election of Auctus Fund, LLC during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to 60% of the lowest closing bid price of the Company’s common stock for the thirty trading days prior to conversion.

 

On June 15, 2020, The Company entered into an amended agreement with Auctus whereby the Company agreed to discharge the principal amount of the note by nine equal monthly installments of $25,000 commencing in October 2020. During the year ended December 31, 2021, the Company repaid Auctus the principal sum of $50,000.

 

During March 2022, the Company paid $20,000 of principal on the convertible note, thereby reducing the principal outstanding to $80,000. The note matured May 7, 2020, Auctus Fund LLC has not declared a default and we are in constant discussion with the lender on settling the note.

 

During February 2023, the Company paid $10,000 of principal on the convertible note, thereby reducing the principal outstanding to $70,000. The note matured May 7, 2020, Auctus Fund LLC has not declared a default and we are in constant discussion with the lender on settling the note. 

 

 15

 


ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 
7. Short-term Convertible Notes (continued)

  

Ed Blasiak

 

On September 14, 2020, the Company entered into a Securities Purchase Agreement with Ed Blasiak (“Blasiak”), pursuant to which the Company issued a senior secured convertible promissory note in the aggregate principal amount of $55,000, including an original issue discount of $5,000. The note bears interest at 6.5% per annum and matures on September 14, 2021. The note is senior to any future borrowings and commencing on October 1, 2020 the Company will make monthly payments of the accrued interest under the note. The note may be prepaid at certain prepayment penalties and is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions; or 80% of the price per share of subsequent equity financings or; after six months 60% of the lowest trading price during the preceding six month period.

 

The note has matured and is in default, Ed Blasiak has not declared a default under the note and we are in communication with Mr. Blasiak on our ability to repay the note. 

 

Joshua Bauman

 

On September 14, 2020, the Company entered into a Securities Purchase Agreement with Bauman, pursuant to which the Company issued a senior secured convertible promissory note in the aggregate principal amount of $110,000, including an original issue discount of $10,000. The note bears interest at 6.5% per annum and matures on September 14, 2021. The note is senior to any future borrowings and commencing on October 1, 2020 the Company will make monthly payments of the accrued interest under the note. The note may be prepaid at certain prepayment penalties and is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions; or 80% of the price per share of subsequent equity financings or; after six months 60% of the lowest trading price during the preceding six month period.

 

On June 8, 2021, in terms of a conversion notice received by the Company, Bauman converted the aggregate principal sum of $100,000 including interest thereon of $5,563 into 106,313,288 shares of common stock.

 

On October 25, 2021, in terms of a conversion notice received by the Company, Bauman converted the aggregate principal sum of $37,500 including interest thereon of $1,155 into 39,405,310 shares of common stock, thereby extinguishing the note.

  

On October 21, 2021, the Company entered into a Securities Purchase Agreement with Bauman, pursuant to which the Company issued a senior secured convertible promissory note in the aggregate principal amount of $150,000, including an original issue discount of $16,250. The note bears interest at 11.0% per annum, which is guaranteed and earned in full on issue date and matured on October 21, 2022. The note is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions.

 

The note has matured and is in default, Mr. Bauman has not declared a default under the note and we are in communication with Mr. Bauman on our ability to repay the note. 

 

Series N convertible notes

 

Between January 28, 2019 and June 11, 2020, the Company closed several tranches of Series N Convertible notes in which it raised $3,229,000 in principal from accredited investors through the issuance to the investors of the Company’s Series N convertible notes, in the total original principal amount of $3,229,000, which Notes are convertible into the Company’s common stock at a conversion price of $0.08 per share together with three year warrants to purchase up to a total of 52,237,500 shares of the Company’s common stock at an exercise price of $0.12 per share. Both the conversion price under the Notes and the exercise price under the warrants are subject to standard adjustment mechanisms. The notes matured one year from the date of issuance.

 

The series N convertible notes matured and are in default. The Company is considering its options to settle these notes.

 

 16

 

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

8. Short-term Notes

 

Leonite Capital, LLC

 

Secured Promissory Notes  

 

On March 1, 2022, the Company entered into a secured Promissory Note in the aggregate principal amount of $124,000 for net proceeds of $100,000 after an original issue discount of $24,000. Due to the failure to repay the note by due date, a penalty of $37,200 was added to the principal outstanding and the Company incurs a monthly monitoring fee of $2,000 per month. In addition the note earns interest at a default rate of 24% per annum on the total balance outstanding, including the monthly monitoring fee and accrued interest.

 

The Note had a maturity date of April 1, 2022. This note has not been repaid at the date of this report. We are in negotiations with Leonite to settle the balance outstanding and no default has been declared.

 

The balance outstanding on the note, including default penalty, interest accrued and monthly monitoring fees is $231,481 as of March 31, 2023.

 

On May 3, 2022, the Company, entered into a secured Promissory Note in the aggregate principal amount of $76,250 for net proceeds of $61,000 after an original issue discount of $15,250. Due to the failure to repay the note by due date, a penalty of $22,875 was added to the principal outstanding and the Company incurs a monthly monitoring fee of $2,000 per month. In addition the note earns interest at a default rate of 24% per annum on the total balance outstanding, including the monthly monitoring fee and accrued interest.

 

The Note had a maturity date of June 17, 2022. This note has not been repaid at the date of this report. We are in negotiations with Leonite to settle the balance outstanding and no default has been declared.

 

The balance outstanding on the note, including default penalty, interest accrued and monthly monitoring fees is $143,634 as of March 31, 2023.

 

LXR Biotech

 

On April 12, 2019, the Company, entered into a secured Promissory Note in the aggregate principal amount of CDN$133,130. The Note had a maturity date of April 11, 2020 and bears interest at the rate of six percent per annum from the date on which the Note was issued.

 

This note has not been repaid, is in default and remains outstanding. The balance outstanding at March 31, 2023 was $121,806.

 

9. Mortgage loans

 

Mortgage loans is disclosed as follows:

 

    Interest 
rate		     Maturity date   Principal 
Outstanding		     Accrued 
interest		     March 31,
2023		     December 31,
2022
                                 
Cranberry Cove Holdings, Ltd.                               
Pace Mortgage     4.2 %   July 19, 2022   $  3,473,334     $ 4,796     $ 3,478,130      $ 3,504,605
Disclosed as follows:                                     
Short-term portion                          $ 3,478,130     $ 3,504,605
                                           

 

Cranberry Cove Holdings, Ltd. (“CCH”)


On July 19, 2017, CCH, a wholly owned subsidiary, closed on a loan agreement in the principal amount of CDN$5,500,000. The loan is secured by a first mortgage on the premises owned by CCH located at 3571 Muskoka Road 169, Bala, Ontario.

 

The loan bears interest at the fixed rate of 4.2% with a 5-year primary term and a 25-year amortization. The Company has guaranteed the loan and the Company’s chief executive officer and controlling shareholder also has personally guaranteed the Loan. CCH and the Company have granted the Lender a general security interest in its assets to secure repayment of the Loan. The loan is amortized with monthly installments of CDN $29,531.

 

The loan matured on July 19, 2022, and negotiations with the lender continue, no new terms have been presented to the Company as yet. The Company has continued to make installments in terms of the original mortgage agreement. 

 

 17

 

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

10. Government assistance loans

 

On December 1, 2020, CCH was granted a Covid-19 related government assistance loan in the aggregate principal amount of CDN$ 40,000 (Approximately $31,000). the grant is interest free and CDN$ 10,000 is forgivable if the loan is repaid in full by December 31, 2022. The maturity date of this loan was extended by an additional year to December 31, 2023.

 

On January 12, 2021, CCH received a further CDN$ 20,000 Covid-19 related government assistance loan. The loan is interest free and if repaid by December 31, 2022, CDN$ 10,000 is forgivable.

 

On May 3, 2021, ARIA was granted a government assistance loan in the aggregate principal amount of $157,367. The loan is forgivable if the Company demonstrates that the proceeds were used for expenses such as employee costs during the pandemic. Should the loan not be forgiven, interest is payable on the loan at the rate of 1% per annum and the principal is repayable and interest is payable over an 18 month period.

 

On September 21, 2022, ARIA received partial forgiveness of the government assistance loan of $104,368, the balance of the loan plus accrued interest is due and payable. On December 30, 2022, the Company sold ARIA to its Chairman and CEO and agreed to assume the repayment of the government assistance loan. As of March 31, 2023, the balance outstanding, including interest thereon was $44,336.

 

11. Receivables funding

 

September 26, 2022 Funding

 On September 26, 2022, the Company, through its 75% held subsidiary, Evernia Health Center, LLC, entered into a Receivables Sale Agreement with Itria Ventures LLC (“Itria”), whereby $310,000 of the Receivables of Evernia were sold to Itria, for gross proceeds of $250,000. The Company also incurred fees of $5,500, resulting in net proceeds of $244,500. The Company is obliged to pay 7.41% of the receivables until the amount of $310,000 is paid in full, with periodic repayments of $6,458 per week. The guarantor of the funding is a minority shareholder in ATHI.

 

The Company made weekly cash payments of $6,458 totaling $167,917 on the September 26, 2022 funding. The balance outstanding at March 31, 2023 was $147,083, less unamortized discount of $30,949.

 

December 13, 2022 Funding 

On December 13, 2022, the Company, through its 75% held subsidiary, Evernia Health Center, LLC entered into a Receivables Sale Agreement with Itria Ventures LLC (“Itria”), whereby $305,000 of the Receivables of Evernia were sold to Itria, for gross proceeds of $250,000. The Company also incurred fees of $2,500, resulting in net proceeds of $247,500. The Company is obliged to pay 6.08% of the receivables until the amount of $305,000 is paid in full, with periodic repayments of $6,354 per week. The guarantor of the funding is a minority shareholder in ATHI.

 

The Company made weekly cash payments of $6,354 totaling $88,958 on the December 13, 2022 funding. The balance outstanding at March 31, 2023 was $211,042, less unamortized discount of $40,228.

 

January 19, 2023 Funding

On January 19, 2023, the Company received funding from an agreement entered into on December 14, 2022 through its 75% held subsidiary, Evernia Health Center, LLC entered into a Receivables Sale Agreement with Bizfund.com (“Bizfund)”), whereby $132,000 of the Receivables of Evernia were sold to Bizfund, for gross proceeds of $100,000. The Company is obliged to pay 15.0% of the receivables until the amount of $132,000 is paid in full, with periodic repayments of $2,750 per week. The guarantor of the funding is a minority shareholder in ATHI.

 

The Company made weekly cash payments of $2,750 totaling $24,750 on the January 19, 2023 funding. The balance outstanding at March 31, 2023 was $107,250, less unamortized discount of $26,536.

 

February 14, 2023 Funding 

On February 14, 2023, the Company, through its 75% held subsidiary, Evernia Health Center, LLC entered into a Receivables Sale Agreement with Fox Business Funding (“Fox”), whereby $118,800 of the Receivables of Evernia were sold to Fox, for gross proceeds of $90,000. The Company is obliged to pay 8.0% of the receivables until the amount of $118,800 is paid in full, with periodic repayments of $2,970 per week. The guarantor of the funding is a minority shareholder in ATHI.

 

The Company made weekly cash payments of $2,970 totaling $17,820 on the February 14, 2023 funding. The balance outstanding at March 31, 2023 was $100,980, less unamortized discount of $25,183.

 

 18

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

12. Third Party loans

 

On April 12, 2019, Eileen Greene, a related party assigned CDN$1,000,000 of the amount owed by the Company to her, to a third party. The loan bears interest at 12% per annum which the Company agreed to pay. As of March 31, 2023 the balance of principal and interest outstanding on third party loans was CDN$798,950 ($590,372).

 

13. Related party transactions

 

Shawn E. Leon

As of March 31, 2023 and December 31, 2022, the Company had a payable to Shawn Leon of $389,476 and $411,611, respectively. Mr. Leon is a director and CEO of the Company. The balances payable are non-interest bearing and has no fixed repayment terms.

 

On December 30, 2022, the Company sold its wholly owned subsidiaries, Greenestone Muskoka and ARIA, to Mr. Leon for gross proceeds of $0. The Company realized a gain on disposal of $628,567 which was recorded as an increase in Additional Paid in Capital due to the related party nature of the transaction.

 

Due to the current financial position of the Group, Mr. Leon forfeited the management fees due to him for the three months ended March 31, 2023 and the year ended December 31, 2022.

 

Leon Developments, Ltd.

As of March 31, 2023 and December 31, 2022, the Company owed Leon Developments, Ltd., $851,672 and $850,607, respectively, for funds advanced to the Company.

 

Eileen Greene

As of March 31, 2023 and December 31, 2022, the Company owed Eileen Greene, the spouse of our CEO, Shawn Leon, $1,414,828 and $1,451,610, respectively. The amount owed to Ms. Greene is non-interest bearing and has no fixed repayment terms.

 

All related party transactions occur in the normal course of operations and in terms of agreements entered into between the parties.

   

14. Stockholder’s deficit

 

  a) Common shares

 

Authorized and outstanding 

The Company has authorized 10,000,000,000 shares with a par value of $0.01 per share. The company has issued 3,729,053,805 shares of common stock at March 31, 2023 and December 31, 2022.

 

  b) Series A Preferred shares

 

Authorized, issued and outstanding 

The Company has authorized 10,000,000 Series A preferred shares with a par value of $0.01 per share. The company has issued and outstanding 4,000,000 Series A Preferred shares at March 31, 2023 and December 31, 2022.

 

  c) Series B Preferred shares

 

Authorized and outstanding 

The Company has authorized 400,000 Series B preferred shares with a par value of $1.00 per share. The company has issued and outstanding 400,000 Series B Preferred shares at March 31, 2023 and December 31, 2022.

 

The Series B preferred shares are senior secured and were mandatorily redeemable by the Company on July 1, 2021, and were originally classified as mezzanine debt. These Series B preferred shares have been reclassified as current liabilities for the three months ended March 31, 2023 as they meet the definition of liabilities in terms of ASC 480- debt and are no longer contingently convertible, due to the fact that the redemption date has passed and the Company is currently negotiating with the preferred note holders to settle the total liabilities owing to them, including certain convertible notes. The Company continues to accrue dividends at the rate of 6% per annum.

  

 19

 

 

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 
14. Stockholder’s deficit (continued)

 

  d) Stock options

 

Our board of directors adopted the Greenstone Healthcare Corporation 2013 Stock Option Plan (the “Plan”) to promote our long-term growth and profitability by (i) providing our key directors, officers and employees with incentives to improve stockholder value and contribute to our growth and financial success and (ii) enable us to attract, retain and reward the best available persons for positions of substantial responsibility. A total of 10,000,000 shares of our common stock have been reserved for issuance upon exercise of options granted pursuant to the Plan. The Plan allows us to grant options to our employees, officers and directors and those of our subsidiaries; provided that only our employees and those of our subsidiaries may receive incentive stock options under the Plan. We have no issued options at March 31, 2023 under the Plan.

 

  e) Warrants

 

All of the warrants have cashless exercise terms whereby in-the-money warrants may be exercised by reducing the number of shares issued in terms of the warrant exercise to offset the proceeds due on the exercise.

 

All of the warrants have price protection features whereby any securities issued subsequent to the date of the warrant issuance date, were issued at a lower price, or have conversion features that are lower than the current exercise price, or were converted at a lower price, or are exercisable at a lower price, to the current warrant exercise price, will result in the exercise price of the warrant being set to the lower issue, conversion or exercise price.

  

A summary of the Company’s warrant activity during the period from January 1, 2022 to March 31, 2023 is as follows:

 

    No. of shares   Exercise price
per share		   Weighted
average exercise
price
             
Outstanding as of January 1, 2022     623,777,506       $0.000675 to $0.12     $ 0.0052875  
Granted     —         —         —    
Forfeited/cancelled     (20,925,000 )     $0.12       0.12  
Exercised     —         —         —    
Outstanding as of December 31, 2022     602,852,506       $0.000675 to $0.00205     $ 0.001306  
Granted     —         —         —    
Forfeited/cancelled     —         —         —    
Exercised     —         —         —    
Outstanding as of March 31, 2023     602,852,506       $0.000675 to $0.00205     $ 0.001306  

   

  

The following table summarizes information about warrants outstanding at March 31, 2023:

 

      Warrants outstanding     Warrants exercisable  
Exercise price     No. of shares    

Weighted average

remaining years

    

Weighted average

exercise price

     No. of shares    

Weighted average

exercise price

  
                                 
$0.000675       326,286,847       2.28               326,286,847          
$0.002050       276,565,659       2.77               276,565,659          
        602,852,506       2.51     $ 0.001306       602,852,506     $ 0.001306  

 

All of the warrants outstanding at March 31, 2023 are vested. The warrants outstanding at March 31, 2023 have an intrinsic value of $0. 

 

 20

 

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

15. Segment information

 

The Company has two reportable operating segments:

 

  a. Rental income from the property owned by CCH subsidiary located at 3571 Muskoka Road, #169, Bala, on which the operations of the Canadian Rehab Clinic were located prior to disposal on February 14, 2017 and subsequently leased to the purchasers of the business of the Canadian Rehab Clinic, for a period of 5 years renewable for a further three five-year periods and with an option to acquire the property at a fixed price.

 

  b. Rehabilitation Services provided to customers, these services were provided to customers at our Evernia, Addiction Recovery Institute of America and Seastone of Delray operations.

 

The segment operating results of the reportable segments for the three months ended March 31, 2023 is disclosed as follows:

 

                      
   Three months ended March 31, 2023
   Rental
Operations		  In-Patient
services		  Total
          
Revenue  $89,419   $1,210,627   $1,300,046 
Operating expenses   30,120    1,194,900    1,225,020 
                
Operating income   59,299    15,727    75,026 
                
Other (expense) income               
Interest expense   (47,733)   (109,363)   (157,096)
Amortization of debt discount   —      (76,921)   (76,921)
Foreign exchange movements   (1,035)   (1,920)   (2,955)
Net income (loss) before taxes   10,531    (172,477)   (161,946)
Taxes   —      (13,771)   (13,771)
Net income (loss)  $10,531   $(186,248)  $(175,717)

 

The operating assets and liabilities of the reportable segments as of March 31, 2023 is as follows:

 

                      
   March 31, 2023
   Rental
Operations		  In-Patient
services		  Total
          
Purchase of fixed assets  $—     $52,418   $52,418 
Assets               
Current assets   233    689,431    689,664 
Non-current assets   2,441,143    3,474,998    5,916,141 
Liabilities               
Current liabilities   (4,985,120)   (9,083,220)   (14,068,340)
Non-current liabilities   (619,856)   (1,350,792)   (1,970,648)
Intercompany balances   (1,299,110)   1,299,110    —   
Net liability position  $(4,462,710)  $(4,970,473)  $(9,433,183)

 

 21

 

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 
15. Segment information (continued)

 

The segment operating results of the reportable segments for the three months ended March 31, 2022 is disclosed as follows:

                      
   Three months ended March 31, 2022
   Rental
Operations		  In-Patient
services		  Total
          
Revenue  $93,874   $929,441   $1,023,315 
Operating expenses   (33,316)   (915,059)   (948,375)
                
Operating income   60,558    14,382    74,940 
                
Other (expense) income               
Other income   —      10,018    10,018 
Interest expense   (53,607)   (27,161)   (80,768)
Amortization of debt discount   —      (252,832)   (252,832)
Derivative liability movement   —      197,476    197,476 
Foreign exchange movements   (21,829)   (73,727)   (95,556)
Net loss before taxes   (14,878)   (131,844)   (146,722)
Taxes   —      (18,263)   (18,263)
Net loss  $(14,878)  $(150,107)  $(164,985)

 

The operating assets and liabilities of the reportable segments as of March 31, 2022 is as follows:

 

                      
   March 31, 2022
   Rental
Operations		  In-Patient
services		  Total
          
Purchase of fixed assets  $—     $72,858   $72,858 
Assets               
Current assets   551    355,167    355,718 
Non-current assets   2,773,914    3,426,324    6,200,238 
Liabilities               
Current liabilities   (1,590,715)   (12,078,894)   (13,669,609)
Non-current liabilities   (636,577)   (1,710,232)   (2,346,809)
Mandatory redeemable preferred shares   —      (400,000)   (400,000)
Intercompany balances   1,238,399    (1,238,399)   —   
Net liability position  $1,785,572   $(11,646,034)  $(9,860,462)

 

16. Net income (loss) per common share

 

For the three months ended March 31, 2023 and 2022, the following warrants and convertible securities were excluded from the computation of diluted net loss per share as the results would have been anti-dilutive.

 

   Three months ended
March 31,
2023		  Three months ended
March 31,
2022
       
Warrants to purchase shares of common stock   602,852,506    611,140,006 
Convertible notes   582,290,570    458,435,448 
    1,185,143,076    1,069,575,454 

 

 22

 

ETHEMA HEALTH CORPORATION

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

17. Commitments and contingencies

 

  a. Options granted to purchase shares in ATHI

 

On July 12, 2020, the Company entered into a five year option agreement with Leonite Capital LLC (“Leonite”) and other investors (collectively the “Transferees”). The Company agreed to sell to Leonite a portion of the total outstanding shares of ATHI from the shares of ATHI held by the company. The Company provided Leonite an option to purchase 4,000,000 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $400), based on the advances that Leonite made to the Company totaling $396,000. Leonite shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Leonite to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.

 

On September 14, 2020, the Company entered into a five year option agreement with Ed Blasiak (“Blasiak”) whereby the Company agreed to sell to Blasiak a portion of the total outstanding shares of ATHI. The Company provided Blasiak an option to purchase 571,428 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $57), based on the advances that Blasiak made to the Company totaling $50,000. Blasiak shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Blasiak to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.

 

On October 29, 2020, the Company entered into a five year option agreement with First Fire whereby the Company agreed to sell to First Fire a portion of the total outstanding shares of ATHI. The Company provided First Fire an option to purchase 1,428,571 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $143), based on the advances that First Fire made to the Company totaling $120,000. First Fire shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by First Fire to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.

 

On October 29, 2020, the Company entered into a five year option agreement entered into with Bauman, so that the Company agreed to sell to Bauman a portion of the total outstanding shares of ATHI. The Company provided Bauman an option to purchase 1,428,571 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $143), based on the advances that Bauman made to the Company totaling $120,000. Bauman shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Bauman to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.

 

  b. Mortgage loans

 

The company has a mortgage loan as disclosed in note 9 above. The mortgage loan matured on July 19, 2022 and the Company currently owes $3,478,130. The terms of the loan are currently being negotiated.

 

  c. Other

 

The Company has principal and interest payment commitments under the Convertible notes disclosed under Note 7 above. Conversion of these notes are at the option of the investor, if not converted these notes may need to be repaid.

 

From time to time, the Company and its subsidiaries enter into legal disputes in the ordinary course of business. The Company believes there are no material legal or administrative matters pending that are likely to have, individually or in the aggregate, a material adverse effect on its business or results of operations.

    

18. Subsequent events

 

The Company has evaluated subsequent events through the date of the condensed consolidated financial statements were issued, we did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

  

 

 23

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis is intended as a review of significant factors affecting our financial condition and results of operations for the periods indicated. The discussion should be read in conjunction with our condensed consolidated financial statements and the notes presented herein and the consolidated financial statements and the other information set forth in our Annual Report on Form 10- K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 31, 2023. In addition to historical information, the following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ significantly from those anticipated in these forward-looking statements as a result of certain factors discussed herein and any other periodic reports filed and to be filed with the Securities and Exchange Commission.

 

Plan of Operation

 

During the next twelve months, the Company plans to continue to grow the Evernia business.

 

For the three months ended March 31, 2023 and March 31, 2022.

 

Revenues

 

Revenues were $1,300,046 and $1,023,315 for the three months ended March 31, 2023 and 2022, respectively, an increase of $276,731 or 27.0%. The revenue from in-patient services related to Evernia was $1,210,627 and $929,441 for the three months ended March 31, 2023 and 2022, respectively. The increase is due to the expansion of the Evernia facility during the prior year. The revenue from rental properties was $89,419 and $93,874 and included the rental escalation as per the agreement and an improvement in the currency exchange rate against the Canadian Dollar over the prior period.

 

Operating Expenses

 

Operating expenses were $1,225,020 and $948,375 for the three months ended March 31, 2023 and 2022, respectively, an increase of $328,661 or 34.7%. The increase is primarily due to the following:

 

● General and administrative expenses was $241,238 and 209,932 for the three months ended March 31, 2023 and 2022, respectively, an increase of $31,306 or 14.9%. The increase is primarily due to the increase in activity at the Evernia treatment facility with an increase in bed count and revenues requiring additional increases in operating expenditure. The increase consist of an increase in several individually insignificant amounts.

     

● Rent expense was $114,564 and $90,031 for the three months ended March 31, 2023 and 2022, respectively, an increase of $24,533 or 27.2%. The increase is due to additional property rented on short term leases to accommodate additional patients.

     

● Management fees were $27,500 and $30,000 for the three months ended March 31, 2023 and 2022,  respectively, a decrease of $2,500 or 8.3%.

 

● Professional fees was $111,204 and $49,587 for the three months ended March 31, 2023 and 2022, respectively, an increase of $61,617 or 124.3%. The increase is due to additional contractor expense to facilitate the increase in additional patients and additional revenues

     

● Salaries and wages was $592,036 and $436,825 for the three months ended March 31, 2023 and 2022, respectively, an increase of $155,211 or 35.5%. The increase is due the expansion of the Evernia facility which resulted in additional patients and revenues.

    

● Depreciation expense was $138,479 and $132,000 for the three months ended March 31, 2023 and 2022, respectively, an  increase of $6,479 or 4.9%, primarily due to the expansion of the Evernia facility.

 

Operating Income

 

The operating income was $75,026 and $74,940 for the three months ended March 31, 2023 and 2022, respectively, an increase of $86 or 0.1%. The increase in revenues of $276,731 was offset by the increase in operating expenses of $328,667 as discussed under revenue and operating expenses above.

 

 24

 

 

Other income

Other income was $0 and $10,018 for the three months ended March 31, 2023 and 2022, an increase of $10,018 or 100%.

 

Interest expense

 

Interest expense was $157,096 and $80,768 for the three months ended March 31, 2023 and 2022, respectively, an increase of $76,328 or 94.5%, primarily due to penalty interest rates incurred on convertible notes and short term notes which had matured during previous periods.

 

Amortization of debt discount

 

Amortization of debt discount was $76,921 and $252,832 for the three months ended March 31, 2022 and 2021, respectively, a decrease of $175,911 or 69.6%. In the prior year the conversion of convertible debt resulted in the acceleration of the amortization of debt discount. In the current period amortization of debt discount related to short -term receivables funding.

 

Derivative liability movement

 

The derivative liability movement was $0 and $197,476 for the three months ended March 31, 2023 and 2022, respectively. The derivative liability movement represents the mark to market movements of variably priced convertible notes and warrants issued during the current and prior comparative period. The decrease in the mark to market movement of $197,476, using a Black-Scholes valuation model with a calculated stock price ranging from $0.0006 to $0.0010 per share, a risk free interest rate of $0.06% to 2.45% and expected lives of convertible notes and warrants of 3 to 39 months, with an expected underlying volatility of 167.1% to 238.1%, with no dividends expected for the foreseeable future. The decrease in the derivative liability was primarily due to the conversion and repayment of several convertible notes during the past twelve months and an overall reduction in our stock price, impacting favorably on the mark-to-market adjustment.

 

Foreign exchange movements

 

Foreign exchange movements was $(2,955) and $(95,556) for the three months ended March 31, 2023 and 2022, respectively, representing the realized exchange gains and (losses) on monetary assets and liabilities settled during the current year as well as mark to market adjustments on monetary assets and liabilities reflected on the balance sheet and denominated in Canadian Dollars. The Dollar strengthened against the Canadian Dollar during the current period, resulting in an unrealized loss on Canadian denominated assets.

 

Taxation

 

Taxation was $13,771 and $18,263 for the three months ended March 31, 2023 and 2022, respectively, a decrease of $4,492 or 24.6%. A slight decrease in profit generated by the Evernia operations resulted in a lower tax provision.

 

Net loss

 

Net loss was $175,717 and $164,985 for the three months ended March 31, 2023 and 2022, respectively, an increase of $10,732 or 6.5%. The increase is primarily due to the increase in interest expense of $76,328, the reduction in the derivative liability movement of $197,476, the reduction in the foreign exchange movement of $92,601, offset by the reduction in amortization of debt discount of $175,911, which is fully discussed above.

 

Commitments and contingencies

 

The company has commitments under operating and finance leases as follows:

 

The amount of future minimum lease payments under finance leases as of March 31, 2023 is as follows:

 

    Amount
Remainder of 2023   $ 7,372  
2024     9,829  
2025     9,829  
2026     6,195  
2027      1,707  
       34,932  

 25

 

 

 

The amount of future minimum lease payments under operating leases are as follows:

 

    Amount
     
Remainder of 2023   $ 262,549  
2024     366,110  
2025     384,416  
2026     403,637  
2027     33,771  
Total undiscounted minimum future lease payments     1,450,483  

    

The company also has commitments under convertible loans, short term loans and mortgage loans. If the convertible loans, as disclosed in note 7, above are not converted they will need to be repaid. The short term loans disclosed in note 8 are repayable on demand and mortgage loans, disclosed on note 9 above have matured.

 

Liquidity and Capital Resources

 

Cash generated by operating activities was $105,874 and cash used in operating activities was $69,074 for the three months ended March 31, 2023 and 2022, respectively, an increase of $174,948. The increase is primarily due to the following:

 

● An increase in net loss of $10,732, as discussed under results of operations above.

     

● Offset by an increase in the movement of non-cash items of $38,461, primarily due to the movement in the amortization of debt discount of $(175,911), offset by the movement in derivative liabilities of $197,476.

     

● Working capital movements increased by $147,219, primarily due to an increase in the movement of accounts payable and accrued liabilities of $273,397 due to an advance by a realty company and an increase in the movement in accounts receivable of $36,744 and the movement in other current assets of $63,305.

 

Cash used in investing activities was $102,418 and $72,858 for the three months ended March 31, 2023 and 2022, respectively. In the current period we invested in leasehold improvements and furniture and fittings to increase capacity at our Evernia facility, and paid an additional deposit of $50,000.

 

Cash used in financing activities was $117,743 and cash provided by financing was $46,846 for the three months ended March 31, 2023 and 2022, respectively, a decrease of $164,589.

 

In the current year the Company received receivables funding of $190,000, and repaid $204,133, in addition mortgage repayments of $29,300 and repayments to related parties of $58,917 during the current period.

 

In the prior year we repaid $201,733 of convertible notes as we reduce our debt to third parties.

 

Over the next twelve months we estimate that the company will require approximately $0.5 million in working capital as it continues to develop the Evernia facility and it is also exploring several other treatment center options and sources of patients throughout the country. The company may have to raise equity or secure debt. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial condition. In the opinion of management, the Company’s liquidity risk is assessed as medium.

 

Recently Issued Accounting Pronouncements

 

The recent Accounting Pronouncements are fully disclosed in note 2 to our unaudited condensed consolidated financial statements.

 

Management does not believe that any other recently issued but not yet effective accounting pronouncements, if adopted, would have an effect on the accompanying unaudited condensed consolidated financial statements.

 

 26

 

 

Off balance sheet arrangements

 

We do not maintain off-balance sheet arrangements nor do we participate in non-exchange traded contracts requiring fair value accounting treatment.

 

Inflation 

The effect of inflation on our revenue and operating results was not significant.

 

Climate Change 

We believe that neither climate change, nor governmental regulations related to climate change, have had, or are expected to have, any material effect on our operations.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

Not applicable.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

The Company has adopted and maintains disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in the reports filed under the Exchange Act, such as this Quarterly Report on Form 10-Q, is collected, recorded, processed, summarized and reported within the time periods specified in the rules of the Securities and Exchange Commission. The Company’s disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. As required under Exchange Act Rule 13a-15, the Company’s management, including the Principal Executive Officer and the Principal Financial Officer, has conducted an evaluation of the effectiveness of disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the Company’s CEO and CFO concluded that due to a lack of segregation of duties the Company’s disclosure controls and procedures are not effective to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Subject to receipt of additional financing or revenue generated from operations, the Company intends to retain additional individuals to remedy the ineffective controls.

 

Changes in Internal Control

 

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during our fiscal quarter ended March 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 27

 

 

PART II

 

Item 1. Legal Proceedings.

 

 

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

Item 1A. Risk Factors.

 

Not applicable because we are a smaller reporting company.

 

Item 2. Unregistered sales of equity securities and use of proceeds

  

None.

 

Item 3. Defaults upon senior securities

 

None.

 

Item 4. Mine Safety Disclosures.

 

None.

 

Item 5. Other Information.

 

Not applicable.

 

 28

 

 

Item 6. Exhibits

 

Exhibit No.  Description
   
31.1 Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 302 of 2002 *
   
32.1 Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002*
   
101.INS Inline XBRL Instance Document
101.SCH  Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline Taxonomy Extension CAL XBRL Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB  Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
101 Cover Page Interactive Data File (embedded within the Inline XBRL Document)

 

* filed herewith

 29

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

ETHEMA HEALTH CORPORATION

 

Date: May 22, 2023

By:/s/ Shawn E. Leon 

Name: Shawn E. Leon 

Title: Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Name   Position   Date
         
/s/Shawn E. Leon   Chief Executive Officer (Principal Executive Officer),   May 22, 2023
Shawn Leon   Chief Financial Officer (Principal Financial Officer), President and Director    
         
/s/ John O’Bireck   Director   May 22, 2023
John O’Bireck        
         
/s/ Gerald T. Miller   Director   May 22, 2023
         

 

 30

 

 EX-31.1 2 ex31_1.htm

Exhibit 31.1

 

CERTIFICATION PURSUANT TO RULE 13a-14 OR RULE

15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Shawn E. Leon, certify that: 

 

I have reviewed this Quarterly Report on Form 10-Q of Ethema Health Corporation; 

 

1. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

  

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

  

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: May 22, 2023

 

  /s/ Shawn E. Leon
 

Chief Executive Officer and Chief Financial Officer 

(Principal Executive Officer and Principal Financial Officer)

 EX-32.1 3 ex32_1.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, 

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Ethema Health Corporation, a Colorado corporation (the “Company”), on Form 10-Q for the three months ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Shawn E. Leon, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to Section 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: 

 

  (1) The Report fully complies with the requirements of Section 13(a) and 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  /s/ Shawn E. Leon
 

Chief Executive Officer and Chief Financial Officer 

(Principal Executive Officer and Principal Financial Officer)

  May 22, 2023

 

 

 

 

 EX-101.SCH 4 grst-20230331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Going concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Property and equipment link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Intangibles link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Short-term Convertible Notes link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Short-term Notes link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Mortgage loans link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Government assistance loans link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Receivables funding link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Third Party loans link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Related party transactions link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Stockholder’s deficit link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Segment information link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Net income (loss) per common share link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Property and equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Intangibles (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Short-term Convertible Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Mortgage loans (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stockholder’s deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Segment information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Net income (loss) per common share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Summary of significant accounting policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Property and equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Property and equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Intangibles (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Leases (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Leases (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Leases (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Leases (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Short-term Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Mortgage loans (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Stockholders deficit (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Stockholders deficit (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Net income (loss) per common share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 grst-20230331_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 grst-20230331_def.xml XBRL DEFINITION FILE EX-101.LAB 7 grst-20230331_lab.xml XBRL LABEL FILE Class of Stock [Axis] Redeemable B Preferred Stock [Member] Redeemable Preferred Stock [Member] Redeemable A Preferred Stock [Member] Preferred Class A [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Discount In Par Value [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Long-Lived Tangible Asset [Axis] Land [Member] Property, Plant and Equipment [Member] Leasehold Improvements [Member] Furniture and Fixtures [Member] Vehicles [Member] Computer Equipment [Member] Debt Instrument [Axis] Leonite Capital L L C [Member] Leonite Fund I L P [Member] Auctus Fund L L C [Member] Labrys Fund L P [Member] Ed Blasiak [Member] Joshua Bauman [Member] Series N Convertible Notes [Member] Series N Convertible [Member] Cranberry Cove Holdings Ltd [Member] Exercise Price Range [Axis] Excercise 1 [Member] Excercise 2 [Member] Segments [Axis] In Patient Services [Member] Total [Member] Rental Operations [Member] Antidilutive Securities [Axis] Warrants [Member] Convertible Note [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS Current assets Cash Accounts receivable, net Prepaid expenses Other current assets Total current assets Non-current assets Property and equipment Intangible assets, net Right of use assets Deposits paid Total non-current assets Total assets Current liabilities Accounts payable and accrued liabilities Taxes payable Convertible notes, net of discounts Short-term notes Mortgage loans Receivables funding Government assistance loans Operating lease liability Finance lease liability Preferred stock - Series A; $0.01 par value, 10,000,000 shares authorized; 4,000,000 shares outstanding as of March 31, 2023 and December 31, 2022. Accrued dividends Related party payables Total current liabilities Non-current liabilities Government assistance loans Deferred taxation Third party loans Operating lease liability Finance lease liability Total non-current liabilities Total liabilities Common stock - $0.01 par value, 10,000,000,000 shares authorized;  3,729,053,805 shares issued and outstanding as of March 31, 2023 and December 31, 2022. Additional paid-in capital Discount for shares issued below par value Accumulated other comprehensive loss Accumulated deficit Stockholders’ deficit attributable to Ethema Health Corporation stockholders’ Non-controlling interest Total stockholders’ deficit Total liabilities and stockholders’ deficit Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Outstanding Preferred Stock, Shares Issued Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Income Statement [Abstract] Revenues Operating expenses General and administrative Rent expense Management fees Professional fees Salaries and wages Depreciation expense Total operating expenses Operating Income Other (expense) income Other income Interest expense Amortization of debt discount Derivative liability movement Foreign exchange movements Loss before taxation Taxation Consolidated Net loss Net income attributable to non-controlling interest Net loss attributable to Ethema Health Corporation Stockholders’ Preferred stock dividend Net loss available to common shareholders of Ethema Health Corporation Accumulated other comprehensive (loss) income Foreign currency translation adjustment Total comprehensive loss Basic and diluted loss per common share Weighted average common shares outstanding – Basic and diluted Beginning balance, value Shares, Outstanding, Beginning Balance Foreign currency translation Net loss Dividends accrued Conversion of convertible notes Stock Issued During Period, Shares, Conversion of Units Ending balance, value Shares, Outstanding, Ending Balance Statement of Cash Flows [Abstract] Operating activities Consolidated net loss Adjustment to reconcile consolidated net loss to net cash provided by (used in) operating activities: Depreciation and amortization expense Amortization of debt discount Derivative liability movements Amortization of right of use asset Deferred taxation movement Changes in operating assets and liabilities Accounts receivable Prepaid expenses Other current assets Accounts payable and accrued liabilities Operating lease liabilities Taxes payable Net cash provided by (used in) operating activities Investing activities Deposits paid Purchase of property and equipment Net cash used in investing activities Financing activities Repayment of mortgage Proceeds from receivables funding Repayment of receivables funding Repayment of convertible notes Proceeds from promissory notes Repayment of government assistance loans Repayment of third party loans Repayment of finance leases Proceeds from related party notes Repayment of related party notes Net cash (used in) provided by financing activities Effect of exchange rate on cash Net change in cash Beginning cash balance Ending cash balance Supplemental cash flow information Cash paid for interest Cash paid for income taxes Non-cash investing and financing activities Conversion of convertible notes Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of business Accounting Policies [Abstract] Summary of significant accounting policies Going concern Property, Plant and Equipment [Abstract] Property and equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangibles Leases Leases Debt Disclosure [Abstract] Short-term Convertible Notes Short-term Notes Mortgage Loans Mortgage loans Government Assistance Loans Government assistance loans Receivables Funding Receivables funding Third Party Loans Third Party loans Related Party Transactions [Abstract] Related party transactions Equity [Abstract] Stockholder’s deficit Segment Information Segment information Earnings Per Share [Abstract] Net income (loss) per common share Commitments and Contingencies Disclosure [Abstract] Commitments and contingencies Subsequent Events [Abstract] Subsequent events Use of Estimates Principals of consolidation and foreign currency translation Business Combinations Cash and cash equivalents Accounts receivable Allowance for Doubtful Accounts, Contractual and Other Discounts Property and equipment Intangible assets Leases Derivatives Financial instruments Related parties Revenue recognition Income taxes Net income (loss) per Share Stock based compensation Financial instruments risks Allowance for credit losses Recent accounting pronouncements Schedule of sale of property Schedule of Intangible assets Schedule of Right of use assets Schedule of finance and operating lease Schedule of Other lease Schedule of Finance lease liability Schedule of Operating lease liability Schedule of short-term convertible notes Schedule of mortgage loans Schedule of warrants outstanding Schedule of assumption Schedule of segment information Schedule of Antidilutive Securities Federal Deposit Insurance Receivables Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Net Depreciation expense Useful life Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Net amortization expense Right-of-use assets – finance leases, net of depreciation, included in Property and equipment Right-of-use assets - operating leases, net of amortization Amortization of right-of-use assets Interest expense on finance lease liabilities   Operating lease cost Lease cost Operating cash flows from finance leases Operating cash flows from operating leases Financing cash flows from finance leases Net Change in leases [custom:WeightedAverageLeaseTermFinanceLeasesTerm] [custom:WeightedAverageRemainingLeaseTermOperatingLeases] [custom:DiscountRateFinanceLeases] [custom:DiscountRateOperatingLeases] Remainder of 2023 2024 2025 2026 2027   Imputed interest Lease liability Current portion Non-Current portion Remainder of 2023 2024 2025 2026 2027 Total undiscounted minimum future lease payments Imputed interest Total operating lease liability Current portion Non-Current portion  Lease liability Derived rental income Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Short-Term Debt, Interest Rate Increase Maturity Date Principal amount Interest short-term convertible Debt Instrument, Interest Rate, Stated Percentage Principal Amount Outstanding on Loans Securitized or Asset-Backed Financing Arrangement Debt Instrument, Increase, Accrued Interest Loans Payable Loans Payable, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] [custom:WarrantsOutstanding] [custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm] Warrants exercisable Weighted average exercise price [custom:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable] Revenue Operating expenses Operating income Interest expense Amortization of debt discount Foreign exchange movements Net loss before taxes Taxes Net loss Purchase of fixed assets Current assets Non-current assets Current liabilities Non-current liabilities Intercompany balances Net liability position Revenue Operating income Other (expense) income Derivative liability movement Non-current liabilities Mandatory redeemable preferred shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Assets, Current Assets, Noncurrent Assets Liabilities, Current GovernmentAssistanceLoansNonCurrent Operating Lease, Liability, Noncurrent Liabilities, Noncurrent Liabilities Common Stock, Discount on Shares Operating Expenses Interest Expense, Debt, Excluding Amortization Derivative, Gain (Loss) on Derivative, Net Dividends, Preferred Stock Deferred Policy Acquisition Cost, Foreign Currency Translation Adjustment and Other Shares, Outstanding Stock Issued During Period, Value, Dividend Reinvestment Plan Amortization of Other Deferred Charges Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense Increase (Decrease) in Other Current Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accrued Taxes Payable Payments for Deposits Payments to Acquire Productive Assets Net Cash Provided by (Used in) Investing Activities Repayments of First Mortgage Bond Repayments of Accounts Receivable Securitization Repayments of Convertible Debt Repayments of Other Debt Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents ConversionOfConvertibleNotes Property, Plant and Equipment Disclosure [Text Block] Lessee, Operating Leases [Text Block] MortgageLoansTextBlock GovernmentAssistanceLoansTextBlock ReceivablesFundingTextBlock Property, Plant and Equipment, Policy [Policy Text Block] Lessee, Leases [Policy Text Block] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Depreciation Finite-Lived Intangible Assets, Accumulated Amortization TotalUndiscountedMinimumFutureLeasePayment Purchase Obligation, to be Paid, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Four Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Costs and Expenses Interest Expense Amortization of Debt Issuance Costs and Discounts ForeignExchangeMovementsOne NetIncomeLossOne OperatingAssetsAndLiabilities Other Liabilities, Noncurrent EX-101.PRE 8 grst-20230331_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
 3 Months Ended
Mar. 31, 2023
May 19, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2023  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 000-54748  
Entity Registrant Name ETHEMA HEALTH CORPORATION.  
Entity Central Index Key 0000792935  
Entity Tax Identification Number 84-1227328  
Entity Incorporation, State or Country Code CO  
Entity Address, Address Line One 950 Evernia Street  
Entity Address, City or Town West Palm Beach  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33401  
City Area Code (416)  
Local Phone Number 500-0020  
Title of 12(b) Security Common shares  
Trading Symbol GRST  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   3,729,053,805
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Current assets    
Cash $ 27,580 $ 140,757
Accounts receivable, net 543,119 337,074
Prepaid expenses 34,142 44,718
Other current assets 84,823 20,347
Total current assets 689,664 542,896
Non-current assets    
Property and equipment 2,979,853 2,974,395
Intangible assets, net 1,163,437 1,252,932
Right of use assets 1,322,851 1,393,071
Deposits paid 450,000 400,000
Total non-current assets 5,916,141 6,020,398
Total assets 6,605,805 6,563,294
Current liabilities    
Accounts payable and accrued liabilities 372,830 170,934
Taxes payable 282,878 248,644
Convertible notes, net of discounts 5,351,270 5,269,250
Short-term notes 496,923 460,534
Mortgage loans 3,478,130 3,504,605
Receivables funding 443,459 416,731
Government assistance loans 61,473 14,818
Operating lease liability 299,027 287,017
Finance lease liability 8,017 7,891
Accrued dividends 218,357 194,829
Related party payables 2,655,976 2,713,878
Total current liabilities 14,068,340 13,289,131
Non-current liabilities    
Government assistance loans 29,484 79,555
Deferred taxation 201,919 217,451
Third party loans 590,372 578,335
Operating lease liability 1,125,990 1,206,413
Finance lease liability 22,883 24,952
Total non-current liabilities 1,970,648 2,106,706
Total liabilities 16,038,988 15,395,837
Common stock - $0.01 par value, 10,000,000,000 shares authorized;  3,729,053,805 shares issued and outstanding as of March 31, 2023 and December 31, 2022. 37,290,539 37,290,539
Additional paid-in capital 23,419,917 23,419,917
Discount for shares issued below par value (27,363,367) (27,363,367)
Accumulated other comprehensive loss (6,569) (5,065)
Accumulated deficit (43,686,855) (43,484,751)
Stockholders’ deficit attributable to Ethema Health Corporation stockholders’ (10,306,335) (10,102,727)
Non-controlling interest 873,152 870,184
Total stockholders’ deficit (9,433,183) (9,232,543)
Total liabilities and stockholders’ deficit 6,605,805 6,563,294
Redeemable B Preferred Stock [Member]    
Current liabilities    
Preferred stock - Series A; $0.01 par value, 10,000,000 shares authorized; 4,000,000 shares outstanding as of March 31, 2023 and December 31, 2022. 400,000
Redeemable Preferred Stock [Member]    
Current liabilities    
Preferred stock - Series A; $0.01 par value, 10,000,000 shares authorized; 4,000,000 shares outstanding as of March 31, 2023 and December 31, 2022. 400,000
Redeemable A Preferred Stock [Member]    
Current liabilities    
Preferred stock - Series A; $0.01 par value, 10,000,000 shares authorized; 4,000,000 shares outstanding as of March 31, 2023 and December 31, 2022. $ 40,000 $ 40,000
XML 11 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Common Stock, Par or Stated Value Per Share   $ 0.01
Common Stock, Shares Authorized   10,000,000,000
Common Stock, Shares, Issued   3,729,053,805
Redeemable Preferred Stock [Member]    
Preferred Stock, Par or Stated Value Per Share $ 1.00 $ 1.00
Preferred Stock, Shares Authorized 10,000,000 10,000,000
Preferred Stock, Shares Outstanding 400,000 400,000
Redeemable A Preferred Stock [Member]    
Preferred Stock, Par or Stated Value Per Share   $ 0.01
Preferred Stock, Shares Authorized   10,000,000
Preferred Stock, Shares Issued   4,000,000
XML 12 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenues $ 1,300,046 $ 1,023,315
Operating expenses    
General and administrative 241,237 209,932
Rent expense 114,564 90,031
Management fees 27,500 30,000
Professional fees 111,204 49,587
Salaries and wages 592,036 436,825
Depreciation expense 138,479 132,000
Total operating expenses 1,225,020 948,375
Operating Income 75,026 74,940
Other (expense) income    
Other income 10,018
Interest expense (157,096) (80,768)
Amortization of debt discount (76,921) (252,832)
Derivative liability movement 197,476
Foreign exchange movements (2,955) (95,556)
Loss before taxation (161,946) (146,722)
Taxation (13,771) (18,263)
Consolidated Net loss (175,717) (164,985)
Net income attributable to non-controlling interest (2,968) (9,462)
Net loss attributable to Ethema Health Corporation Stockholders’ (178,685) (174,447)
Preferred stock dividend (23,419) (24,613)
Net loss available to common shareholders of Ethema Health Corporation (202,104) (199,060)
Accumulated other comprehensive (loss) income    
Foreign currency translation adjustment (1,504) 34,517
Total comprehensive loss $ (203,608) $ (164,543)
Basic and diluted loss per common share $ (0.00) $ (0.00)
Weighted average common shares outstanding – Basic and diluted 3,729,053,805 3,630,720,472
XML 13 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT - USD ($)
Preferred Class A [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Discount In Par Value [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Dec. 31, 2021 $ 40,000 $ 3,570,539 $ 22,791,350 $ (26,013,367) $ 816,532 $ (44,103,311) $ 822,876 $ (9,855,381)
Shares, Outstanding, Beginning Balance at Dec. 31, 2021 4,000,000 3,579,053,805            
Foreign currency translation 34,517 34,517
Net loss   (174,447) 9,462 (164,985)
Dividends accrued (24,613) (24,613)
Conversion of convertible notes $ 1,500,000 (1,350,000) 150,000
Stock Issued During Period, Shares, Conversion of Units   150,000,000            
Ending balance, value at Mar. 31, 2022 $ 40,000 $ 37,290,539 22,791,350 (27,363,367) 851,049 (44,302,371) 832,338 (9,860,462)
Shares, Outstanding, Ending Balance at Mar. 31, 2022 4,000,000 3,729,053,805            
Beginning balance, value at Dec. 31, 2022 $ 40,000 $ 37,290,539 23,419,917 (27,363,367) (5,065) (43,484,751) 870,184 (9,232,543)
Shares, Outstanding, Beginning Balance at Dec. 31, 2022 4,000,000 3,729,053,805            
Foreign currency translation (1,504) (1,504)
Net loss   (178,685) 2,968 (175,717)
Dividends accrued (23,419) (23,419)
Ending balance, value at Mar. 31, 2023 $ 40,000 $ 37,290,539 $ 234,199,117 $ (27,363,367) $ (6,569) $ (43,686,855) $ 873,152 $ (9,433,183)
Shares, Outstanding, Ending Balance at Mar. 31, 2023 4,000,000 3,729,053,805            
XML 14 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating activities    
Consolidated net loss $ (175,717) $ (164,985)
Adjustment to reconcile consolidated net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization expense 138,479 132,000
Amortization of debt discount 76,921 252,832
Derivative liability movements (197,476)
Amortization of right of use asset 70,219 63,064
Deferred taxation movement (15,532) (18,794)
Changes in operating assets and liabilities    
Accounts receivable (151,744) (115,000)
Prepaid expenses 10,576 10,456
Other current assets (64,476) (1,171)
Accounts payable and accrued liabilities 251,384 (22,013)
Operating lease liabilities (68,413) (57,156)
Taxes payable 34,177 49,169
Net cash provided by (used in) operating activities 105,874 (69,074)
Investing activities    
Deposits paid (50,000)
Purchase of property and equipment (52,418) (72,858)
Net cash used in investing activities (102,418) (72,858)
Financing activities    
Repayment of mortgage (29,300) (29,850)
Proceeds from receivables funding 190,000
Repayment of receivables funding (204,133)
Repayment of convertible notes (10,000) (201,733)
Proceeds from promissory notes 100,000
Repayment of government assistance loans (3,449)
Repayment of third party loans (78,977)
Repayment of finance leases (1,944) (1,822)
Proceeds from related party notes 259,228
Repayment of related party notes (58,917)
Net cash (used in) provided by financing activities (117,743) 46,846
Effect of exchange rate on cash 1,110 73,288
Net change in cash (113,177) (21,798)
Beginning cash balance 140,757 48,822
Ending cash balance 27,580 27,024
Supplemental cash flow information    
Cash paid for interest 53,310 43,304
Cash paid for income taxes
Non-cash investing and financing activities    
Conversion of convertible notes $ 150,000
XML 15 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Nature of business
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of business

1. Nature of business

 

Since 2010, the Company has operated addiction treatment centers. Initially the Company operated an addiction treatment center in Ontario Canada under its Greenestone Muskoka clinic, which was sold on February 14, 2017. Simultaneously with this sale the Company purchased buildings and operated an addiction treatment center in Delray Beach Florida under its Addiction Recovery Institute of America subsidiary with a license obtained in December 2016, initially through owned properties in Delray Beach and subsequently though leased properties in West Palm Beach, Florida. Since June 30, 2020, the Company has been actively involved in the management of a treatment center operated by Evernia in West Palm Beach, Florida. On July 1, 2021, the Company closed on the acquisition of 75% of ATHI, which owns 100% of Evernia, once the probationary approval of a license was obtained from the Department of Children and Family Services of Florida. Evernia is the only active treatment center operated by the Company.

 

The Company also owns the real estate on which its Greenstone Muskoka clinic operated. The current tenant operates an addiction treatment center on these premises. The Company collects rent on this property, which is treated as a separate business segment. 

     
XML 16 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Summary of significant accounting policies

2. Summary of significant accounting policies

 

 Financial Reporting

 

The (a) unaudited condensed consolidated balance sheets as of March 31, 2023, which have been derived from the unaudited condensed consolidated financial statements, and as of December 31, 2022, which have been derived from audited consolidated financial statements, and (b) the unaudited condensed consolidated statements of operations, stockholders’ deficit and cash flows of the Company, have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of results that may be expected for the year ending December 31, 2023. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023.

 

All amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.

 

a) Use of Estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

 

b) Principals of consolidation and foreign currency translation

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and all of its subsidiaries. All intercompany transactions and balances have been eliminated on consolidation.

 

Certain of the Company’s subsidiaries functional currency is the Canadian dollar, while the Company’s reporting currency is the U.S. dollar. All transactions initiated in Canadian dollars are translated into US dollars in accordance with ASC 830, “Foreign Currency Translation” as follows:

 

  ● Monetary assets and liabilities at the rate of exchange in effect at the balance sheet date.

 

  ● Certain non-monetary assets and liabilities and equity at historical rates.

 

  ● Revenue and expense items and cash flows at the average rate of exchange prevailing during the year.

 

 Adjustments arising from such translations are deferred until realization and are included as a separate component of stockholders’ deficit as a component of accumulated other comprehensive income or loss. Therefore, translation adjustments are not included in determining net income (loss) but reported as other comprehensive income (loss).

 

 

For foreign currency transactions, the Company translates these amounts to the Company’s functional currency at the exchange rate effective on the invoice date. If the exchange rate changes between the time of purchase and the time actual payment is made, a foreign exchange transaction gain or loss results which is included in determining net income for the year.

 

The relevant translation rates are as follows: For the three months ended March 31, 2023, a closing rate of CDN$1 equals US$0.7389 and an average exchange rate of CDN$1 equals US$0.7394, for the year ended December 31, 2022, a closing rate of CDN$1.0000 equals US$0.7383 and an average exchange rate of CDN$1.0000 equals US$0.7686.

 

c) Business Combinations

 

The Company allocates the fair value of purchase consideration to the tangible and intangible assets acquired and liabilities assumed for business combinations with third parties based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill.

 

Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired users, acquired technology, and trade names from a market participant perspective, useful lives and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates.

 

 

d) Cash and cash equivalents

 

For purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with several financial institution in the USA and Canada. There were no cash equivalents at

March 31, 2023 and December 31, 2022.

 

The Company primarily places cash balances in the USA with high-credit quality financial institutions located in the United States which are insured by the Federal Deposit Insurance Corporation up to a limit of $250,000 per institution, in Canada which are insured by the Canadian Deposit Insurance Corporation up to a limit of CDN$100,000 per institution.

 

e) Accounts receivable

 

Accounts receivable primarily consists of amounts due from third-party payors (non-governmental) and private pay patients and is recorded net of allowances for doubtful accounts and contractual discounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s unaudited condensed consolidated financial statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimating net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies denying claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients.

 

 

 

f) Allowance for Doubtful Accounts, Contractual and Other Discounts

  

The Company derives the majority of its revenues from commercial payors at in-network rates. Management estimates the allowance for contractual and other discounts based on its historical collection experience and contractual rates. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account is written off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.

 

g) Property and equipment

  

Property and equipment is recorded at cost. Depreciation is calculated on the straight line basis over the estimated life of the asset.

 

h) Intangible assets

 

Intangible assets are stated at acquisition cost less accumulated amortization, if applicable, less any adjustments for impairment losses.

 

Amortization is charged on a straight-line basis over the estimated remaining useful lives of the individual intangibles. Where intangibles are deemed to be impaired the Company recognizes an impairment loss measured as the difference between the estimated fair value of the intangible and its book value.

 

Licenses to provide substance abuse rehabilitation services are amortized over the expected life of the contract, including any anticipated renewals. The Company expects its licenses to remain in operation for a period of five years.

   

i) Leases

 

 The Company accounts for leases in terms of AC 842 whereby leases are classified as either finance or operating leases. Leases that transfer substantially all of the benefits and inherent risks of ownership of property to the Company are accounted for as finance leases. At the time a finance lease is entered into, an asset is recorded together with its related long-term obligation to reflect the acquisition and financing. Property and equipment recorded under finance leases is amortized on the same basis as described above. Operating leases are recognized on the balance sheet as a lease liability with a corresponding right of use asset for all leases with a term that is more than twelve months. Payments under operating leases are expensed as incurred.

 

j) Derivatives

 

The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. The Company previously used a Black Scholes Option Pricing model to estimate the fair value of convertible debt conversion features at the end of each applicable reporting period. Changes in the fair value of these derivatives during each reporting period were included in the statements of operations. Inputs into the Black Scholes Option Pricing model require estimates, including such items as estimated volatility of the Company’s stock, risk free interest rate and the estimated life of the financial instruments being fair valued.

 

If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion feature.

 

 

k) Financial instruments

 

The Company initially measures its financial assets and liabilities at fair value. The Company subsequently measures all its financial assets and financial liabilities at amortized cost.

 

Financial assets measured at amortized cost include cash and accounts receivable.

 

Financial liabilities measured at amortized cost include bank indebtedness, accounts payable and accrued liabilities, harmonized sales tax payable, withholding taxes payable, convertible notes payable, loans payable and related party notes.

 

Financial assets measured at cost are tested for impairment when there are indicators of impairment. The amount of the write-down is recognized in net income. The previously recognized impairment loss may be reversed to the extent of the improvement, directly or by adjusting the allowance account, provided it is no greater than the amount that would have been reported at the date of the reversal had the impairment not been recognized previously. The amount of the reversal is recognized in net income. The Company recognizes its transaction costs in net income in the period incurred. However, financial instruments that will not be subsequently measured at fair value are adjusted by the transaction costs that are directly attributable to their origination, issuance or assumption.

 

FASB ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

  ● Level 1. Observable inputs such as quoted prices in active markets;
  ●  Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
  ● Level 3. Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions.

 

The Company measures its convertible debt and derivative liabilities associated therewith at fair value. These liabilities are revalued periodically and the resultant gain or loss is realized through the consolidated Statement of Operations and Comprehensive Loss.

 

l) Related parties

 

Parties are considered to be related to the Company if the parties directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged.

 

m) Revenue recognition

 

ASC 606 requires companies to exercise more judgment and recognize revenue using a five-step process.

 

The Company’s provision for doubtful accounts are recorded as a direct reduction to revenue instead of being presented as a separate line item on the consolidated statements of operations and comprehensive loss.

 

As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities.

 

 

The Company receives payments from the following sources for services rendered in our U.S. Facility: (i) commercial insurers; and (ii) individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and does not adjust for the effects of a significant financing component.

 

The Company derives a significant portion of its revenue from other payors that receive discounts from established billing rates. The various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.

 

Settlements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s receivables were $543,119 and $337,074 at March 31, 2023 and December 31, 2022, respectively. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount.

 

The Company’s revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those services. The Company derives its revenues from the sale of its services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its revenue transactions: 

 

  i. identify the contract with a customer;
  ii. identify the performance obligations in the contract;
  iii. determine the transaction price;
  iv. allocate the transaction price to performance obligations in the contract; and
  v. recognize revenue as the performance obligation is satisfied.

 

n) Income taxes

 

The Company accounts for income taxes under the provisions of ASC Topic 740, “Income Taxes”. Under ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes are provided using the liability method. Under this method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The tax basis of an asset or liability is the amount attributed to that asset or liability for tax purposes. The effect on deferred taxes of a change in tax rates is recognized in income in the period of change. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion of, or all of, the deferred tax assets will not be realized.

  

 

ASC Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions taken or expected to be taken in a tax return. The first step is to determine if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company recognizes interest and penalties accrued on unrecognized tax benefits within general and administrative expense. To the extent that accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction in general and administrative expenses in the period that such determination is made. The tax returns for fiscal 2019, through 2022 are subject to audit or review by the US tax authorities, whereas fiscal 2011 through 2022 are subject to audit or review by the Canadian tax authority.

 

o) Net income (loss) per Share

 

Basic net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the year.

 

Diluted net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation.

 

Dilution is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share). 

 

p) Stock based compensation

 

Stock based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over the employee’s requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized in the consolidated statements of operations for the three months ended March 31, 2023 and 2022 is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. We have no awards with performance conditions and no awards dependent on market conditions.

 

q) Financial instruments risks

 

The Company is exposed to various risks through its financial instruments. The following analysis provides a measure of the Company’s risk exposure and concentrations at the balance sheet dates, March 31, 2023 and December 31, 2022.

 

  i. Credit risk

 

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Financial instruments that subject the Company to credit risk consist primarily of accounts receivable.

 

Credit risk associated with accounts receivable is mitigated as only a percentage of the revenue billed to health insurance companies is recognized as income until such time as the actual funds are collected. The revenue is concentrated amongst several health insurance companies located in the US.

 

 

  ii. Liquidity risk

 

Liquidity risk is the risk the Company will not be able to meet its financial obligations as they fall due. The Company is exposed to liquidity risk through its working capital deficiency of approximately $13.4 million, and an accumulated deficit of approximately $43.7 million. The Company is dependent upon the raising of additional capital in order to implement its business plan. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial condition. In the opinion of management, liquidity risk is assessed as high, material and remains unchanged from that of the prior year.

 

  iii. Market risk

 

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of three types of risk: interest rate risk, currency risk, and other price risk. The Company is exposed to interest rate risk and currency risk.

 

  a. Interest rate risk

 

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its convertible debt, mortgage loans, short term loans, third party loans and government assistance loans as of March 31, 2023. In the opinion of management, interest rate risk is assessed as moderate.

 

  b. Currency risk

 

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company is subject to currency risk as it has subsidiaries that operate in Canada and are subject to fluctuations in the Canadian dollar. A substantial portion of the Company’s financial assets and liabilities are denominated in Canadian dollars, however net earnings in foreign currency is minimal and a 5% depreciation or appreciation of the Canadian dollar against the U.S. dollar would result in an immaterial increase or decrease in the Company’s after tax net income from operations. The Company has not entered into any hedging agreements to mitigate this risk. In the opinion of management, currency risk is assessed as low, material and remains unchanged from that of the prior year.

 

  c. Other price risk

 

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. In the opinion of management, the Company is not exposed to this risk and remains unchanged from the prior year.

 

 

q) Allowance for credit losses

 

 The Company recognizes revenue based on historical collections received from healthcare providers, recognizing only a percentage of revenues actually billed. Effectively recognizing revenue net of any expected billing differentials. Based on the Company’s collection experience, the percentage of revenue recognized is adjusted on a periodic basis, thereby taking into account expected credit losses in the revenue recognition process. The revenue we recognize is already net of expected credit losses.

 

We constantly evaluate our collections experience and consider the market conditions and current economic developments facing the Company’s operations . We have not experienced significantly different collections to revenues we have recognized and we have not seen any deterioration in the payment patterns from the healthcare providers that the Company works with, we cannot predict with any certainty that the payment patterns the Company experiences may change and we may be required to adjust the percentage of revenue recognized.

 

r) Recent accounting pronouncements

 

The Financial Accounting Standards Board (“FASB”) issued additional updates during the three months ended March 31, 2023. None of these standards are either applicable to the Company or require adoption at a future date and none are expected to have a material impact on the Company’s consolidated financial statements upon adoption.

 

  
XML 17 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Going concern
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going concern

3. Going concern

 

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with US GAAP applicable to a going concern, which assumes that the Company will be able to meet its obligations and continue its operations in the normal course of business. At March 31, 2023 the Company has a working capital deficiency of $13.4 million, and total liabilities in excess of assets in the amount of $9.4 million . Management believes that current available resources will not be sufficient to fund the Company’s planned expenditures over the next 12 months. These factors, individually and collectively indicate that a material uncertainty exists that raises substantial doubt about the Company's ability to continue as a going concern for one year from the date of issuance of these condensed interim consolidated financial statements. 

 

The Company will be dependent upon the raising of additional capital through placement of common shares, and/or debt financing in order to implement its business plan and generating sufficient revenue in excess of costs. If the Company raises additional capital through the issuance of equity securities or securities convertible into equity, stockholders will experience dilution, and such securities may have rights, preferences or privileges senior to those of the holders of common stock or convertible senior notes. If the Company raises additional funds by issuing debt, the Company may be subject to limitations on its operations, through debt covenants or other restrictions. If the Company obtains additional funds through arrangements with collaborators or strategic partners, the Company may be required to relinquish its rights to certain geographical areas, or techniques that it might otherwise seek to retain. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial condition. These unaudited condensed consolidated financial statements do not include any adjustments to the amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

  
XML 18 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Property and equipment
 3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
Property and equipment

4. Property and equipment

  

Property and equipment consists of the following:  

  

      March 31,
2023		   December 31, 2022
 

Useful

lives

   Cost   Accumulated depreciation   Net book value   Net book value
Land Indefinite   $ 158,871     $ —       $ 158,871     $ 158,742  
Property 25 years     3,005,354       (723,081 )     2,282,273       2,310,448  
Leasehold improvements Life of lease     446,065       (54,164 )     391,901       373,320  
Furniture and fittings 6 years     139,889       (29,106 )     110,783       92,941  
Vehicles 5 years     55,949       (20,668 )     35,281       38,079  
Computer equipment 3 years     1,450       (706 )     744       865  
      $ 3,807,578     $ (827,725 )   $ 2,979,853     $ 2,974,395  

 

Depreciation expense for the three months ended March 31, 2023 and 2022 was $48,494 and $42,505, respectively.

   
XML 19 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Intangibles
 3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangibles

5. Intangibles

 

Intangible assets consist of the following:

 

   Useful
lives		  March 31,
2023		  December 31, 2022
      Cost  Accumulated amortization  Net book value  Net book value
Health care Provider license  5 years  $1,789,903   $(626,466)  $1,163,437   $1,252,932 
                        

 

The Company evaluates intangible assets for impairment on an annual basis during the last month of each year and at an interim date if indications of impairment exist. Intangible asset impairment is determined by comparing the fair value of the asset to its carrying amount with an impairment being recognized only when the fair value is less than carrying value and the impairment is deemed to be permanent in nature.

 

The Company recorded $89,495 in amortization expense for finite-lived assets for each of the three months ended March 31, 2023 and 2022.

 

  
XML 20 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
 3 Months Ended
Mar. 31, 2023
Leases  
Leases

6. Leases

 

Right of use assets are included in the consolidated balance sheet are as follows:

   March 31,
2023		  December 31,
2022
Non-current assets          
Right-of-use assets – finance leases, net of depreciation, included in Property and equipment  $35,281   $38,079 
Right-of-use assets - operating leases, net of amortization  $1,322,851   $1,393,071 

  

Lease costs consists of the following: 

 

              
   Three  months ended March 31,
   2023  2022
 Finance lease cost:          
Amortization of right-of-use assets  $2,797   $2,797 
Interest expense on finance lease liabilities   526    648 
    3,323    3,445 
           
Operating lease cost  $86,127   $63,064 
Lease cost  $89,450   $186,727 

 

Other lease information: 

   Three months ended March 31,
   2023  2022
Cash paid for amounts included in the measurement of lease liabilities      
Operating cash flows from finance leases  $(526)  $(648)
Operating cash flows from operating leases   (86,127)   (63,064)
Financing cash flows from finance leases   (1,944)   (1,809)
Cash paid for amounts included in the measurement of lease liabilities  $(88,597)  $(65,521)
           
Weighted average lease term – finance leases   3 years and seven months    4 years and seven months 
Weighted average remaining lease term – operating leases   3 years and 10 months    4 years and 10 months 
           
Discount rate – finance leases   6.60%   6.61%
Discount rate – operating leases   4.64%   4.64%

 

Maturity of Leases

 

Finance lease liability

 

The amount of future minimum lease payments under finance leases as of March 31, 2023 is as follows:

 

 

   Amount
Remainder of 2023  $7,372 
2024   9,829 
2025   9,829 
2026   6,195 
2027   1,707 
    34,932 
Imputed interest   (4,032)
Total finance lease liability  $30,900 
Disclosed as:     
Current portion  $8,017 
Non-Current portion   22,883 
Lease liability  $30,900 

 

 

Operating lease liability

 

The amount of future minimum lease payments under operating leases are as follows:

 Schedule of Operating lease liability

   Amount
    
Remainder of 2023  $262,549 
2024   366,110 
2025   384,416 
2026   403,637 
2027   33,771 
Total undiscounted minimum future lease payments   1,450,483 
Imputed interest   (25,465)
Total operating lease liability  $1,425,017 
      
Disclosed as:     
Current portion  $299,027 
Non-Current portion   1,125,990 
 Lease liability  $1,425,017 

    

Lessor Property

 

The Company’s wholly owned subsidiary CCH owns a property located at 3571 Muskoka Road, #169, Bala, on which the operations of the Canadian Rehab Clinic were located prior to disposal on February 14, 2017, The property is leased to the purchasers of the business of the Canadian Rehab Clinic, initially for a period of 5 years, which was renewed for an additional 5 years, with a further two 5 year renewal periods available to the lessee. The lessee has an option to acquire the property for CDN$10 million. The Company considers the likelihood of the option being exercised as remote at this time.

 

The Lease was considered in terms of ASC 842, Leases and determined to be an operating lease as the criteria for the lease to be a sales-type lease or a direct financing lease were not met, including the possibility of the lessee exercising the option to purchase the property being considered as remote.

 

The Company derived rental income of CDN$126 942 ($89,419) for the three months ended March 31, 2023.

 
XML 21 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Short-term Convertible Notes
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Short-term Convertible Notes

7. Short-term Convertible Notes

 

The short-term convertible notes consist of the following:

  

    Interest rate   Maturity Date   Principal   Interest   March 31, 2023   December 31, 2022
Leonite Capital, LLC     12.0 %   On Demand    $ 129,379      $ 59,198      $ 188,577      $ 184,749  
Leonite Fund I, LP     Variable     March 1, 2023     745,375       19,738       765,113       720,830  
                                             
Auctus Fund, LLC     0.0 %   On Demand     70,000       —         70,000       80,000  
                                             
Labrys Fund, LP     12.0 %   On Demand     —         —         —         8,826  
                                             
Ed Blasiak     6.5 %   On Demand     55,000       9,216       64,216       63,322  
                                             
Joshua Bauman     11.0 %   October 21, 2022     150,000       23,778       173,778       169,710  
                                             
Series N convertible notes     6.0 %   On Demand     3,229,000       860,586       4,089,586       4,041,813  
                                             
                 $ 4,378,754      $ 972,516     $ 5,351,270     $ 5,269,250  

    

 

 

Leonite Capital, LLC

 

On July 12, 2020, the Company entered into a Senior Secured Convertible Note agreement with Leonite for $440,000 with an original issue discount of $40,000 for gross proceeds of $400,000, the initial tranche advanced will be for cash of $200,000 plus the OID of $20,000, the remaining advances will be at the discretion of the Leonite. The loan bears interest at 6.5% per annum and matures on June 12, 2021. The Company is required to make monthly payments of the accrued interest on the advances made. The note is convertible into common shares at the option of the holder at $0.10 per share, or 80% multiplied by the price per share paid in subsequent financings or after a six month period from the effective date at 60% of the lowest trading price during the preceding 21 consecutive trading days. The note has both conversion price protection and anti-dilution protection provisions.

 

On February 28, 2022, in terms of a conversion notice, Leonite converted the principal sum of $149,250 of the Leonite Note into 150,000,000 shares of common stock at a conversion price of $0.0010 per share.

 

On March 1, 2023, the Company entered into a forbearance agreement with Leonite whereby the parties agreed to extend the maturity date of the note to June 8, 2023, the Company will continue to pay interest on the note, until repaid. The note has not been repaid as yet and the Company in continuing to negotiate the resolution of the note. 

 

Leonite Fund I, LP

 

Effective June 1, 2022, The Company entered into a Note Exchange Agreement whereby the convertible promissory notes entered into with Labrys Fund LP on May 7, 2021, with. A principal outstanding of $341,000, and on June 2, 2021 with a principal outstanding of $230,000 and accrued interest thereon of $25,300, were exchanged for a new Senior Secured Convertible Promissory note in the principal amount of $745,375, including an OID of $149,075. The Note matured on March 1, 2023, and bore interest at the minimum of 10% per annum or the Wall Street Journal quoted prime rate plus 5.75%. The note is currently in default, although no default has been declared and management is negotiating with Leonite on a resolution.

 

Interest is payable monthly and the note may be prepaid with a prepayment penalty of 10%. The note is convertible into common stock at a fixed conversion price of $0.01 per share, subject to anti-dilution adjustments and a fundamental transaction clause allowing the note holder to receive the same consideration as common stockholders would receive.

 

The convertible note is secured by all of the assets of Ethema Health Corporation and Addiction Recovery Institute of America, LLC.

 

On March 1, 2023, the Company entered into a forbearance agreement with Leonite whereby the parties agreed to extend the maturity date of the note to June 8, 2023, the Company will continue to pay interest on the note, until repaid. The note has not been repaid as yet and the Company in continuing to negotiate the resolution of the note. 

 

Auctus Fund, LLC

 

On August 7, 2019, the Company, entered into a Securities Purchase Agreement with Auctus Fund, LLC, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $225,000. The Note had a maturity date of May 7, 2020 and bore interest at the rate of ten percent per annum from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company had the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note is convertible at any time and from time to time at the election of Auctus Fund, LLC during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to 60% of the lowest closing bid price of the Company’s common stock for the thirty trading days prior to conversion.

 

On June 15, 2020, The Company entered into an amended agreement with Auctus whereby the Company agreed to discharge the principal amount of the note by nine equal monthly installments of $25,000 commencing in October 2020. During the year ended December 31, 2021, the Company repaid Auctus the principal sum of $50,000.

 

During March 2022, the Company paid $20,000 of principal on the convertible note, thereby reducing the principal outstanding to $80,000. The note matured May 7, 2020, Auctus Fund LLC has not declared a default and we are in constant discussion with the lender on settling the note.

 

During February 2023, the Company paid $10,000 of principal on the convertible note, thereby reducing the principal outstanding to $70,000. The note matured May 7, 2020, Auctus Fund LLC has not declared a default and we are in constant discussion with the lender on settling the note. 


  

Ed Blasiak

 

On September 14, 2020, the Company entered into a Securities Purchase Agreement with Ed Blasiak (“Blasiak”), pursuant to which the Company issued a senior secured convertible promissory note in the aggregate principal amount of $55,000, including an original issue discount of $5,000. The note bears interest at 6.5% per annum and matures on September 14, 2021. The note is senior to any future borrowings and commencing on October 1, 2020 the Company will make monthly payments of the accrued interest under the note. The note may be prepaid at certain prepayment penalties and is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions; or 80% of the price per share of subsequent equity financings or; after six months 60% of the lowest trading price during the preceding six month period.

 

The note has matured and is in default, Ed Blasiak has not declared a default under the note and we are in communication with Mr. Blasiak on our ability to repay the note. 

 

Joshua Bauman

 

On September 14, 2020, the Company entered into a Securities Purchase Agreement with Bauman, pursuant to which the Company issued a senior secured convertible promissory note in the aggregate principal amount of $110,000, including an original issue discount of $10,000. The note bears interest at 6.5% per annum and matures on September 14, 2021. The note is senior to any future borrowings and commencing on October 1, 2020 the Company will make monthly payments of the accrued interest under the note. The note may be prepaid at certain prepayment penalties and is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions; or 80% of the price per share of subsequent equity financings or; after six months 60% of the lowest trading price during the preceding six month period.

 

On June 8, 2021, in terms of a conversion notice received by the Company, Bauman converted the aggregate principal sum of $100,000 including interest thereon of $5,563 into 106,313,288 shares of common stock.

 

On October 25, 2021, in terms of a conversion notice received by the Company, Bauman converted the aggregate principal sum of $37,500 including interest thereon of $1,155 into 39,405,310 shares of common stock, thereby extinguishing the note.

  

On October 21, 2021, the Company entered into a Securities Purchase Agreement with Bauman, pursuant to which the Company issued a senior secured convertible promissory note in the aggregate principal amount of $150,000, including an original issue discount of $16,250. The note bears interest at 11.0% per annum, which is guaranteed and earned in full on issue date and matured on October 21, 2022. The note is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions.

 

The note has matured and is in default, Mr. Bauman has not declared a default under the note and we are in communication with Mr. Bauman on our ability to repay the note. 

 

Series N convertible notes

 

Between January 28, 2019 and June 11, 2020, the Company closed several tranches of Series N Convertible notes in which it raised $3,229,000 in principal from accredited investors through the issuance to the investors of the Company’s Series N convertible notes, in the total original principal amount of $3,229,000, which Notes are convertible into the Company’s common stock at a conversion price of $0.08 per share together with three year warrants to purchase up to a total of 52,237,500 shares of the Company’s common stock at an exercise price of $0.12 per share. Both the conversion price under the Notes and the exercise price under the warrants are subject to standard adjustment mechanisms. The notes matured one year from the date of issuance.

 

The series N convertible notes matured and are in default. The Company is considering its options to settle these notes.

 

 
XML 22 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Short-term Notes
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Short-term Notes

8. Short-term Notes

 

Leonite Capital, LLC

 

Secured Promissory Notes  

 

On March 1, 2022, the Company entered into a secured Promissory Note in the aggregate principal amount of $124,000 for net proceeds of $100,000 after an original issue discount of $24,000. Due to the failure to repay the note by due date, a penalty of $37,200 was added to the principal outstanding and the Company incurs a monthly monitoring fee of $2,000 per month. In addition the note earns interest at a default rate of 24% per annum on the total balance outstanding, including the monthly monitoring fee and accrued interest.

 

The Note had a maturity date of April 1, 2022. This note has not been repaid at the date of this report. We are in negotiations with Leonite to settle the balance outstanding and no default has been declared.

 

The balance outstanding on the note, including default penalty, interest accrued and monthly monitoring fees is $231,481 as of March 31, 2023.

 

On May 3, 2022, the Company, entered into a secured Promissory Note in the aggregate principal amount of $76,250 for net proceeds of $61,000 after an original issue discount of $15,250. Due to the failure to repay the note by due date, a penalty of $22,875 was added to the principal outstanding and the Company incurs a monthly monitoring fee of $2,000 per month. In addition the note earns interest at a default rate of 24% per annum on the total balance outstanding, including the monthly monitoring fee and accrued interest.

 

The Note had a maturity date of June 17, 2022. This note has not been repaid at the date of this report. We are in negotiations with Leonite to settle the balance outstanding and no default has been declared.

 

The balance outstanding on the note, including default penalty, interest accrued and monthly monitoring fees is $143,634 as of March 31, 2023.

 

LXR Biotech

 

On April 12, 2019, the Company, entered into a secured Promissory Note in the aggregate principal amount of CDN$133,130. The Note had a maturity date of April 11, 2020 and bears interest at the rate of six percent per annum from the date on which the Note was issued.

 

This note has not been repaid, is in default and remains outstanding. The balance outstanding at March 31, 2023 was $121,806.

 
XML 23 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Mortgage loans
 3 Months Ended
Mar. 31, 2023
Mortgage Loans  
Mortgage loans

9. Mortgage loans

 

Mortgage loans is disclosed as follows:

 

    Interest 
rate		     Maturity date   Principal 
Outstanding		     Accrued 
interest		     March 31,
2023		     December 31,
2022
                                 
Cranberry Cove Holdings, Ltd.                               
Pace Mortgage     4.2 %   July 19, 2022   $  3,473,334     $ 4,796     $ 3,478,130      $ 3,504,605
Disclosed as follows:                                     
Short-term portion                          $ 3,478,130     $ 3,504,605
                                           

 

Cranberry Cove Holdings, Ltd. (“CCH”)


On July 19, 2017, CCH, a wholly owned subsidiary, closed on a loan agreement in the principal amount of CDN$5,500,000. The loan is secured by a first mortgage on the premises owned by CCH located at 3571 Muskoka Road 169, Bala, Ontario.

 

The loan bears interest at the fixed rate of 4.2% with a 5-year primary term and a 25-year amortization. The Company has guaranteed the loan and the Company’s chief executive officer and controlling shareholder also has personally guaranteed the Loan. CCH and the Company have granted the Lender a general security interest in its assets to secure repayment of the Loan. The loan is amortized with monthly installments of CDN $29,531.

 

The loan matured on July 19, 2022, and negotiations with the lender continue, no new terms have been presented to the Company as yet. The Company has continued to make installments in terms of the original mortgage agreement. 

 

 
XML 24 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Government assistance loans
 3 Months Ended
Mar. 31, 2023
Government Assistance Loans  
Government assistance loans

10. Government assistance loans

 

On December 1, 2020, CCH was granted a Covid-19 related government assistance loan in the aggregate principal amount of CDN$ 40,000 (Approximately $31,000). the grant is interest free and CDN$ 10,000 is forgivable if the loan is repaid in full by December 31, 2022. The maturity date of this loan was extended by an additional year to December 31, 2023.

 

On January 12, 2021, CCH received a further CDN$ 20,000 Covid-19 related government assistance loan. The loan is interest free and if repaid by December 31, 2022, CDN$ 10,000 is forgivable.

 

On May 3, 2021, ARIA was granted a government assistance loan in the aggregate principal amount of $157,367. The loan is forgivable if the Company demonstrates that the proceeds were used for expenses such as employee costs during the pandemic. Should the loan not be forgiven, interest is payable on the loan at the rate of 1% per annum and the principal is repayable and interest is payable over an 18 month period.

 

On September 21, 2022, ARIA received partial forgiveness of the government assistance loan of $104,368, the balance of the loan plus accrued interest is due and payable. On December 30, 2022, the Company sold ARIA to its Chairman and CEO and agreed to assume the repayment of the government assistance loan. As of March 31, 2023, the balance outstanding, including interest thereon was $44,336.

 
XML 25 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Receivables funding
 3 Months Ended
Mar. 31, 2023
Receivables Funding  
Receivables funding

11. Receivables funding

 

September 26, 2022 Funding

 On September 26, 2022, the Company, through its 75% held subsidiary, Evernia Health Center, LLC, entered into a Receivables Sale Agreement with Itria Ventures LLC (“Itria”), whereby $310,000 of the Receivables of Evernia were sold to Itria, for gross proceeds of $250,000. The Company also incurred fees of $5,500, resulting in net proceeds of $244,500. The Company is obliged to pay 7.41% of the receivables until the amount of $310,000 is paid in full, with periodic repayments of $6,458 per week. The guarantor of the funding is a minority shareholder in ATHI.

 

The Company made weekly cash payments of $6,458 totaling $167,917 on the September 26, 2022 funding. The balance outstanding at March 31, 2023 was $147,083, less unamortized discount of $30,949.

 

December 13, 2022 Funding 

On December 13, 2022, the Company, through its 75% held subsidiary, Evernia Health Center, LLC entered into a Receivables Sale Agreement with Itria Ventures LLC (“Itria”), whereby $305,000 of the Receivables of Evernia were sold to Itria, for gross proceeds of $250,000. The Company also incurred fees of $2,500, resulting in net proceeds of $247,500. The Company is obliged to pay 6.08% of the receivables until the amount of $305,000 is paid in full, with periodic repayments of $6,354 per week. The guarantor of the funding is a minority shareholder in ATHI.

 

The Company made weekly cash payments of $6,354 totaling $88,958 on the December 13, 2022 funding. The balance outstanding at March 31, 2023 was $211,042, less unamortized discount of $40,228.

 

January 19, 2023 Funding

On January 19, 2023, the Company received funding from an agreement entered into on December 14, 2022 through its 75% held subsidiary, Evernia Health Center, LLC entered into a Receivables Sale Agreement with Bizfund.com (“Bizfund)”), whereby $132,000 of the Receivables of Evernia were sold to Bizfund, for gross proceeds of $100,000. The Company is obliged to pay 15.0% of the receivables until the amount of $132,000 is paid in full, with periodic repayments of $2,750 per week. The guarantor of the funding is a minority shareholder in ATHI.

 

The Company made weekly cash payments of $2,750 totaling $24,750 on the January 19, 2023 funding. The balance outstanding at March 31, 2023 was $107,250, less unamortized discount of $26,536.

 

February 14, 2023 Funding 

On February 14, 2023, the Company, through its 75% held subsidiary, Evernia Health Center, LLC entered into a Receivables Sale Agreement with Fox Business Funding (“Fox”), whereby $118,800 of the Receivables of Evernia were sold to Fox, for gross proceeds of $90,000. The Company is obliged to pay 8.0% of the receivables until the amount of $118,800 is paid in full, with periodic repayments of $2,970 per week. The guarantor of the funding is a minority shareholder in ATHI.

 

The Company made weekly cash payments of $2,970 totaling $17,820 on the February 14, 2023 funding. The balance outstanding at March 31, 2023 was $100,980, less unamortized discount of $25,183.

 

 
XML 26 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Third Party loans
 3 Months Ended
Mar. 31, 2023
Third Party Loans  
Third Party loans

12. Third Party loans

 

On April 12, 2019, Eileen Greene, a related party assigned CDN$1,000,000 of the amount owed by the Company to her, to a third party. The loan bears interest at 12% per annum which the Company agreed to pay. As of March 31, 2023 the balance of principal and interest outstanding on third party loans was CDN$798,950 ($590,372).

 
XML 27 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Related party transactions
 3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
Related party transactions

13. Related party transactions

 

Shawn E. Leon

As of March 31, 2023 and December 31, 2022, the Company had a payable to Shawn Leon of $389,476 and $411,611, respectively. Mr. Leon is a director and CEO of the Company. The balances payable are non-interest bearing and has no fixed repayment terms.

 

On December 30, 2022, the Company sold its wholly owned subsidiaries, Greenestone Muskoka and ARIA, to Mr. Leon for gross proceeds of $0. The Company realized a gain on disposal of $628,567 which was recorded as an increase in Additional Paid in Capital due to the related party nature of the transaction.

 

Due to the current financial position of the Group, Mr. Leon forfeited the management fees due to him for the three months ended March 31, 2023 and the year ended December 31, 2022.

 

Leon Developments, Ltd.

As of March 31, 2023 and December 31, 2022, the Company owed Leon Developments, Ltd., $851,672 and $850,607, respectively, for funds advanced to the Company.

 

Eileen Greene

As of March 31, 2023 and December 31, 2022, the Company owed Eileen Greene, the spouse of our CEO, Shawn Leon, $1,414,828 and $1,451,610, respectively. The amount owed to Ms. Greene is non-interest bearing and has no fixed repayment terms.

 

All related party transactions occur in the normal course of operations and in terms of agreements entered into between the parties.

   
XML 28 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholder’s deficit
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Stockholder’s deficit

14. Stockholder’s deficit

 

  a) Common shares

 

Authorized and outstanding 

The Company has authorized 10,000,000,000 shares with a par value of $0.01 per share. The company has issued 3,729,053,805 shares of common stock at March 31, 2023 and December 31, 2022.

 

  b) Series A Preferred shares

 

Authorized, issued and outstanding 

The Company has authorized 10,000,000 Series A preferred shares with a par value of $0.01 per share. The company has issued and outstanding 4,000,000 Series A Preferred shares at March 31, 2023 and December 31, 2022.

 

  c) Series B Preferred shares

 

Authorized and outstanding 

The Company has authorized 400,000 Series B preferred shares with a par value of $1.00 per share. The company has issued and outstanding 400,000 Series B Preferred shares at March 31, 2023 and December 31, 2022.

 

The Series B preferred shares are senior secured and were mandatorily redeemable by the Company on July 1, 2021, and were originally classified as mezzanine debt. These Series B preferred shares have been reclassified as current liabilities for the three months ended March 31, 2023 as they meet the definition of liabilities in terms of ASC 480- debt and are no longer contingently convertible, due to the fact that the redemption date has passed and the Company is currently negotiating with the preferred note holders to settle the total liabilities owing to them, including certain convertible notes. The Company continues to accrue dividends at the rate of 6% per annum.

  

 

  d) Stock options

 

Our board of directors adopted the Greenstone Healthcare Corporation 2013 Stock Option Plan (the “Plan”) to promote our long-term growth and profitability by (i) providing our key directors, officers and employees with incentives to improve stockholder value and contribute to our growth and financial success and (ii) enable us to attract, retain and reward the best available persons for positions of substantial responsibility. A total of 10,000,000 shares of our common stock have been reserved for issuance upon exercise of options granted pursuant to the Plan. The Plan allows us to grant options to our employees, officers and directors and those of our subsidiaries; provided that only our employees and those of our subsidiaries may receive incentive stock options under the Plan. We have no issued options at March 31, 2023 under the Plan.

 

  e) Warrants

 

All of the warrants have cashless exercise terms whereby in-the-money warrants may be exercised by reducing the number of shares issued in terms of the warrant exercise to offset the proceeds due on the exercise.

 

All of the warrants have price protection features whereby any securities issued subsequent to the date of the warrant issuance date, were issued at a lower price, or have conversion features that are lower than the current exercise price, or were converted at a lower price, or are exercisable at a lower price, to the current warrant exercise price, will result in the exercise price of the warrant being set to the lower issue, conversion or exercise price.

  

A summary of the Company’s warrant activity during the period from January 1, 2022 to March 31, 2023 is as follows:

 

    No. of shares   Exercise price
per share		   Weighted
average exercise
price
             
Outstanding as of January 1, 2022     623,777,506       $0.000675 to $0.12     $ 0.0052875  
Granted     —         —         —    
Forfeited/cancelled     (20,925,000 )     $0.12       0.12  
Exercised     —         —         —    
Outstanding as of December 31, 2022     602,852,506       $0.000675 to $0.00205     $ 0.001306  
Granted     —         —         —    
Forfeited/cancelled     —         —         —    
Exercised     —         —         —    
Outstanding as of March 31, 2023     602,852,506       $0.000675 to $0.00205     $ 0.001306  

   

  

The following table summarizes information about warrants outstanding at March 31, 2023:

 

      Warrants outstanding     Warrants exercisable  
Exercise price     No. of shares    

Weighted average

remaining years

    

Weighted average

exercise price

     No. of shares    

Weighted average

exercise price

  
                                 
$0.000675       326,286,847       2.28               326,286,847          
$0.002050       276,565,659       2.77               276,565,659          
        602,852,506       2.51     $ 0.001306       602,852,506     $ 0.001306  

 

All of the warrants outstanding at March 31, 2023 are vested. The warrants outstanding at March 31, 2023 have an intrinsic value of $0. 

 

 
XML 29 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Segment information
 3 Months Ended
Mar. 31, 2023
Segment Information  
Segment information

15. Segment information

 

The Company has two reportable operating segments:

 

  a. Rental income from the property owned by CCH subsidiary located at 3571 Muskoka Road, #169, Bala, on which the operations of the Canadian Rehab Clinic were located prior to disposal on February 14, 2017 and subsequently leased to the purchasers of the business of the Canadian Rehab Clinic, for a period of 5 years renewable for a further three five-year periods and with an option to acquire the property at a fixed price.

 

  b. Rehabilitation Services provided to customers, these services were provided to customers at our Evernia, Addiction Recovery Institute of America and Seastone of Delray operations.

 

The segment operating results of the reportable segments for the three months ended March 31, 2023 is disclosed as follows:

 

                      
   Three months ended March 31, 2023
   Rental
Operations		  In-Patient
services		  Total
          
Revenue  $89,419   $1,210,627   $1,300,046 
Operating expenses   30,120    1,194,900    1,225,020 
                
Operating income   59,299    15,727    75,026 
                
Other (expense) income               
Interest expense   (47,733)   (109,363)   (157,096)
Amortization of debt discount   —      (76,921)   (76,921)
Foreign exchange movements   (1,035)   (1,920)   (2,955)
Net income (loss) before taxes   10,531    (172,477)   (161,946)
Taxes   —      (13,771)   (13,771)
Net income (loss)  $10,531   $(186,248)  $(175,717)

 

The operating assets and liabilities of the reportable segments as of March 31, 2023 is as follows:

 

                      
   March 31, 2023
   Rental
Operations		  In-Patient
services		  Total
          
Purchase of fixed assets  $—     $52,418   $52,418 
Assets               
Current assets   233    689,431    689,664 
Non-current assets   2,441,143    3,474,998    5,916,141 
Liabilities               
Current liabilities   (4,985,120)   (9,083,220)   (14,068,340)
Non-current liabilities   (619,856)   (1,350,792)   (1,970,648)
Intercompany balances   (1,299,110)   1,299,110    —   
Net liability position  $(4,462,710)  $(4,970,473)  $(9,433,183)

 

 

The segment operating results of the reportable segments for the three months ended March 31, 2022 is disclosed as follows:

                      
   Three months ended March 31, 2022
   Rental
Operations		  In-Patient
services		  Total
          
Revenue  $93,874   $929,441   $1,023,315 
Operating expenses   (33,316)   (915,059)   (948,375)
                
Operating income   60,558    14,382    74,940 
                
Other (expense) income               
Other income   —      10,018    10,018 
Interest expense   (53,607)   (27,161)   (80,768)
Amortization of debt discount   —      (252,832)   (252,832)
Derivative liability movement   —      197,476    197,476 
Foreign exchange movements   (21,829)   (73,727)   (95,556)
Net loss before taxes   (14,878)   (131,844)   (146,722)
Taxes   —      (18,263)   (18,263)
Net loss  $(14,878)  $(150,107)  $(164,985)

 

The operating assets and liabilities of the reportable segments as of March 31, 2022 is as follows:

 

                      
   March 31, 2022
   Rental
Operations		  In-Patient
services		  Total
          
Purchase of fixed assets  $—     $72,858   $72,858 
Assets               
Current assets   551    355,167    355,718 
Non-current assets   2,773,914    3,426,324    6,200,238 
Liabilities               
Current liabilities   (1,590,715)   (12,078,894)   (13,669,609)
Non-current liabilities   (636,577)   (1,710,232)   (2,346,809)
Mandatory redeemable preferred shares   —      (400,000)   (400,000)
Intercompany balances   1,238,399    (1,238,399)   —   
Net liability position  $1,785,572   $(11,646,034)  $(9,860,462)

 
XML 30 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Net income (loss) per common share
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Net income (loss) per common share

16. Net income (loss) per common share

 

For the three months ended March 31, 2023 and 2022, the following warrants and convertible securities were excluded from the computation of diluted net loss per share as the results would have been anti-dilutive.

 

   Three months ended
March 31,
2023		  Three months ended
March 31,
2022
       
Warrants to purchase shares of common stock   602,852,506    611,140,006 
Convertible notes   582,290,570    458,435,448 
    1,185,143,076    1,069,575,454 

 
XML 31 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and contingencies
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies

17. Commitments and contingencies

 

  a. Options granted to purchase shares in ATHI

 

On July 12, 2020, the Company entered into a five year option agreement with Leonite Capital LLC (“Leonite”) and other investors (collectively the “Transferees”). The Company agreed to sell to Leonite a portion of the total outstanding shares of ATHI from the shares of ATHI held by the company. The Company provided Leonite an option to purchase 4,000,000 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $400), based on the advances that Leonite made to the Company totaling $396,000. Leonite shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Leonite to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.

 

On September 14, 2020, the Company entered into a five year option agreement with Ed Blasiak (“Blasiak”) whereby the Company agreed to sell to Blasiak a portion of the total outstanding shares of ATHI. The Company provided Blasiak an option to purchase 571,428 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $57), based on the advances that Blasiak made to the Company totaling $50,000. Blasiak shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Blasiak to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.

 

On October 29, 2020, the Company entered into a five year option agreement with First Fire whereby the Company agreed to sell to First Fire a portion of the total outstanding shares of ATHI. The Company provided First Fire an option to purchase 1,428,571 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $143), based on the advances that First Fire made to the Company totaling $120,000. First Fire shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by First Fire to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.

 

On October 29, 2020, the Company entered into a five year option agreement entered into with Bauman, so that the Company agreed to sell to Bauman a portion of the total outstanding shares of ATHI. The Company provided Bauman an option to purchase 1,428,571 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $143), based on the advances that Bauman made to the Company totaling $120,000. Bauman shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Bauman to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.

 

  b. Mortgage loans

 

The company has a mortgage loan as disclosed in note 9 above. The mortgage loan matured on July 19, 2022 and the Company currently owes $3,478,130. The terms of the loan are currently being negotiated.

 

  c. Other

 

The Company has principal and interest payment commitments under the Convertible notes disclosed under Note 7 above. Conversion of these notes are at the option of the investor, if not converted these notes may need to be repaid.

 

From time to time, the Company and its subsidiaries enter into legal disputes in the ordinary course of business. The Company believes there are no material legal or administrative matters pending that are likely to have, individually or in the aggregate, a material adverse effect on its business or results of operations.

    
XML 32 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent events
 3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
Subsequent events

18. Subsequent events

 

The Company has evaluated subsequent events through the date of the condensed consolidated financial statements were issued, we did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

  
XML 33 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies (Policies)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Use of Estimates

a) Use of Estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

 
Principals of consolidation and foreign currency translation

b) Principals of consolidation and foreign currency translation

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and all of its subsidiaries. All intercompany transactions and balances have been eliminated on consolidation.

 

Certain of the Company’s subsidiaries functional currency is the Canadian dollar, while the Company’s reporting currency is the U.S. dollar. All transactions initiated in Canadian dollars are translated into US dollars in accordance with ASC 830, “Foreign Currency Translation” as follows:

 

  ● Monetary assets and liabilities at the rate of exchange in effect at the balance sheet date.

 

  ● Certain non-monetary assets and liabilities and equity at historical rates.

 

  ● Revenue and expense items and cash flows at the average rate of exchange prevailing during the year.

 

 Adjustments arising from such translations are deferred until realization and are included as a separate component of stockholders’ deficit as a component of accumulated other comprehensive income or loss. Therefore, translation adjustments are not included in determining net income (loss) but reported as other comprehensive income (loss).

 

 

For foreign currency transactions, the Company translates these amounts to the Company’s functional currency at the exchange rate effective on the invoice date. If the exchange rate changes between the time of purchase and the time actual payment is made, a foreign exchange transaction gain or loss results which is included in determining net income for the year.

 

The relevant translation rates are as follows: For the three months ended March 31, 2023, a closing rate of CDN$1 equals US$0.7389 and an average exchange rate of CDN$1 equals US$0.7394, for the year ended December 31, 2022, a closing rate of CDN$1.0000 equals US$0.7383 and an average exchange rate of CDN$1.0000 equals US$0.7686.

 
Business Combinations

c) Business Combinations

 

The Company allocates the fair value of purchase consideration to the tangible and intangible assets acquired and liabilities assumed for business combinations with third parties based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill.

 

Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired users, acquired technology, and trade names from a market participant perspective, useful lives and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates.

 

 
Cash and cash equivalents

d) Cash and cash equivalents

 

For purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with several financial institution in the USA and Canada. There were no cash equivalents at

March 31, 2023 and December 31, 2022.

 

The Company primarily places cash balances in the USA with high-credit quality financial institutions located in the United States which are insured by the Federal Deposit Insurance Corporation up to a limit of $250,000 per institution, in Canada which are insured by the Canadian Deposit Insurance Corporation up to a limit of CDN$100,000 per institution.

 
Accounts receivable

e) Accounts receivable

 

Accounts receivable primarily consists of amounts due from third-party payors (non-governmental) and private pay patients and is recorded net of allowances for doubtful accounts and contractual discounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s unaudited condensed consolidated financial statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimating net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies denying claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients.

 

 

 
Allowance for Doubtful Accounts, Contractual and Other Discounts

f) Allowance for Doubtful Accounts, Contractual and Other Discounts

  

The Company derives the majority of its revenues from commercial payors at in-network rates. Management estimates the allowance for contractual and other discounts based on its historical collection experience and contractual rates. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account is written off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.

 
Property and equipment

g) Property and equipment

  

Property and equipment is recorded at cost. Depreciation is calculated on the straight line basis over the estimated life of the asset.

 
Intangible assets

h) Intangible assets

 

Intangible assets are stated at acquisition cost less accumulated amortization, if applicable, less any adjustments for impairment losses.

 

Amortization is charged on a straight-line basis over the estimated remaining useful lives of the individual intangibles. Where intangibles are deemed to be impaired the Company recognizes an impairment loss measured as the difference between the estimated fair value of the intangible and its book value.

 

Licenses to provide substance abuse rehabilitation services are amortized over the expected life of the contract, including any anticipated renewals. The Company expects its licenses to remain in operation for a period of five years.

   
Leases

i) Leases

 

 The Company accounts for leases in terms of AC 842 whereby leases are classified as either finance or operating leases. Leases that transfer substantially all of the benefits and inherent risks of ownership of property to the Company are accounted for as finance leases. At the time a finance lease is entered into, an asset is recorded together with its related long-term obligation to reflect the acquisition and financing. Property and equipment recorded under finance leases is amortized on the same basis as described above. Operating leases are recognized on the balance sheet as a lease liability with a corresponding right of use asset for all leases with a term that is more than twelve months. Payments under operating leases are expensed as incurred.

 
Derivatives

j) Derivatives

 

The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. The Company previously used a Black Scholes Option Pricing model to estimate the fair value of convertible debt conversion features at the end of each applicable reporting period. Changes in the fair value of these derivatives during each reporting period were included in the statements of operations. Inputs into the Black Scholes Option Pricing model require estimates, including such items as estimated volatility of the Company’s stock, risk free interest rate and the estimated life of the financial instruments being fair valued.

 

If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion feature.

 

 
Financial instruments

k) Financial instruments

 

The Company initially measures its financial assets and liabilities at fair value. The Company subsequently measures all its financial assets and financial liabilities at amortized cost.

 

Financial assets measured at amortized cost include cash and accounts receivable.

 

Financial liabilities measured at amortized cost include bank indebtedness, accounts payable and accrued liabilities, harmonized sales tax payable, withholding taxes payable, convertible notes payable, loans payable and related party notes.

 

Financial assets measured at cost are tested for impairment when there are indicators of impairment. The amount of the write-down is recognized in net income. The previously recognized impairment loss may be reversed to the extent of the improvement, directly or by adjusting the allowance account, provided it is no greater than the amount that would have been reported at the date of the reversal had the impairment not been recognized previously. The amount of the reversal is recognized in net income. The Company recognizes its transaction costs in net income in the period incurred. However, financial instruments that will not be subsequently measured at fair value are adjusted by the transaction costs that are directly attributable to their origination, issuance or assumption.

 

FASB ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

  ● Level 1. Observable inputs such as quoted prices in active markets;
  ●  Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
  ● Level 3. Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions.

 

The Company measures its convertible debt and derivative liabilities associated therewith at fair value. These liabilities are revalued periodically and the resultant gain or loss is realized through the consolidated Statement of Operations and Comprehensive Loss.

 
Related parties

l) Related parties

 

Parties are considered to be related to the Company if the parties directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged.

 
Revenue recognition

m) Revenue recognition

 

ASC 606 requires companies to exercise more judgment and recognize revenue using a five-step process.

 

The Company’s provision for doubtful accounts are recorded as a direct reduction to revenue instead of being presented as a separate line item on the consolidated statements of operations and comprehensive loss.

 

As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities.

 

 

The Company receives payments from the following sources for services rendered in our U.S. Facility: (i) commercial insurers; and (ii) individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and does not adjust for the effects of a significant financing component.

 

The Company derives a significant portion of its revenue from other payors that receive discounts from established billing rates. The various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.

 

Settlements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s receivables were $543,119 and $337,074 at March 31, 2023 and December 31, 2022, respectively. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount.

 

The Company’s revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those services. The Company derives its revenues from the sale of its services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its revenue transactions: 

 

  i. identify the contract with a customer;
  ii. identify the performance obligations in the contract;
  iii. determine the transaction price;
  iv. allocate the transaction price to performance obligations in the contract; and
  v. recognize revenue as the performance obligation is satisfied.

 
Income taxes

n) Income taxes

 

The Company accounts for income taxes under the provisions of ASC Topic 740, “Income Taxes”. Under ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes are provided using the liability method. Under this method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The tax basis of an asset or liability is the amount attributed to that asset or liability for tax purposes. The effect on deferred taxes of a change in tax rates is recognized in income in the period of change. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion of, or all of, the deferred tax assets will not be realized.

  

 

ASC Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions taken or expected to be taken in a tax return. The first step is to determine if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company recognizes interest and penalties accrued on unrecognized tax benefits within general and administrative expense. To the extent that accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction in general and administrative expenses in the period that such determination is made. The tax returns for fiscal 2019, through 2022 are subject to audit or review by the US tax authorities, whereas fiscal 2011 through 2022 are subject to audit or review by the Canadian tax authority.

 
Net income (loss) per Share

o) Net income (loss) per Share

 

Basic net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the year.

 

Diluted net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation.

 

Dilution is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share). 

 
Stock based compensation

p) Stock based compensation

 

Stock based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over the employee’s requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized in the consolidated statements of operations for the three months ended March 31, 2023 and 2022 is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. We have no awards with performance conditions and no awards dependent on market conditions.

 
Financial instruments risks

q) Financial instruments risks

 

The Company is exposed to various risks through its financial instruments. The following analysis provides a measure of the Company’s risk exposure and concentrations at the balance sheet dates, March 31, 2023 and December 31, 2022.

 

  i. Credit risk

 

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Financial instruments that subject the Company to credit risk consist primarily of accounts receivable.

 

Credit risk associated with accounts receivable is mitigated as only a percentage of the revenue billed to health insurance companies is recognized as income until such time as the actual funds are collected. The revenue is concentrated amongst several health insurance companies located in the US.

 

 

  ii. Liquidity risk

 

Liquidity risk is the risk the Company will not be able to meet its financial obligations as they fall due. The Company is exposed to liquidity risk through its working capital deficiency of approximately $13.4 million, and an accumulated deficit of approximately $43.7 million. The Company is dependent upon the raising of additional capital in order to implement its business plan. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial condition. In the opinion of management, liquidity risk is assessed as high, material and remains unchanged from that of the prior year.

 

  iii. Market risk

 

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of three types of risk: interest rate risk, currency risk, and other price risk. The Company is exposed to interest rate risk and currency risk.

 

  a. Interest rate risk

 

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its convertible debt, mortgage loans, short term loans, third party loans and government assistance loans as of March 31, 2023. In the opinion of management, interest rate risk is assessed as moderate.

 

  b. Currency risk

 

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company is subject to currency risk as it has subsidiaries that operate in Canada and are subject to fluctuations in the Canadian dollar. A substantial portion of the Company’s financial assets and liabilities are denominated in Canadian dollars, however net earnings in foreign currency is minimal and a 5% depreciation or appreciation of the Canadian dollar against the U.S. dollar would result in an immaterial increase or decrease in the Company’s after tax net income from operations. The Company has not entered into any hedging agreements to mitigate this risk. In the opinion of management, currency risk is assessed as low, material and remains unchanged from that of the prior year.

 

  c. Other price risk

 

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. In the opinion of management, the Company is not exposed to this risk and remains unchanged from the prior year.

 

 
Allowance for credit losses

q) Allowance for credit losses

 

 The Company recognizes revenue based on historical collections received from healthcare providers, recognizing only a percentage of revenues actually billed. Effectively recognizing revenue net of any expected billing differentials. Based on the Company’s collection experience, the percentage of revenue recognized is adjusted on a periodic basis, thereby taking into account expected credit losses in the revenue recognition process. The revenue we recognize is already net of expected credit losses.

 

We constantly evaluate our collections experience and consider the market conditions and current economic developments facing the Company’s operations . We have not experienced significantly different collections to revenues we have recognized and we have not seen any deterioration in the payment patterns from the healthcare providers that the Company works with, we cannot predict with any certainty that the payment patterns the Company experiences may change and we may be required to adjust the percentage of revenue recognized.

 
Recent accounting pronouncements

r) Recent accounting pronouncements

 

The Financial Accounting Standards Board (“FASB”) issued additional updates during the three months ended March 31, 2023. None of these standards are either applicable to the Company or require adoption at a future date and none are expected to have a material impact on the Company’s consolidated financial statements upon adoption.

 

  
XML 34 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Property and equipment (Tables)
 3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of sale of property

  

      March 31,
2023		   December 31, 2022
 

Useful

lives

   Cost   Accumulated depreciation   Net book value   Net book value
Land Indefinite   $ 158,871     $ —       $ 158,871     $ 158,742  
Property 25 years     3,005,354       (723,081 )     2,282,273       2,310,448  
Leasehold improvements Life of lease     446,065       (54,164 )     391,901       373,320  
Furniture and fittings 6 years     139,889       (29,106 )     110,783       92,941  
Vehicles 5 years     55,949       (20,668 )     35,281       38,079  
Computer equipment 3 years     1,450       (706 )     744       865  
      $ 3,807,578     $ (827,725 )   $ 2,979,853     $ 2,974,395  
XML 35 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Intangibles (Tables)
 3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible assets

 

   Useful
lives		  March 31,
2023		  December 31, 2022
      Cost  Accumulated amortization  Net book value  Net book value
Health care Provider license  5 years  $1,789,903   $(626,466)  $1,163,437   $1,252,932 
                        
XML 36 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Tables)
 3 Months Ended
Mar. 31, 2023
Leases  
Schedule of Right of use assets

   March 31,
2023		  December 31,
2022
Non-current assets          
Right-of-use assets – finance leases, net of depreciation, included in Property and equipment  $35,281   $38,079 
Right-of-use assets - operating leases, net of amortization  $1,322,851   $1,393,071 
Schedule of finance and operating lease

 

              
   Three  months ended March 31,
   2023  2022
 Finance lease cost:          
Amortization of right-of-use assets  $2,797   $2,797 
Interest expense on finance lease liabilities   526    648 
    3,323    3,445 
           
Operating lease cost  $86,127   $63,064 
Lease cost  $89,450   $186,727 
Schedule of Other lease

   Three months ended March 31,
   2023  2022
Cash paid for amounts included in the measurement of lease liabilities      
Operating cash flows from finance leases  $(526)  $(648)
Operating cash flows from operating leases   (86,127)   (63,064)
Financing cash flows from finance leases   (1,944)   (1,809)
Cash paid for amounts included in the measurement of lease liabilities  $(88,597)  $(65,521)
           
Weighted average lease term – finance leases   3 years and seven months    4 years and seven months 
Weighted average remaining lease term – operating leases   3 years and 10 months    4 years and 10 months 
           
Discount rate – finance leases   6.60%   6.61%
Discount rate – operating leases   4.64%   4.64%
Schedule of Finance lease liability

   Amount
Remainder of 2023  $7,372 
2024   9,829 
2025   9,829 
2026   6,195 
2027   1,707 
    34,932 
Imputed interest   (4,032)
Total finance lease liability  $30,900 
Disclosed as:     
Current portion  $8,017 
Non-Current portion   22,883 
Lease liability  $30,900 
Schedule of Operating lease liability

 Schedule of Operating lease liability

   Amount
    
Remainder of 2023  $262,549 
2024   366,110 
2025   384,416 
2026   403,637 
2027   33,771 
Total undiscounted minimum future lease payments   1,450,483 
Imputed interest   (25,465)
Total operating lease liability  $1,425,017 
      
Disclosed as:     
Current portion  $299,027 
Non-Current portion   1,125,990 
 Lease liability  $1,425,017 
XML 37 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Short-term Convertible Notes (Tables)
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Schedule of short-term convertible notes

  

    Interest rate   Maturity Date   Principal   Interest   March 31, 2023   December 31, 2022
Leonite Capital, LLC     12.0 %   On Demand    $ 129,379      $ 59,198      $ 188,577      $ 184,749  
Leonite Fund I, LP     Variable     March 1, 2023     745,375       19,738       765,113       720,830  
                                             
Auctus Fund, LLC     0.0 %   On Demand     70,000       —         70,000       80,000  
                                             
Labrys Fund, LP     12.0 %   On Demand     —         —         —         8,826  
                                             
Ed Blasiak     6.5 %   On Demand     55,000       9,216       64,216       63,322  
                                             
Joshua Bauman     11.0 %   October 21, 2022     150,000       23,778       173,778       169,710  
                                             
Series N convertible notes     6.0 %   On Demand     3,229,000       860,586       4,089,586       4,041,813  
                                             
                 $ 4,378,754      $ 972,516     $ 5,351,270     $ 5,269,250  
XML 38 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Mortgage loans (Tables)
 3 Months Ended
Mar. 31, 2023
Mortgage Loans  
Schedule of mortgage loans

 

    Interest 
rate		     Maturity date   Principal 
Outstanding		     Accrued 
interest		     March 31,
2023		     December 31,
2022
                                 
Cranberry Cove Holdings, Ltd.                               
Pace Mortgage     4.2 %   July 19, 2022   $  3,473,334     $ 4,796     $ 3,478,130      $ 3,504,605
Disclosed as follows:                                     
Short-term portion                          $ 3,478,130     $ 3,504,605
                                           
XML 39 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholder’s deficit (Tables)
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Schedule of warrants outstanding

 

    No. of shares   Exercise price
per share		   Weighted
average exercise
price
             
Outstanding as of January 1, 2022     623,777,506       $0.000675 to $0.12     $ 0.0052875  
Granted     —         —         —    
Forfeited/cancelled     (20,925,000 )     $0.12       0.12  
Exercised     —         —         —    
Outstanding as of December 31, 2022     602,852,506       $0.000675 to $0.00205     $ 0.001306  
Granted     —         —         —    
Forfeited/cancelled     —         —         —    
Exercised     —         —         —    
Outstanding as of March 31, 2023     602,852,506       $0.000675 to $0.00205     $ 0.001306  
Schedule of assumption

 

      Warrants outstanding     Warrants exercisable  
Exercise price     No. of shares    

Weighted average

remaining years

    

Weighted average

exercise price

     No. of shares    

Weighted average

exercise price

  
                                 
$0.000675       326,286,847       2.28               326,286,847          
$0.002050       276,565,659       2.77               276,565,659          
        602,852,506       2.51     $ 0.001306       602,852,506     $ 0.001306  
XML 40 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Segment information (Tables)
 3 Months Ended
Mar. 31, 2023
Segment Information  
Schedule of segment information

 

                      
   Three months ended March 31, 2023
   Rental
Operations		  In-Patient
services		  Total
          
Revenue  $89,419   $1,210,627   $1,300,046 
Operating expenses   30,120    1,194,900    1,225,020 
                
Operating income   59,299    15,727    75,026 
                
Other (expense) income               
Interest expense   (47,733)   (109,363)   (157,096)
Amortization of debt discount   —      (76,921)   (76,921)
Foreign exchange movements   (1,035)   (1,920)   (2,955)
Net income (loss) before taxes   10,531    (172,477)   (161,946)
Taxes   —      (13,771)   (13,771)
Net income (loss)  $10,531   $(186,248)  $(175,717)

 

The operating assets and liabilities of the reportable segments as of March 31, 2023 is as follows:

 

                      
   March 31, 2023
   Rental
Operations		  In-Patient
services		  Total
          
Purchase of fixed assets  $—     $52,418   $52,418 
Assets               
Current assets   233    689,431    689,664 
Non-current assets   2,441,143    3,474,998    5,916,141 
Liabilities               
Current liabilities   (4,985,120)   (9,083,220)   (14,068,340)
Non-current liabilities   (619,856)   (1,350,792)   (1,970,648)
Intercompany balances   (1,299,110)   1,299,110    —   
Net liability position  $(4,462,710)  $(4,970,473)  $(9,433,183)

 

 

The segment operating results of the reportable segments for the three months ended March 31, 2022 is disclosed as follows:

                      
   Three months ended March 31, 2022
   Rental
Operations		  In-Patient
services		  Total
          
Revenue  $93,874   $929,441   $1,023,315 
Operating expenses   (33,316)   (915,059)   (948,375)
                
Operating income   60,558    14,382    74,940 
                
Other (expense) income               
Other income   —      10,018    10,018 
Interest expense   (53,607)   (27,161)   (80,768)
Amortization of debt discount   —      (252,832)   (252,832)
Derivative liability movement   —      197,476    197,476 
Foreign exchange movements   (21,829)   (73,727)   (95,556)
Net loss before taxes   (14,878)   (131,844)   (146,722)
Taxes   —      (18,263)   (18,263)
Net loss  $(14,878)  $(150,107)  $(164,985)

 

The operating assets and liabilities of the reportable segments as of March 31, 2022 is as follows:

 

                      
   March 31, 2022
   Rental
Operations		  In-Patient
services		  Total
          
Purchase of fixed assets  $—     $72,858   $72,858 
Assets               
Current assets   551    355,167    355,718 
Non-current assets   2,773,914    3,426,324    6,200,238 
Liabilities               
Current liabilities   (1,590,715)   (12,078,894)   (13,669,609)
Non-current liabilities   (636,577)   (1,710,232)   (2,346,809)
Mandatory redeemable preferred shares   —      (400,000)   (400,000)
Intercompany balances   1,238,399    (1,238,399)   —   
Net liability position  $1,785,572   $(11,646,034)  $(9,860,462)
XML 41 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Net income (loss) per common share (Tables)
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities

 

   Three months ended
March 31,
2023		  Three months ended
March 31,
2022
       
Warrants to purchase shares of common stock   602,852,506    611,140,006 
Convertible notes   582,290,570    458,435,448 
    1,185,143,076    1,069,575,454 
XML 42 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies (Details Narrative) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Federal Deposit Insurance $ 250,000  
Receivables $ 543,119 $ 337,074
XML 43 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Property and equipment (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross $ 3,807,578  
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (827,725)  
Property, Plant and Equipment, Net 2,979,853 $ 2,974,395
Land [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross 158,871  
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment  
Property, Plant and Equipment, Net 158,871 158,742
Property, Plant and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross 3,005,354  
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (723,081)  
Property, Plant and Equipment, Net 2,282,273 2,310,448
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross 446,065  
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (54,164)  
Property, Plant and Equipment, Net 391,901 373,320
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross 139,889  
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (29,106)  
Property, Plant and Equipment, Net 110,783 92,941
Vehicles [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross 55,949  
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (20,668)  
Property, Plant and Equipment, Net 35,281 38,079
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross 1,450  
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (706)  
Property, Plant and Equipment, Net $ 744 $ 865
XML 44 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Property and equipment (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 48,494 $ 42,505
XML 45 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Intangibles (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
Useful life 5 years  
Finite-Lived Intangible Assets, Gross $ 1,789,903  
Finite-Lived Intangible Assets, Accumulated Amortization (626,466)  
Finite-Lived Intangible Assets, Net $ 1,163,437 $ 1,252,932
XML 46 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Intangibles (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
amortization expense $ 89,495 $ 89,495
XML 47 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Leases    
Right-of-use assets – finance leases, net of depreciation, included in Property and equipment $ 35,281 $ 38,079
Right-of-use assets - operating leases, net of amortization $ 1,322,851 $ 1,393,071
XML 48 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Details 1) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Leases    
Amortization of right-of-use assets $ 2,797 $ 2,797
Interest expense on finance lease liabilities 526 648
  3,323 3,445
Operating lease cost 86,127 63,064
Lease cost $ 89,450 $ 186,727
XML 49 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Details 2) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Leases    
Operating cash flows from finance leases $ (526) $ (648)
Operating cash flows from operating leases (86,127) (63,064)
Financing cash flows from finance leases (1,944) (1,809)
Net Change in leases $ (88,597) $ (65,521)
[custom:WeightedAverageLeaseTermFinanceLeasesTerm] 3 years and seven months 4 years and seven months
[custom:WeightedAverageRemainingLeaseTermOperatingLeases] 3 years and 10 months 4 years and 10 months
[custom:DiscountRateFinanceLeases] 6.60% 6.61%
[custom:DiscountRateOperatingLeases] 4.64% 4.64%
XML 50 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Details 3) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Leases    
Remainder of 2023 $ 7,372  
2024 9,829  
2025 9,829  
2026 6,195  
2027 1,707  
  34,932  
Imputed interest (4,032)  
Lease liability 30,900  
Current portion 8,017 $ 7,891
Non-Current portion $ 22,883 $ 24,952
XML 51 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Details 4) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Leases    
Remainder of 2023 $ 262,549  
2024 366,110  
2025 384,416  
2026 403,637  
2027 33,771  
Total undiscounted minimum future lease payments 1,450,483  
Imputed interest (25,465)  
Total operating lease liability 1,425,017  
Current portion 299,027 $ 287,017
Non-Current portion 1,125,990 $ 1,206,413
 Lease liability $ 1,425,017  
XML 52 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Details Narrative)
 3 Months Ended
Mar. 31, 2023
USD ($)
Leases  
Derived rental income $ 89,419
XML 53 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Short-term Convertible Notes (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Short-Term Debt [Line Items]    
Principal amount $ 4,378,754  
Interest 972,516  
short-term convertible $ 5,351,270 $ 5,269,250
Leonite Capital L L C [Member]    
Short-Term Debt [Line Items]    
Short-Term Debt, Interest Rate Increase 12.00%  
Maturity Date On Demand  
Principal amount $ 129,379  
Interest 59,198  
short-term convertible $ 188,577 184,749
Leonite Fund I L P [Member]    
Short-Term Debt [Line Items]    
Maturity Date March 1, 2023  
Principal amount $ 745,375  
Interest 19,738  
short-term convertible $ 765,113 720,830
Auctus Fund L L C [Member]    
Short-Term Debt [Line Items]    
Short-Term Debt, Interest Rate Increase 0.00%  
Maturity Date On Demand  
Principal amount $ 70,000  
Interest  
short-term convertible $ 70,000 80,000
Labrys Fund L P [Member]    
Short-Term Debt [Line Items]    
Short-Term Debt, Interest Rate Increase 12.00%  
Maturity Date On Demand  
Principal amount  
Interest  
short-term convertible 8,826
Ed Blasiak [Member]    
Short-Term Debt [Line Items]    
Short-Term Debt, Interest Rate Increase 6.50%  
Maturity Date On Demand  
Principal amount $ 55,000  
Interest 9,216  
short-term convertible $ 64,216 63,322
Joshua Bauman [Member]    
Short-Term Debt [Line Items]    
Short-Term Debt, Interest Rate Increase 11.00%  
Maturity Date October 21, 2022  
Principal amount $ 150,000  
Interest 23,778  
short-term convertible $ 173,778 169,710
Series N Convertible Notes [Member]    
Short-Term Debt [Line Items]    
Short-Term Debt, Interest Rate Increase 6.00%  
Principal amount $ 3,229,000  
Interest 860,586  
short-term convertible $ 4,089,586 $ 4,041,813
Series N Convertible [Member]    
Short-Term Debt [Line Items]    
Maturity Date On Demand  
XML 54 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Mortgage loans (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Short-Term Debt [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 4.20%  
Principal Amount Outstanding on Loans Securitized or Asset-Backed Financing Arrangement $ 3,473,334  
Debt Instrument, Increase, Accrued Interest 4,796  
Cranberry Cove Holdings Ltd [Member]    
Short-Term Debt [Line Items]    
Loans Payable 3,478,130 $ 3,504,605
Loans Payable, Current $ 3,478,130 $ 3,504,605
XML 55 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders deficit (Details) - $ / shares
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Equity [Abstract]    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance 602,852,506 623,777,506
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance $ 0.001306 $ 0.0052875
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (20,925,000)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price $ 0.12
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period 20,925,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance 602,852,506 602,852,506
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance $ 0.001306 $ 0.001306
XML 56 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders deficit (Details 1)
 3 Months Ended
Mar. 31, 2023
$ / shares
shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
[custom:WarrantsOutstanding] 602,852,506
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm] 2 years 6 months 3 days
Warrants exercisable 602,852,506
Weighted average exercise price | $ / shares $ 0.001306
[custom:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable] | $ / shares $ 0.001306
Excercise 2 [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Warrants exercisable 276,565,659
Excercise 1 [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
[custom:WarrantsOutstanding] 326,286,847
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm] 2 years 3 months 10 days
Warrants exercisable 326,286,847
Excercise 2 [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
[custom:WarrantsOutstanding] 276,565,659
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm] 2 years 9 months 7 days
XML 57 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Revenue $ 89,419    
Operating expenses 30,120    
Operating income 59,299    
Other (expense) income      
Interest expense (47,733)    
Amortization of debt discount    
Foreign exchange movements (1,035)    
Net loss before taxes 10,531    
Taxes    
Net loss 10,531    
Purchase of fixed assets 52,418    
Current assets 689,664   $ 542,896
Non-current assets 5,916,141   $ 6,020,398
Current liabilities (14,068,340)    
Non-current liabilities (1,970,648)    
Intercompany balances    
Net liability position (9,433,183)    
Revenue 1,300,046 $ 1,023,315  
Operating income 75,026 74,940  
Other (expense) income      
Non-current liabilities 1,970,648    
In Patient Services [Member]      
Revenue 1,210,627    
Operating expenses 1,194,900 (915,059)  
Operating income 15,727    
Other (expense) income      
Interest expense (109,363) (27,161)  
Amortization of debt discount (76,921) (252,832)  
Foreign exchange movements (1,920)    
Net loss before taxes (172,477) (131,844)  
Taxes (13,771) (18,263)  
Net loss (186,248) (150,107)  
Purchase of fixed assets 52,418 72,858  
Current assets 689,431 355,167  
Non-current assets 3,474,998 3,426,324  
Current liabilities (9,083,220) (12,078,894)  
Non-current liabilities (1,350,792) 1,710,232  
Intercompany balances 1,299,110 (1,238,399)  
Net liability position (4,970,473) (11,646,034)  
Revenue   929,441  
Operating income   14,382  
Other (expense) income      
Derivative liability movement   197,476  
Non-current liabilities 1,350,792 (1,710,232)  
Mandatory redeemable preferred shares   (400,000)  
Total [Member]      
Revenue 1,300,046    
Operating expenses 1,225,020 (948,375)  
Operating income 75,026    
Other (expense) income      
Interest expense (157,096) (80,768)  
Amortization of debt discount (76,921) (252,832)  
Foreign exchange movements (2,955)    
Net loss before taxes (161,946) (146,722)  
Taxes (13,771) (18,263)  
Net loss (175,717) (164,985)  
Purchase of fixed assets   72,858  
Current assets   355,718  
Non-current assets   6,200,238  
Current liabilities   (13,669,609)  
Non-current liabilities   2,346,809  
Intercompany balances    
Net liability position   (9,860,462)  
Revenue   1,023,315  
Operating income   74,940  
Other (expense) income      
Derivative liability movement   197,476  
Non-current liabilities   (2,346,809)  
Mandatory redeemable preferred shares   (400,000)  
Rental Operations [Member]      
Operating expenses   (33,316)  
Other (expense) income      
Interest expense   (53,607)  
Amortization of debt discount    
Net loss before taxes   (14,878)  
Taxes    
Net loss   (14,878)  
Purchase of fixed assets  
Current assets 233 551  
Non-current assets 2,441,143 2,773,914  
Current liabilities (4,985,120) (1,590,715)  
Non-current liabilities (619,856) 636,577  
Intercompany balances (1,299,110) 1,238,399  
Net liability position (4,462,710) 1,785,572  
Revenue   93,874  
Operating income   60,558  
Other (expense) income      
Derivative liability movement    
Non-current liabilities $ 619,856 (636,577)  
Mandatory redeemable preferred shares    
XML 58 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Net income (loss) per common share (Details) - shares
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,185,143,076 1,069,575,454
Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 602,852,506 611,140,006
Convertible Note [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 582,290,570 458,435,448
XML 59 grst_10q_htm.xml IDEA: XBRL DOCUMENT 0000792935 2023-01-01 2023-03-31 0000792935 2023-05-19 0000792935 2023-03-31 0000792935 2022-12-31 0000792935 grst:RedeemableBPreferredStockMember 2023-03-31 0000792935 grst:RedeemableBPreferredStockMember 2022-12-31 0000792935 us-gaap:RedeemablePreferredStockMember 2023-03-31 0000792935 us-gaap:RedeemablePreferredStockMember 2022-12-31 0000792935 grst:RedeemableAPreferredStockMember 2023-03-31 0000792935 grst:RedeemableAPreferredStockMember 2022-12-31 0000792935 2022-01-01 2022-03-31 0000792935 us-gaap:PreferredClassAMember 2022-12-31 0000792935 us-gaap:CommonStockMember 2022-12-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000792935 grst:DiscountInParValueMember 2022-12-31 0000792935 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000792935 us-gaap:RetainedEarningsMember 2022-12-31 0000792935 us-gaap:NoncontrollingInterestMember 2022-12-31 0000792935 us-gaap:PreferredClassAMember 2021-12-31 0000792935 us-gaap:CommonStockMember 2021-12-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000792935 grst:DiscountInParValueMember 2021-12-31 0000792935 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000792935 us-gaap:RetainedEarningsMember 2021-12-31 0000792935 us-gaap:NoncontrollingInterestMember 2021-12-31 0000792935 2021-12-31 0000792935 us-gaap:PreferredClassAMember 2023-01-01 2023-03-31 0000792935 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000792935 grst:DiscountInParValueMember 2023-01-01 2023-03-31 0000792935 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000792935 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000792935 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000792935 us-gaap:PreferredClassAMember 2022-01-01 2022-03-31 0000792935 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000792935 grst:DiscountInParValueMember 2022-01-01 2022-03-31 0000792935 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000792935 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000792935 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000792935 us-gaap:PreferredClassAMember 2023-03-31 0000792935 us-gaap:CommonStockMember 2023-03-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000792935 grst:DiscountInParValueMember 2023-03-31 0000792935 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000792935 us-gaap:RetainedEarningsMember 2023-03-31 0000792935 us-gaap:NoncontrollingInterestMember 2023-03-31 0000792935 us-gaap:PreferredClassAMember 2022-03-31 0000792935 us-gaap:CommonStockMember 2022-03-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000792935 grst:DiscountInParValueMember 2022-03-31 0000792935 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000792935 us-gaap:RetainedEarningsMember 2022-03-31 0000792935 us-gaap:NoncontrollingInterestMember 2022-03-31 0000792935 2022-03-31 0000792935 us-gaap:LandMember 2023-03-31 0000792935 us-gaap:LandMember 2022-12-31 0000792935 us-gaap:PropertyPlantAndEquipmentMember 2023-03-31 0000792935 us-gaap:PropertyPlantAndEquipmentMember 2022-12-31 0000792935 us-gaap:LeaseholdImprovementsMember 2023-03-31 0000792935 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000792935 us-gaap:FurnitureAndFixturesMember 2023-03-31 0000792935 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000792935 us-gaap:VehiclesMember 2023-03-31 0000792935 us-gaap:VehiclesMember 2022-12-31 0000792935 us-gaap:ComputerEquipmentMember 2023-03-31 0000792935 us-gaap:ComputerEquipmentMember 2022-12-31 0000792935 grst:LeoniteCapitalLLCMember 2023-01-01 2023-03-31 0000792935 grst:LeoniteCapitalLLCMember 2022-01-01 2022-12-31 0000792935 grst:LeoniteFundILPMember 2023-01-01 2023-03-31 0000792935 grst:LeoniteFundILPMember 2022-01-01 2022-12-31 0000792935 grst:AuctusFundLLCMember 2023-01-01 2023-03-31 0000792935 grst:AuctusFundLLCMember 2022-01-01 2022-12-31 0000792935 grst:LabrysFundLPMember 2023-01-01 2023-03-31 0000792935 grst:LabrysFundLPMember 2022-01-01 2022-12-31 0000792935 grst:EdBlasiakMember 2023-01-01 2023-03-31 0000792935 grst:EdBlasiakMember 2022-01-01 2022-12-31 0000792935 grst:JoshuaBaumanMember 2023-01-01 2023-03-31 0000792935 grst:JoshuaBaumanMember 2022-01-01 2022-12-31 0000792935 grst:SeriesNConvertibleNotesMember 2023-01-01 2023-03-31 0000792935 grst:SeriesNConvertibleMember 2023-01-01 2023-03-31 0000792935 grst:SeriesNConvertibleNotesMember 2022-01-01 2022-12-31 0000792935 2022-01-01 2022-12-31 0000792935 grst:CranberryCoveHoldingsLtdMember 2023-03-31 0000792935 grst:CranberryCoveHoldingsLtdMember 2022-12-31 0000792935 grst:Excercise1Member 2023-01-01 2023-03-31 0000792935 grst:Excercise2Member 2023-01-01 2023-03-31 0000792935 grst:Excercise2Member 2023-01-01 2023-03-31 0000792935 grst:InPatientServicesMember 2023-01-01 2023-03-31 0000792935 grst:TotalMember 2023-01-01 2023-03-31 0000792935 grst:RentalOperationsMember 2023-03-31 0000792935 grst:InPatientServicesMember 2023-03-31 0000792935 grst:RentalOperationsMember 2022-01-01 2022-03-31 0000792935 grst:InPatientServicesMember 2022-01-01 2022-03-31 0000792935 grst:TotalMember 2022-01-01 2022-03-31 0000792935 grst:RentalOperationsMember 2022-03-31 0000792935 grst:InPatientServicesMember 2022-03-31 0000792935 grst:TotalMember 2022-03-31 0000792935 grst:WarrantsMember 2023-01-01 2023-03-31 0000792935 grst:WarrantsMember 2022-01-01 2022-03-31 0000792935 grst:ConvertibleNoteMember 2023-01-01 2023-03-31 0000792935 grst:ConvertibleNoteMember 2022-01-01 2022-03-31 iso4217:USD shares iso4217:USD shares pure 0000792935 false Q1 2023 --12-31 10-Q true 2023-03-31 false 000-54748 ETHEMA HEALTH CORPORATION. CO 84-1227328 950 Evernia Street West Palm Beach FL 33401 (416) 500-0020 Yes Yes Non-accelerated Filer true false false Common shares GRST 3729053805 27580 140757 543119 337074 34142 44718 84823 20347 689664 542896 2979853 2974395 1163437 1252932 1322851 1393071 450000 400000 5916141 6020398 6605805 6563294 372830 170934 282878 248644 5351270 5269250 496923 460534 3478130 3504605 443459 416731 61473 14818 299027 287017 8017 7891 1.00 10000000 400000 400000 218357 194829 2655976 2713878 14068340 13289131 29484 79555 201919 217451 590372 578335 1125990 1206413 22883 24952 1970648 2106706 16038988 15395837 1.00 10000000 400000 400000 0.01 10000000 4000000 40000 40000 0.01 10000000000 3729053805 37290539 37290539 23419917 23419917 27363367 27363367 -6569 -5065 -43686855 -43484751 -10306335 -10102727 873152 870184 -9433183 -9232543 6605805 6563294 1300046 1023315 241237 209932 114564 90031 27500 30000 111204 49587 592036 436825 138479 132000 1225020 948375 75026 74940 10018 157096 80768 -76921 -252832 -197476 -2955 -95556 -161946 -146722 -13771 -18263 -175717 -164985 -2968 -9462 -178685 -174447 23419 24613 -202104 -199060 1504 -34517 -203608 -164543 -0.00 -0.00 3729053805 3630720472 4000000 40000 3729053805 37290539 23419917 -27363367 -5065 -43484751 870184 -9232543 -1504 -1504 -178685 2968 -175717 23419 23419 4000000 40000 3729053805 37290539 234199117 -27363367 -6569 -43686855 873152 -9433183 4000000 40000 3579053805 3570539 22791350 -26013367 816532 -44103311 822876 -9855381 150000000 1500000 -1350000 150000 34517 34517 -174447 9462 -164985 24613 24613 4000000 40000 3729053805 37290539 22791350 -27363367 851049 -44302371 832338 -9860462 -175717 -164985 138479 132000 76921 252832 -197476 70219 63064 -15532 -18794 151744 115000 10576 10456 -64476 -1171 251384 -22013 -68413 -57156 34177 49169 105874 -69074 50000 52418 72858 -102418 -72858 29300 29850 190000 204133 10000 201733 100000 -3449 78977 1944 1822 259228 -58917 -117743 46846 1110 73288 -113177 -21798 140757 48822 27580 27024 53310 43304 150000 <p id="xdx_800_eus-gaap--NatureOfOperations_z0wabegGciib" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span style="background-color: white"><span id="xdx_824_zEyLgf3U4xtc">Nature of business</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Since 2010, the Company has operated addiction treatment centers. Initially the Company operated an addiction treatment center in Ontario Canada under its Greenestone Muskoka clinic, which was sold on February 14, 2017. Simultaneously with this sale the Company purchased buildings and operated an addiction treatment center in Delray Beach Florida under its Addiction Recovery Institute of America subsidiary with a license obtained in December 2016, initially through owned properties in Delray Beach and subsequently though leased properties in West Palm Beach, Florida. Since June 30, 2020, the Company has been actively involved in the management of a treatment center operated by Evernia in West Palm Beach, Florida. On July 1, 2021, the Company closed on the acquisition of 75% of ATHI, which owns 100% of Evernia, once the probationary approval of a license was obtained from the Department of Children and Family Services of Florida. Evernia is the only active treatment center operated by the Company.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company also owns the real estate on which its Greenstone Muskoka clinic operated. The current tenant operates an addiction treatment center on these premises. The Company collects rent on this property, which is treated as a separate business segment.<b> </b></span></p> <p style="margin: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">    <b> </b></span></p> <p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_z3VPt2inRhC1" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_82E_zx3NItzeo59g">Summary of significant accounting policies</span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> <b>Financial Reporting</b></span></p> <p style="margin: 0 0.05in 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0.05in 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The (a) unaudited condensed consolidated balance sheets as of March 31, 2023, which have been derived from the unaudited condensed consolidated financial statements, and as of December 31, 2022, which have been derived from audited consolidated financial statements, and (b) the unaudited condensed consolidated statements of operations, stockholders’ deficit and cash flows of the Company, have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of results that may be expected for the year ending December 31, 2023. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023.</span></p> <p style="margin: 0 0.05in 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0.05in 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">All amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.</span></p> <p style="margin: 0 0.05in 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--UseOfEstimates_zFBaCPmj256b" style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>a) <span id="xdx_864_zAbSom8XZTEc">Use of Estimates</span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p> <p style="margin: 0 0 0 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zFEMfu7zSps" style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>b) <span id="xdx_862_zXs9ptllr1ik">Principals of consolidation and foreign currency translation</span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and all of its subsidiaries. All intercompany transactions and balances have been eliminated on consolidation.</span></p> <p style="margin: 0 0 0 0.25in; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain of the Company’s subsidiaries functional currency is the Canadian dollar, while the Company’s reporting currency is the U.S. dollar. All transactions initiated in Canadian dollars are translated into US dollars in accordance with ASC 830, “Foreign Currency Translation” as follows:</span></p> <p style="margin: 0 0 0 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; padding-left: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="width: 94%; padding-left: 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monetary assets and liabilities at the rate of exchange in effect at the balance sheet date.</span></td></tr> </table> <p style="margin: 0 0 0 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; padding-left: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="width: 94%; padding-left: 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain non-monetary assets and liabilities and equity at historical rates.</span></td></tr> </table> <p style="margin: 0 0 0 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; padding-left: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="width: 94%; padding-left: 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue and expense items and cash flows at the average rate of exchange prevailing during the year.</span></td></tr> </table> <p style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> Adjustments arising from such translations are deferred until realization and are included as a separate component of stockholders’ deficit as a component of accumulated other comprehensive income or loss. Therefore, translation adjustments are not included in determining net income (loss) but reported as other comprehensive income (loss).</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For foreign currency transactions, the Company translates these amounts to the Company’s functional currency at the exchange rate effective on the invoice date. If the exchange rate changes between the time of purchase and the time actual payment is made, a foreign exchange transaction gain or loss results which is included in determining net income for the year.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The relevant translation rates are as follows: For the three months ended March 31, 2023, a closing rate of CDN$1 equals US$0.7389 and an average exchange rate of CDN$1 equals US$0.7394, for the year ended December 31, 2022, a closing rate of CDN$1.0000 equals US$0.7383 and an average exchange rate of CDN$1.0000 equals US$0.7686.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--BusinessCombinationsPolicy_z2pOoQEn2fld" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c) <span style="background-color: white"><span id="xdx_864_z3OvsBgpJM55">Business Combinations</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company allocates the fair value of purchase consideration to the tangible and intangible assets acquired and liabilities assumed for business combinations with third parties based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired users, acquired technology, and trade names from a market participant perspective, useful lives and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zUIVn0DfxFC" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d) <span style="background-color: white"><span id="xdx_868_zTeLq3h8nAEi">Cash and cash equivalents</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with several financial institution in the USA and Canada. There were no cash equivalents at </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">March 31, 2023 and December 31, 2022.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company primarily places cash balances in the USA with high-credit quality financial institutions located in the United States which are insured by the Federal Deposit Insurance Corporation up to a limit of $<span id="xdx_905_eus-gaap--FDICIndemnificationAsset_iI_c20230331_zLNq5raQhtR2" title="Federal Deposit Insurance">250,000</span> per institution, in Canada which are insured by the Canadian Deposit Insurance Corporation up to a limit of CDN$100,000 per institution.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--ReceivablesPolicyTextBlock_zbjVumEhSWvh" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>e) <span style="background-color: white"><span id="xdx_86A_zOB8DcSnulYf">Accounts receivable</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Accounts receivable primarily consists of amounts due from third-party payors (non-governmental) and private pay patients and is recorded net of allowances for doubtful accounts and contractual discounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s unaudited condensed consolidated financial statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimating net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies denying claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--AllowanceForDoubtfulAccountsContractualAndOtherDiscountsPolicyTextBlock_zQbCkcQiiUh2" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f) <span style="background-color: white"><span id="xdx_869_zh1uWLwA7xll">Allowance for Doubtful Accounts, Contractual and Other Discounts</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>  </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company derives the majority of its revenues from commercial payors at in-network rates. Management estimates the allowance for contractual and other discounts based on its historical collection experience and contractual rates. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account is written off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWV6CajnG3Fk" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>g) <span style="background-color: white"><span id="xdx_86B_z2sqVPYNkvbf">Property and equipment</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>  </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property and equipment is recorded at cost. Depreciation is calculated on the straight line basis over the estimated life of the asset.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zbsqClJB90N2" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>h) <span style="background-color: white"><span id="xdx_86F_z00wiUroXN1">Intangible assets</span></span></b></span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Intangible assets are stated at acquisition cost less accumulated amortization, if applicable, less any adjustments for impairment losses.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Amortization is charged on a straight-line basis over the estimated remaining useful lives of the individual intangibles. Where intangibles are deemed to be impaired the Company recognizes an impairment loss measured as the difference between the estimated fair value of the intangible and its book value.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Licenses to provide substance abuse rehabilitation services are amortized over the expected life of the contract, including any anticipated renewals. The Company expects its licenses to remain in operation for a period of five years.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">   </span></p> <p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_zMfdmlyAfHM1" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>i) <span style="background-color: white"><span id="xdx_861_zaeo3FvolrT4">Leases</span></span></b></span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b> </b>The Company accounts for leases in terms of AC 842 whereby leases are classified as either finance or operating leases. Leases that transfer substantially all of the benefits and inherent risks of ownership of property to the Company are accounted for as finance leases. At the time a finance lease is entered into, an asset is recorded together with its related long-term obligation to reflect the acquisition and financing. Property and equipment recorded under finance leases is amortized on the same basis as described above. Operating leases are recognized on the balance sheet as a lease liability with a corresponding right of use asset for all leases with a term that is more than twelve months. Payments under operating leases are expensed as incurred.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--DerivativesPolicyTextBlock_zaINdkqFqQ3d" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>j) <span style="background-color: white"><span id="xdx_865_zX5wr5VLGarg">Derivatives</span></span></b></span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. The Company previously used a Black Scholes Option Pricing model to estimate the fair value of convertible debt conversion features at the end of each applicable reporting period. Changes in the fair value of these derivatives during each reporting period were included in the statements of operations. Inputs into the Black Scholes Option Pricing model require estimates, including such items as estimated volatility of the Company’s stock, risk free interest rate and the estimated life of the financial instruments being fair valued.</span></p> <p style="margin: 0 0.6pt 0 0.5in; text-align: justify; text-indent: -0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion feature.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zQUAW7EuERt6" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>k) <span style="background-color: white"><span id="xdx_861_zWKOUukf4yv9">Financial instruments</span></span></b></span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company initially measures its financial assets and liabilities at fair value. The Company subsequently measures all its financial assets and financial liabilities at amortized cost.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial assets measured at amortized cost include cash and accounts receivable.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial liabilities measured at amortized cost include bank indebtedness, accounts payable and accrued liabilities, harmonized sales tax payable, withholding taxes payable, convertible notes payable, loans payable and related party notes.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial assets measured at cost are tested for impairment when there are indicators of impairment. The amount of the write-down is recognized in net income. The previously recognized impairment loss may be reversed to the extent of the improvement, directly or by adjusting the allowance account, provided it is no greater than the amount that would have been reported at the date of the reversal had the impairment not been recognized previously. The amount of the reversal is recognized in net income. The Company recognizes its transaction costs in net income in the period incurred. However, financial instruments that will not be subsequently measured at fair value are adjusted by the transaction costs that are directly attributable to their origination, issuance or assumption.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">FASB ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p> <p style="margin: 0 0 0 45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; padding-right: -32.3pt; padding-left: 17.2pt; text-align: justify; text-indent: 24.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="width: 94%; padding-top: 0.05pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1. Observable inputs such as quoted prices in active markets;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-right: -32.3pt; padding-left: 17.2pt; text-align: justify; text-indent: 24.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● </span></td> <td style="padding-top: 0.05pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-right: -32.3pt; padding-left: 17.2pt; text-align: justify; text-indent: 24.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="padding-top: 0.05pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3. Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions.</span></td></tr> </table> <p style="margin: 0 0 0 45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company measures its convertible debt and derivative liabilities associated therewith at fair value. These liabilities are revalued periodically and the resultant gain or loss is realized through the consolidated Statement of Operations and Comprehensive Loss.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--RelatedPartiesPolicyTextBlock_zPJ6GjfK70P1" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>l) <span style="background-color: white"><span id="xdx_86E_zxrpCSzDVB85">Related parties</span></span></b></span></p> <p style="margin: 0 0 0 40.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Parties are considered to be related to the Company if the parties directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zhYmHVMUeim4" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>m) <span style="background-color: white"><span id="xdx_86C_zYoPHQBheElf">Revenue recognition</span></span></b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">ASC 606 requires companies to exercise more judgment and recognize revenue using a five-step process.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company’s provision for doubtful accounts are recorded as a direct reduction to revenue instead of being presented as a separate line item on the consolidated statements of operations and comprehensive loss.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0.9pt 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company receives payments from the following sources for services rendered in our U.S. Facility: (i) commercial insurers; and (ii) individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and does not adjust for the effects of a significant financing component.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company derives a significant portion of its revenue from other payors that receive discounts from established billing rates. The various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Settlements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s receivables were $<span id="xdx_90D_eus-gaap--AccountsAndNotesReceivableNet_iI_c20230331_zQ7Y5dA3F8Sb" title="Receivables">543,119</span> and $<span id="xdx_90E_eus-gaap--AccountsAndNotesReceivableNet_iI_c20221231_zKRS6ei2Gn5j" title="Receivables">337,074</span> at March 31, 2023 and December 31, 2022, respectively. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company’s revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those services. The Company derives its revenues from the sale of its services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its revenue transactions: </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="width: 91%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify the contract with a customer;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify the performance obligations in the contract;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine the transaction price;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate the transaction price to performance obligations in the contract; and</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize revenue as the performance obligation is satisfied.</span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_z4YR93mhnE88" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>n) <span style="background-color: white"><span id="xdx_863_zXHWa1HLRE97">Income taxes</span></span></b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company accounts for income taxes under the provisions of ASC Topic 740, <i>“Income Taxes”. </i>Under ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes are provided using the liability method. Under this method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The tax basis of an asset or liability is the amount attributed to that asset or liability for tax purposes. The effect on deferred taxes of a change in tax rates is recognized in income in the period of change. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion of, or all of, the deferred tax assets will not be realized.</span></p> <p style="margin: 0 0 0 45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">  </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">ASC Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions taken or expected to be taken in a tax return. The first step is to determine if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company recognizes interest and penalties accrued on unrecognized tax benefits within general and administrative expense. To the extent that accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction in general and administrative expenses in the period that such determination is made. The tax returns for fiscal 2019, through 2022 are subject to audit or review by the US tax authorities, whereas fiscal 2011 through 2022 are subject to audit or review by the Canadian tax authority.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zoAErjKVQMRe" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>o) <span style="background-color: white"><span id="xdx_86C_zcJuqcH99428">Net income (loss) per Share</span></span></b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Basic net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the year.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Diluted net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Dilution is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share). </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_z6cSBqsr6DFg" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>p) <span style="background-color: white"><span id="xdx_866_zTGc31hmCug3">Stock based compensation</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over the employee’s requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized in the consolidated statements of operations for the three months ended March 31, 2023 and 2022 is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. We have no awards with performance conditions and no awards dependent on market conditions.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_ecustom--FinancialnstrumentsRisksPolicyTextBlock_zCOkES5JkYZa" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>q) <span style="background-color: white"><span id="xdx_86F_zP6hS5XDlYVc">Financial instruments risks</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company is exposed to various risks through its financial instruments. The following analysis provides a measure of the Company’s risk exposure and concentrations at the balance sheet dates, March 31, 2023 and December 31, 2022.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 7%; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; padding-left: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>i.</i></b></span></td> <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Credit risk</i></b></span></td></tr> </table> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="margin: 0 0 0 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Financial instruments that subject the Company to credit risk consist primarily of accounts receivable.</span></p> <p style="margin: 0 0 0 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Credit risk associated with accounts receivable is mitigated as only a percentage of the revenue billed to health insurance companies is recognized as income until such time as the actual funds are collected. The revenue is concentrated amongst several health insurance companies located in the US.</span></p> <p style="margin: 0 0 0 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 7%; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ii.</i></b></span></td> <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity risk</i></b></span></td></tr> </table> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="margin: 0 0 0 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Liquidity risk is the risk the Company will not be able to meet its financial obligations as they fall due. The Company is exposed to liquidity risk through its working capital deficiency of approximately $13.4 million, and an accumulated deficit of approximately $43.7 million. The Company is dependent upon the raising of additional capital in order to implement its business plan. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial condition. In the opinion of management, liquidity risk is assessed as high, material and remains unchanged from that of the prior year.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>iii.</i></b></span></td> <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market risk</i></b></span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="margin: 0 13.5pt 0 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of three types of risk: interest rate risk, currency risk, and other price risk. The Company is exposed to interest rate risk and currency risk.</span></p> <p style="margin: 0 0 0 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>a.</i></b></span></td> <td style="width: 87%; padding-right: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest rate risk</b></span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 4.5pt 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its convertible debt, mortgage loans, short term loans, third party loans and government assistance loans as of March 31, 2023. In the opinion of management, interest rate risk is assessed as moderate.</span></p> <p style="margin: 0 0 0 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>b.</i></b></span></td> <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Currency risk</b></span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company is subject to currency risk as it has subsidiaries that operate in Canada and are subject to fluctuations in the Canadian dollar. A substantial portion of the Company’s financial assets and liabilities are denominated in Canadian dollars, however net earnings in foreign currency is minimal and a 5% depreciation or appreciation of the Canadian dollar against the U.S. dollar would result in an immaterial increase or decrease in the Company’s after tax net income from operations. The Company has not entered into any hedging agreements to mitigate this risk. In the opinion of management, currency risk is assessed as low, material and remains unchanged from that of the prior year.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>c.</i></b></span></td> <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other price risk</b></span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. In the opinion of management, the Company is not exposed to this risk and remains unchanged from the prior year.</span></p> <p style="margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_ecustom--AllowanceForCreditLossesPolicyTextBlock_zIdj329D9Eo8" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>q) <span style="background-color: white"><span id="xdx_868_zldEB23vnpZi">Allowance for credit losses</span></span></b></span></p> <p style="margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The Company recognizes revenue based on historical collections received from healthcare providers, recognizing only a percentage of revenues actually billed. Effectively recognizing revenue net of any expected billing differentials. Based on the Company’s collection experience, the percentage of revenue recognized is adjusted on a periodic basis, thereby taking into account expected credit losses in the revenue recognition process. The revenue we recognize is already net of expected credit losses.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We constantly evaluate our collections experience and consider the market conditions and current economic developments facing the Company’s operations . We have not experienced significantly different collections to revenues we have recognized and we have not seen any deterioration in the payment patterns from the healthcare providers that the Company works with, we cannot predict with any certainty that the payment patterns the Company experiences may change and we may be required to adjust the percentage of revenue recognized.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFChAGknaPI8" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>r) <span style="background-color: white"><span id="xdx_86D_zEE3o6izqqE7">Recent accounting pronouncements</span></span></b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Financial Accounting Standards Board (“FASB”) issued additional updates during the three months ended March 31, 2023. None of these standards are either applicable to the Company or require adoption at a future date and none are expected to have a material impact on the Company’s consolidated financial statements upon adoption.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> <b> </b></span></p> <p id="xdx_846_eus-gaap--UseOfEstimates_zFBaCPmj256b" style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>a) <span id="xdx_864_zAbSom8XZTEc">Use of Estimates</span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p> <p style="margin: 0 0 0 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zFEMfu7zSps" style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>b) <span id="xdx_862_zXs9ptllr1ik">Principals of consolidation and foreign currency translation</span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and all of its subsidiaries. All intercompany transactions and balances have been eliminated on consolidation.</span></p> <p style="margin: 0 0 0 0.25in; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain of the Company’s subsidiaries functional currency is the Canadian dollar, while the Company’s reporting currency is the U.S. dollar. All transactions initiated in Canadian dollars are translated into US dollars in accordance with ASC 830, “Foreign Currency Translation” as follows:</span></p> <p style="margin: 0 0 0 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; padding-left: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="width: 94%; padding-left: 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monetary assets and liabilities at the rate of exchange in effect at the balance sheet date.</span></td></tr> </table> <p style="margin: 0 0 0 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; padding-left: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="width: 94%; padding-left: 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain non-monetary assets and liabilities and equity at historical rates.</span></td></tr> </table> <p style="margin: 0 0 0 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; padding-left: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="width: 94%; padding-left: 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue and expense items and cash flows at the average rate of exchange prevailing during the year.</span></td></tr> </table> <p style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> Adjustments arising from such translations are deferred until realization and are included as a separate component of stockholders’ deficit as a component of accumulated other comprehensive income or loss. Therefore, translation adjustments are not included in determining net income (loss) but reported as other comprehensive income (loss).</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For foreign currency transactions, the Company translates these amounts to the Company’s functional currency at the exchange rate effective on the invoice date. If the exchange rate changes between the time of purchase and the time actual payment is made, a foreign exchange transaction gain or loss results which is included in determining net income for the year.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The relevant translation rates are as follows: For the three months ended March 31, 2023, a closing rate of CDN$1 equals US$0.7389 and an average exchange rate of CDN$1 equals US$0.7394, for the year ended December 31, 2022, a closing rate of CDN$1.0000 equals US$0.7383 and an average exchange rate of CDN$1.0000 equals US$0.7686.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--BusinessCombinationsPolicy_z2pOoQEn2fld" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c) <span style="background-color: white"><span id="xdx_864_z3OvsBgpJM55">Business Combinations</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company allocates the fair value of purchase consideration to the tangible and intangible assets acquired and liabilities assumed for business combinations with third parties based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired users, acquired technology, and trade names from a market participant perspective, useful lives and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zUIVn0DfxFC" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d) <span style="background-color: white"><span id="xdx_868_zTeLq3h8nAEi">Cash and cash equivalents</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with several financial institution in the USA and Canada. There were no cash equivalents at </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">March 31, 2023 and December 31, 2022.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company primarily places cash balances in the USA with high-credit quality financial institutions located in the United States which are insured by the Federal Deposit Insurance Corporation up to a limit of $<span id="xdx_905_eus-gaap--FDICIndemnificationAsset_iI_c20230331_zLNq5raQhtR2" title="Federal Deposit Insurance">250,000</span> per institution, in Canada which are insured by the Canadian Deposit Insurance Corporation up to a limit of CDN$100,000 per institution.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 250000 <p id="xdx_84A_eus-gaap--ReceivablesPolicyTextBlock_zbjVumEhSWvh" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>e) <span style="background-color: white"><span id="xdx_86A_zOB8DcSnulYf">Accounts receivable</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Accounts receivable primarily consists of amounts due from third-party payors (non-governmental) and private pay patients and is recorded net of allowances for doubtful accounts and contractual discounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s unaudited condensed consolidated financial statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimating net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies denying claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--AllowanceForDoubtfulAccountsContractualAndOtherDiscountsPolicyTextBlock_zQbCkcQiiUh2" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f) <span style="background-color: white"><span id="xdx_869_zh1uWLwA7xll">Allowance for Doubtful Accounts, Contractual and Other Discounts</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>  </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company derives the majority of its revenues from commercial payors at in-network rates. Management estimates the allowance for contractual and other discounts based on its historical collection experience and contractual rates. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account is written off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWV6CajnG3Fk" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>g) <span style="background-color: white"><span id="xdx_86B_z2sqVPYNkvbf">Property and equipment</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>  </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property and equipment is recorded at cost. Depreciation is calculated on the straight line basis over the estimated life of the asset.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zbsqClJB90N2" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>h) <span style="background-color: white"><span id="xdx_86F_z00wiUroXN1">Intangible assets</span></span></b></span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Intangible assets are stated at acquisition cost less accumulated amortization, if applicable, less any adjustments for impairment losses.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Amortization is charged on a straight-line basis over the estimated remaining useful lives of the individual intangibles. Where intangibles are deemed to be impaired the Company recognizes an impairment loss measured as the difference between the estimated fair value of the intangible and its book value.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Licenses to provide substance abuse rehabilitation services are amortized over the expected life of the contract, including any anticipated renewals. The Company expects its licenses to remain in operation for a period of five years.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">   </span></p> <p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_zMfdmlyAfHM1" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>i) <span style="background-color: white"><span id="xdx_861_zaeo3FvolrT4">Leases</span></span></b></span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b> </b>The Company accounts for leases in terms of AC 842 whereby leases are classified as either finance or operating leases. Leases that transfer substantially all of the benefits and inherent risks of ownership of property to the Company are accounted for as finance leases. At the time a finance lease is entered into, an asset is recorded together with its related long-term obligation to reflect the acquisition and financing. Property and equipment recorded under finance leases is amortized on the same basis as described above. Operating leases are recognized on the balance sheet as a lease liability with a corresponding right of use asset for all leases with a term that is more than twelve months. Payments under operating leases are expensed as incurred.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--DerivativesPolicyTextBlock_zaINdkqFqQ3d" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>j) <span style="background-color: white"><span id="xdx_865_zX5wr5VLGarg">Derivatives</span></span></b></span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. The Company previously used a Black Scholes Option Pricing model to estimate the fair value of convertible debt conversion features at the end of each applicable reporting period. Changes in the fair value of these derivatives during each reporting period were included in the statements of operations. Inputs into the Black Scholes Option Pricing model require estimates, including such items as estimated volatility of the Company’s stock, risk free interest rate and the estimated life of the financial instruments being fair valued.</span></p> <p style="margin: 0 0.6pt 0 0.5in; text-align: justify; text-indent: -0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion feature.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zQUAW7EuERt6" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>k) <span style="background-color: white"><span id="xdx_861_zWKOUukf4yv9">Financial instruments</span></span></b></span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company initially measures its financial assets and liabilities at fair value. The Company subsequently measures all its financial assets and financial liabilities at amortized cost.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial assets measured at amortized cost include cash and accounts receivable.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial liabilities measured at amortized cost include bank indebtedness, accounts payable and accrued liabilities, harmonized sales tax payable, withholding taxes payable, convertible notes payable, loans payable and related party notes.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial assets measured at cost are tested for impairment when there are indicators of impairment. The amount of the write-down is recognized in net income. The previously recognized impairment loss may be reversed to the extent of the improvement, directly or by adjusting the allowance account, provided it is no greater than the amount that would have been reported at the date of the reversal had the impairment not been recognized previously. The amount of the reversal is recognized in net income. The Company recognizes its transaction costs in net income in the period incurred. However, financial instruments that will not be subsequently measured at fair value are adjusted by the transaction costs that are directly attributable to their origination, issuance or assumption.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">FASB ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p> <p style="margin: 0 0 0 45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; padding-right: -32.3pt; padding-left: 17.2pt; text-align: justify; text-indent: 24.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="width: 94%; padding-top: 0.05pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1. Observable inputs such as quoted prices in active markets;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-right: -32.3pt; padding-left: 17.2pt; text-align: justify; text-indent: 24.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● </span></td> <td style="padding-top: 0.05pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-right: -32.3pt; padding-left: 17.2pt; text-align: justify; text-indent: 24.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="padding-top: 0.05pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3. Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions.</span></td></tr> </table> <p style="margin: 0 0 0 45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company measures its convertible debt and derivative liabilities associated therewith at fair value. These liabilities are revalued periodically and the resultant gain or loss is realized through the consolidated Statement of Operations and Comprehensive Loss.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--RelatedPartiesPolicyTextBlock_zPJ6GjfK70P1" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>l) <span style="background-color: white"><span id="xdx_86E_zxrpCSzDVB85">Related parties</span></span></b></span></p> <p style="margin: 0 0 0 40.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Parties are considered to be related to the Company if the parties directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zhYmHVMUeim4" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>m) <span style="background-color: white"><span id="xdx_86C_zYoPHQBheElf">Revenue recognition</span></span></b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">ASC 606 requires companies to exercise more judgment and recognize revenue using a five-step process.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company’s provision for doubtful accounts are recorded as a direct reduction to revenue instead of being presented as a separate line item on the consolidated statements of operations and comprehensive loss.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0.9pt 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company receives payments from the following sources for services rendered in our U.S. Facility: (i) commercial insurers; and (ii) individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and does not adjust for the effects of a significant financing component.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company derives a significant portion of its revenue from other payors that receive discounts from established billing rates. The various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Settlements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s receivables were $<span id="xdx_90D_eus-gaap--AccountsAndNotesReceivableNet_iI_c20230331_zQ7Y5dA3F8Sb" title="Receivables">543,119</span> and $<span id="xdx_90E_eus-gaap--AccountsAndNotesReceivableNet_iI_c20221231_zKRS6ei2Gn5j" title="Receivables">337,074</span> at March 31, 2023 and December 31, 2022, respectively. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company’s revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those services. The Company derives its revenues from the sale of its services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its revenue transactions: </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="width: 91%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify the contract with a customer;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify the performance obligations in the contract;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine the transaction price;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate the transaction price to performance obligations in the contract; and</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize revenue as the performance obligation is satisfied.</span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 543119 337074 <p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_z4YR93mhnE88" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>n) <span style="background-color: white"><span id="xdx_863_zXHWa1HLRE97">Income taxes</span></span></b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company accounts for income taxes under the provisions of ASC Topic 740, <i>“Income Taxes”. </i>Under ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes are provided using the liability method. Under this method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The tax basis of an asset or liability is the amount attributed to that asset or liability for tax purposes. The effect on deferred taxes of a change in tax rates is recognized in income in the period of change. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion of, or all of, the deferred tax assets will not be realized.</span></p> <p style="margin: 0 0 0 45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">  </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">ASC Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions taken or expected to be taken in a tax return. The first step is to determine if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company recognizes interest and penalties accrued on unrecognized tax benefits within general and administrative expense. To the extent that accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction in general and administrative expenses in the period that such determination is made. The tax returns for fiscal 2019, through 2022 are subject to audit or review by the US tax authorities, whereas fiscal 2011 through 2022 are subject to audit or review by the Canadian tax authority.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zoAErjKVQMRe" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>o) <span style="background-color: white"><span id="xdx_86C_zcJuqcH99428">Net income (loss) per Share</span></span></b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Basic net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the year.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Diluted net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Dilution is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share). </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_z6cSBqsr6DFg" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>p) <span style="background-color: white"><span id="xdx_866_zTGc31hmCug3">Stock based compensation</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over the employee’s requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized in the consolidated statements of operations for the three months ended March 31, 2023 and 2022 is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. We have no awards with performance conditions and no awards dependent on market conditions.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_ecustom--FinancialnstrumentsRisksPolicyTextBlock_zCOkES5JkYZa" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>q) <span style="background-color: white"><span id="xdx_86F_zP6hS5XDlYVc">Financial instruments risks</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company is exposed to various risks through its financial instruments. The following analysis provides a measure of the Company’s risk exposure and concentrations at the balance sheet dates, March 31, 2023 and December 31, 2022.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 7%; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; padding-left: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>i.</i></b></span></td> <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Credit risk</i></b></span></td></tr> </table> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="margin: 0 0 0 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Financial instruments that subject the Company to credit risk consist primarily of accounts receivable.</span></p> <p style="margin: 0 0 0 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Credit risk associated with accounts receivable is mitigated as only a percentage of the revenue billed to health insurance companies is recognized as income until such time as the actual funds are collected. The revenue is concentrated amongst several health insurance companies located in the US.</span></p> <p style="margin: 0 0 0 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 7%; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ii.</i></b></span></td> <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity risk</i></b></span></td></tr> </table> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="margin: 0 0 0 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Liquidity risk is the risk the Company will not be able to meet its financial obligations as they fall due. The Company is exposed to liquidity risk through its working capital deficiency of approximately $13.4 million, and an accumulated deficit of approximately $43.7 million. The Company is dependent upon the raising of additional capital in order to implement its business plan. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial condition. In the opinion of management, liquidity risk is assessed as high, material and remains unchanged from that of the prior year.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>iii.</i></b></span></td> <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market risk</i></b></span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="margin: 0 13.5pt 0 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of three types of risk: interest rate risk, currency risk, and other price risk. The Company is exposed to interest rate risk and currency risk.</span></p> <p style="margin: 0 0 0 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>a.</i></b></span></td> <td style="width: 87%; padding-right: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest rate risk</b></span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 4.5pt 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its convertible debt, mortgage loans, short term loans, third party loans and government assistance loans as of March 31, 2023. In the opinion of management, interest rate risk is assessed as moderate.</span></p> <p style="margin: 0 0 0 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>b.</i></b></span></td> <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Currency risk</b></span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company is subject to currency risk as it has subsidiaries that operate in Canada and are subject to fluctuations in the Canadian dollar. A substantial portion of the Company’s financial assets and liabilities are denominated in Canadian dollars, however net earnings in foreign currency is minimal and a 5% depreciation or appreciation of the Canadian dollar against the U.S. dollar would result in an immaterial increase or decrease in the Company’s after tax net income from operations. The Company has not entered into any hedging agreements to mitigate this risk. In the opinion of management, currency risk is assessed as low, material and remains unchanged from that of the prior year.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>c.</i></b></span></td> <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other price risk</b></span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. In the opinion of management, the Company is not exposed to this risk and remains unchanged from the prior year.</span></p> <p style="margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_ecustom--AllowanceForCreditLossesPolicyTextBlock_zIdj329D9Eo8" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>q) <span style="background-color: white"><span id="xdx_868_zldEB23vnpZi">Allowance for credit losses</span></span></b></span></p> <p style="margin: 0 0 0 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The Company recognizes revenue based on historical collections received from healthcare providers, recognizing only a percentage of revenues actually billed. Effectively recognizing revenue net of any expected billing differentials. Based on the Company’s collection experience, the percentage of revenue recognized is adjusted on a periodic basis, thereby taking into account expected credit losses in the revenue recognition process. The revenue we recognize is already net of expected credit losses.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We constantly evaluate our collections experience and consider the market conditions and current economic developments facing the Company’s operations . We have not experienced significantly different collections to revenues we have recognized and we have not seen any deterioration in the payment patterns from the healthcare providers that the Company works with, we cannot predict with any certainty that the payment patterns the Company experiences may change and we may be required to adjust the percentage of revenue recognized.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFChAGknaPI8" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>r) <span style="background-color: white"><span id="xdx_86D_zEE3o6izqqE7">Recent accounting pronouncements</span></span></b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Financial Accounting Standards Board (“FASB”) issued additional updates during the three months ended March 31, 2023. None of these standards are either applicable to the Company or require adoption at a future date and none are expected to have a material impact on the Company’s consolidated financial statements upon adoption.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> <b> </b></span></p> <p id="xdx_800_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_ziGik4oAzfm3" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span style="background-color: white"><span id="xdx_820_zEjIMIx5kVca">Going concern</span></span></b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with US GAAP applicable to a going concern, which assumes that the Company will be able to meet its obligations and continue its operations in the normal course of business. At March 31, 2023 the Company has a working capital deficiency of $13.4 million, and total liabilities in excess of assets in the amount of $9.4 million . Management believes that current available resources will not be sufficient to fund the Company’s planned expenditures over the next 12 months. These factors, individually and collectively indicate that a material uncertainty exists that raises substantial doubt about the Company's ability to continue as a going concern for one year from the date of issuance of these condensed interim consolidated financial statements. </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company will be dependent upon the raising of additional capital through placement of common shares, and/or debt financing in order to implement its business plan and generating sufficient revenue in excess of costs. If the Company raises additional capital through the issuance of equity securities or securities convertible into equity, stockholders will experience dilution, and such securities may have rights, preferences or privileges senior to those of the holders of common stock or convertible senior notes. If the Company raises additional funds by issuing debt, the Company may be subject to limitations on its operations, through debt covenants or other restrictions. If the Company obtains additional funds through arrangements with collaborators or strategic partners, the Company may be required to relinquish its rights to certain geographical areas, or techniques that it might otherwise seek to retain. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial condition. These unaudited condensed consolidated financial statements do not include any adjustments to the amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> <b> </b></span></p> <p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zpeqkQnjV0Db" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. <span style="background-color: white"><span id="xdx_82B_zPR7CARZIAM1">Property and equipment</span></span></b></span></p> <p style="margin: 0 0.6pt 0 16.55pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">  </span></p> <p style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property and equipment consists of the following:  </span></p> <p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zeLjhQM2Y7G4" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">  <span id="xdx_8B1_z4rygAEbhCnf" style="display: none">Schedule of sale of property</span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_30E_134_zxFxh7DlGmf2" style="width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Property and equipment (Details)"> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="11" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,<br/> 2023</b></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></td></tr> <tr> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; vertical-align: top"><p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful</b></span></p> <p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>lives</b></span></p></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cost</b></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated depreciation</b></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net book value</b></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net book value</b></span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land</span></td> <td style="vertical-align: top; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indefinite</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zFOm4eyVJhM5" style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,871</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zmEmOFTcris6" style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0599">—</span>  </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_z4DVYdQzuODf" style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,871</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zaxPvCD2RyTg" style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,742</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25 years</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_z7nV1Ndbu981" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,005,354</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zoFOE11R46mj" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(723,081</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zOjbbjF340e5" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,282,273</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zIcMghIg9Oaj" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,310,448</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life of lease</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zeUCuQfIe7tj" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">446,065</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zQ3YW7hpsR9e" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(54,164</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zyTUHvNvb5jh" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">391,901</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zasCVnFCgrIi" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">373,320</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fittings</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 years</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zXSz9FRdA5bk" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139,889</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zSYXQfp0rHfk" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29,106</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zVfao3nSgiE9" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,783</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zv8rR76XDQO4" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,941</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vehicles</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zdhT9SFaS2ad" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,949</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_z8sZHNOnyGq7" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,668</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zIcQxV7wpXIb" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,281</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zoNGdBCGh8wh" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,079</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer equipment</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z6aIGzWVbz" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,450</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zRLv3JOHOVM8" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(706</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_znSSkIsbRPUh" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">744</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zAOikEXowai8" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">865</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331_zoo1Qw5Togm5" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,807,578</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_98C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331_z69UGVyUKETb" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(827,725</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331_zu8Nxl0MZ01b" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,979,853</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231_z9QJtq44FIs1" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,974,395</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A1_zLdbIopNA9Z8" style="margin: 0 0 0 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Depreciation expense for the three months ended March 31, 2023 and 2022 was $<span id="xdx_903_eus-gaap--Depreciation_c20230101__20230331_z7sDpBnIM8df" title="Depreciation expense">48,494</span> and $<span id="xdx_90A_eus-gaap--Depreciation_c20220101__20220331_zkK7iZN1CKcb">42,505</span>, respectively.</span></p> <p style="margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">  <b> </b></span></p> <p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zeLjhQM2Y7G4" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">  <span id="xdx_8B1_z4rygAEbhCnf" style="display: none">Schedule of sale of property</span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_30E_134_zxFxh7DlGmf2" style="width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Property and equipment (Details)"> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="11" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,<br/> 2023</b></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></td></tr> <tr> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; vertical-align: top"><p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful</b></span></p> <p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>lives</b></span></p></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cost</b></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated depreciation</b></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net book value</b></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net book value</b></span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land</span></td> <td style="vertical-align: top; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indefinite</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zFOm4eyVJhM5" style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,871</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zmEmOFTcris6" style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0599">—</span>  </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_z4DVYdQzuODf" style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,871</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zaxPvCD2RyTg" style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,742</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25 years</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_z7nV1Ndbu981" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,005,354</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zoFOE11R46mj" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(723,081</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zOjbbjF340e5" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,282,273</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zIcMghIg9Oaj" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,310,448</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life of lease</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zeUCuQfIe7tj" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">446,065</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zQ3YW7hpsR9e" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(54,164</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zyTUHvNvb5jh" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">391,901</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zasCVnFCgrIi" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">373,320</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fittings</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 years</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zXSz9FRdA5bk" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139,889</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zSYXQfp0rHfk" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29,106</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zVfao3nSgiE9" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,783</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zv8rR76XDQO4" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,941</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vehicles</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zdhT9SFaS2ad" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,949</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_z8sZHNOnyGq7" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,668</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zIcQxV7wpXIb" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,281</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zoNGdBCGh8wh" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,079</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer equipment</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z6aIGzWVbz" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,450</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zRLv3JOHOVM8" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(706</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_znSSkIsbRPUh" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">744</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zAOikEXowai8" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">865</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230331_zoo1Qw5Togm5" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,807,578</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_98C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230331_z69UGVyUKETb" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(827,725</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230331_zu8Nxl0MZ01b" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,979,853</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231_z9QJtq44FIs1" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,974,395</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 158871 158871 158742 3005354 723081 2282273 2310448 446065 54164 391901 373320 139889 29106 110783 92941 55949 20668 35281 38079 1450 706 744 865 3807578 827725 2979853 2974395 48494 42505 <p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_zUhF9voV36Cj" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. <span style="background-color: white"><span id="xdx_82C_zDhjxede0Wve">Intangibles</span></span></b></span></p> <p style="margin: 0 0 0 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Intangible assets consist of the following:</span></p> <p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z50Nfy9G5Usg" style="margin: 0 0 0 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B3_zTC0jWCwyDq2" style="display: none">Schedule of Intangible assets</span> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_307_134_zmxG4EJlue24" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangibles (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful <br/>lives</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,<br/> 2023</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated amortization</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net book value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net book value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 15%; text-align: left; padding-bottom: 1pt">Health care Provider license</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetUsefulLifeOne_c20230101__20230331_zZVLnu5p1AIi" style="width: 15%; text-align: center; padding-bottom: 1pt" title="Useful life">5 years</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20230331_zjX9hAdV40la" style="border-bottom: Black 1pt solid; width: 13%; text-align: right">1,789,903</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20230331_zEPigmhD8d6i" style="border-bottom: Black 1pt solid; width: 13%; text-align: right">(626,466</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20230331_z95wGaJKV8M2" style="border-bottom: Black 1pt solid; width: 13%; text-align: right">1,163,437</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231_zVTrWfKwZSCc" style="border-bottom: Black 1pt solid; width: 13%; text-align: right">1,252,932</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A1_zoPTQeyRjau7" style="margin: 0 0 0 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company evaluates intangible assets for impairment on an annual basis during the last month of each year and at an interim date if indications of impairment exist. Intangible asset impairment is determined by comparing the fair value of the asset to its carrying amount with an impairment being recognized only when the fair value is less than carrying value and the impairment is deemed to be permanent in nature.</span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company recorded $<span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230331_znmCnrxXlHKi" title="amortization expense"><span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20220331_zGve1FdAXJI9" title="amortization expense">89,495</span></span> in amortization expense for finite-lived assets for each of the three months ended March 31, 2023 and 2022.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> <b> </b></span></p> <p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z50Nfy9G5Usg" style="margin: 0 0 0 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B3_zTC0jWCwyDq2" style="display: none">Schedule of Intangible assets</span> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_307_134_zmxG4EJlue24" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangibles (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful <br/>lives</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,<br/> 2023</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated amortization</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net book value</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net book value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 15%; text-align: left; padding-bottom: 1pt">Health care Provider license</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetUsefulLifeOne_c20230101__20230331_zZVLnu5p1AIi" style="width: 15%; text-align: center; padding-bottom: 1pt" title="Useful life">5 years</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20230331_zjX9hAdV40la" style="border-bottom: Black 1pt solid; width: 13%; text-align: right">1,789,903</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20230331_zEPigmhD8d6i" style="border-bottom: Black 1pt solid; width: 13%; text-align: right">(626,466</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20230331_z95wGaJKV8M2" style="border-bottom: Black 1pt solid; width: 13%; text-align: right">1,163,437</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20221231_zVTrWfKwZSCc" style="border-bottom: Black 1pt solid; width: 13%; text-align: right">1,252,932</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> 5 years 1789903 626466 1163437 1252932 89495 89495 <p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_z5tfn1U5qhW2" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. <span style="background-color: white"><span id="xdx_823_zlyzfovpxWZ3">Leases</span></span></b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Right of use assets are included in the consolidated balance sheet are as follows:</span></p> <p id="xdx_89B_eus-gaap--ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock_z554NRp4X8Yl" style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B9_z0QaPBV9yIDc" style="display: none">Schedule of Right of use assets </span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_30E_133_zRZjjaaPVjQ" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49E_20230331_zu7Vv9lJw2hg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,<br/> 2023</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_499_20221231_zt4sJOvNosUe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Non-current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_iI_zCNSSwINSn7e" style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-bottom: 2.5pt">Right-of-use assets – finance leases, net of depreciation, included in Property and equipment</td><td style="width: 8%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">35,281</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 8%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">38,079</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--RightofuseAssetsOperatingLeasesNetOfAmortization_iI_z80lb7T9AGbl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use assets - operating leases, net of amortization</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,322,851</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,393,071</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zr4Qn2emdAI9" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">  </span></p> <p style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Lease costs consists of the following: </span></p> <p id="xdx_89F_ecustom--ScheduleoOfFinanceAndOperatingLeaseTableTextBlock_zO2QBwrRCqvc" style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B5_zUBxfbBAyRLb" style="display: none">Schedule of finance and operating lease</span> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_30B_134_zKGeXWURDA2i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_495_20230101__20230331_zWY7au2qfxxa" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_498_20220101__20220331_za9aMLsVKxel" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="7" style="font-weight: bold; text-align: center">Three  months ended March 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b>Finance lease cost:</b></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_zQNiRY4sQ1Ie" style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left">Amortization of right-of-use assets</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,797</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,797</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--InterestExpenseOnFinanceLeaseLiabilities_z83zFc03KS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Interest expense on finance lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">526</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">648</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FinanceLeasePrincipalPayments_zy8jjE1ttBvl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,323</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,445</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseCost_zAzzrIVMEg6j" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Operating lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">86,127</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">63,064</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LeaseCost_zDCME5pWp9ei" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #CCEEFF; text-align: left; padding-bottom: 1pt">Lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">89,450</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">186,727</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zmmsgXNMtol1" style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Other lease information: </span></p> <p id="xdx_892_ecustom--OtherLeaseTableTextBlock_zOLfACbcqNQ3" style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8BD_zzmbdJzbT964" style="display: none">Schedule of Other lease </span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_307_134_zFxirKIeDuRh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 2)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="7" style="font-weight: bold; text-align: center">Three months ended March 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Cash paid for amounts included in the measurement of lease liabilities</td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Operating cash flows from finance leases</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--OperatingCashFlowsFromFinanceLeases_c20230101__20230331_zCkhsiSLoLv" style="width: 12%; text-align: right" title="Operating cash flows from finance leases">(526</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--OperatingCashFlowsFromFinanceLeases_c20220101__20220331_z74TgTqQKt65" style="width: 12%; text-align: right">(648</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating cash flows from operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--OperatingCashFlowsFromOperatingLeases_c20230101__20230331_ztFPVDsGgCkj" style="text-align: right" title="Operating cash flows from operating leases">(86,127</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--OperatingCashFlowsFromOperatingLeases_c20220101__20220331_zmMvFoBNIpF1" style="text-align: right">(63,064</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Financing cash flows from finance leases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--FinancingCashFlowsFromFinanceLeases_c20230101__20230331_zHTprVs6n1R9" style="border-bottom: Black 1pt solid; text-align: right" title="Financing cash flows from finance leases">(1,944</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--FinancingCashFlowsFromFinanceLeases_c20220101__20220331_z7busPQ1bBgg" style="border-bottom: Black 1pt solid; text-align: right">(1,809</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: white; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash paid for amounts included in the measurement of lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_ecustom--NetChangeInLeases_c20230101__20230331_zKyeA8UMEB54" style="border-bottom: Black 1pt solid; text-align: right" title="Net Change in leases">(88,597</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--NetChangeInLeases_c20220101__20220331_z9oDpginkHVh" style="border-bottom: Black 1pt solid; text-align: right">(65,521</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted average lease term – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WeightedAverageLeaseTermFinanceLeasesTerm_c20230101__20230331_zyidYqZlWLQ8">3 years and seven months</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--WeightedAverageLeaseTermFinanceLeasesTerm_c20220101__20220331_z2FKvjqtpc73">4 years and seven months</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average remaining lease term – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WeightedAverageRemainingLeaseTermOperatingLeases_c20230101__20230331_zmTBJ2n9n4Vk">3 years and 10 months</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--WeightedAverageRemainingLeaseTermOperatingLeases_c20220101__20220331_zBeS0jdHbIj8">4 years and 10 months</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--DiscountRateFinanceLeases_dp_uPure_c20230101__20230331_z7ijZColyMSl" style="text-align: right">6.60</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--DiscountRateFinanceLeases_dp_uPure_c20220101__20220331_zHGo2Ysazmu8" style="text-align: right">6.61</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--DiscountRateOperatingLeases_dp_uPure_c20230101__20230331_zqp4Fyut1Ik7" style="text-align: right">4.64</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--DiscountRateOperatingLeases_dp_uPure_c20220101__20220331_zVvpJqnmCcjg" style="text-align: right">4.64</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A6_z0aQRc6BxSq1" style="margin: 0 0 6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Maturity of Leases</b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Finance lease liability</i></b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The amount of future minimum lease payments under finance leases as of March 31, 2023 is as follows:</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_z14iUNAOkZqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_zTlLiFcL7Rs" style="display: none">Schedule of Finance lease liability</span></p> <table cellpadding="0" cellspacing="0" id="xdx_30F_134_zvyHaXiDiGL7" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 3)"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_494_20230331_zQTCYBo6vjFj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amount</td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zQzs49Sw51E1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 70%; font-size: 10pt">Remainder of 2023</td><td style="width: 10%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 18%; font-size: 10pt; text-align: right">7,372</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_zdRFRSp88kXg" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2024</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">9,829</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_zE4KYdCI0k62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2025</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">9,829</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_z7SG9vp2Xy6h" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2026</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">6,195</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_zVBE9SuMTyU" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">2027</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,707</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--TotalUndiscountedMinimumFutureLeasePayment_iI_zqWFtdLBEsEa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">34,932</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--ImputedInterest_iI_zCBBl5Gzm9rk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Imputed interest</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,032</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--FinanceLeaseLiability_iI_zkcRBR2Wxptb" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total finance lease liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">30,900</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-size: 10pt; font-weight: bold">Disclosed as:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityCurrent_iI_zuUlIRxjvldj" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Current portion</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8,017</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zJZIT8Thznq8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Non-Current portion</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22,883</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinanceLeaseLiability_iI_z96iizSH3ofk" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; color: white; text-align: left; padding-bottom: 1pt">Lease liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">30,900</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p id="xdx_8A4_zv8n3AAmr0E7" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Operating lease liability</i></b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The amount of future minimum lease payments under operating leases are as follows:</span></p> <p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zryACe6RXWhk" style="margin: 0 0 0 22.5pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Schedule of Operating lease liability</span></p> <table cellpadding="0" cellspacing="0" id="xdx_303_134_zzhlqQhyCLzi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 4)"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_491_20230331_zxwbIODA5a75" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_400_eus-gaap--PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_iI_zoKbfeq6Tc49" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 70%">Remainder of 2023</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">262,549</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zK8MBOAS4NK6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">366,110</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zSd2n03zc6E9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">384,416</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zoxvmkn4wSS2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">403,637</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_zJPK3tNWg1Bl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">33,771</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--TotalUndiscountedMinimumFutureLeasePayments_iI_zh4JxsPWb1U" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total undiscounted minimum future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,450,483</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zKgIwO6bONLf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(25,465</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zEDX2y797WTh" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total operating lease liability</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,425,017</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; font-weight: bold">Disclosed as:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zfBKQikLSBa8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">299,027</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zMyMUiofplei" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Non-Current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,125,990</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zW9ZgxEX8Ws" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #CCEEFF; text-align: left; padding-bottom: 1pt"> Lease liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,425,017</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zGBV1jOY6Wra" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">   <b> </b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Lessor Property</b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company’s wholly owned subsidiary </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CCH owns a property located at 3571 Muskoka Road, #169, Bala, on which the operations of the Canadian Rehab Clinic were located prior to disposal on February 14, 2017, The property is leased to the purchasers of the business of the Canadian Rehab Clinic, initially for a period of 5 years, which was renewed for an additional 5 years, with a further two 5 year renewal periods available to the lessee. The lessee has an option to acquire the property for CDN$10 million. The Company considers the likelihood of the option being exercised as remote at this time.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Lease was considered in terms of ASC 842, Leases and determined to be an operating lease as the criteria for the lease to be a sales-type lease or a direct financing lease were not met, including the possibility of the lessee exercising the option to purchase the property being considered as remote.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company derived rental income of CDN$126 942 ($<span id="xdx_90D_ecustom--DerivedRentalIncome_c20230101__20230331_z9gkcQaybSM8" title="Derived rental income">89,419</span>) for the three months ended March 31, 2023.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock_z554NRp4X8Yl" style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B9_z0QaPBV9yIDc" style="display: none">Schedule of Right of use assets </span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_30E_133_zRZjjaaPVjQ" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49E_20230331_zu7Vv9lJw2hg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,<br/> 2023</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_499_20221231_zt4sJOvNosUe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Non-current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_iI_zCNSSwINSn7e" style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-bottom: 2.5pt">Right-of-use assets – finance leases, net of depreciation, included in Property and equipment</td><td style="width: 8%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">35,281</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 8%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">38,079</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--RightofuseAssetsOperatingLeasesNetOfAmortization_iI_z80lb7T9AGbl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use assets - operating leases, net of amortization</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,322,851</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,393,071</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 35281 38079 1322851 1393071 <p id="xdx_89F_ecustom--ScheduleoOfFinanceAndOperatingLeaseTableTextBlock_zO2QBwrRCqvc" style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B5_zUBxfbBAyRLb" style="display: none">Schedule of finance and operating lease</span> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_30B_134_zKGeXWURDA2i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_495_20230101__20230331_zWY7au2qfxxa" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_498_20220101__20220331_za9aMLsVKxel" style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="7" style="font-weight: bold; text-align: center">Three  months ended March 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b>Finance lease cost:</b></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_zQNiRY4sQ1Ie" style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left">Amortization of right-of-use assets</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,797</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,797</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--InterestExpenseOnFinanceLeaseLiabilities_z83zFc03KS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Interest expense on finance lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">526</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">648</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FinanceLeasePrincipalPayments_zy8jjE1ttBvl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,323</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,445</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseCost_zAzzrIVMEg6j" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Operating lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">86,127</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">63,064</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LeaseCost_zDCME5pWp9ei" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #CCEEFF; text-align: left; padding-bottom: 1pt">Lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">89,450</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">186,727</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 2797 2797 526 648 3323 3445 86127 63064 89450 186727 <p id="xdx_892_ecustom--OtherLeaseTableTextBlock_zOLfACbcqNQ3" style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8BD_zzmbdJzbT964" style="display: none">Schedule of Other lease </span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_307_134_zFxirKIeDuRh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 2)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="7" style="font-weight: bold; text-align: center">Three months ended March 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Cash paid for amounts included in the measurement of lease liabilities</td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Operating cash flows from finance leases</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--OperatingCashFlowsFromFinanceLeases_c20230101__20230331_zCkhsiSLoLv" style="width: 12%; text-align: right" title="Operating cash flows from finance leases">(526</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--OperatingCashFlowsFromFinanceLeases_c20220101__20220331_z74TgTqQKt65" style="width: 12%; text-align: right">(648</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating cash flows from operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--OperatingCashFlowsFromOperatingLeases_c20230101__20230331_ztFPVDsGgCkj" style="text-align: right" title="Operating cash flows from operating leases">(86,127</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--OperatingCashFlowsFromOperatingLeases_c20220101__20220331_zmMvFoBNIpF1" style="text-align: right">(63,064</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Financing cash flows from finance leases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--FinancingCashFlowsFromFinanceLeases_c20230101__20230331_zHTprVs6n1R9" style="border-bottom: Black 1pt solid; text-align: right" title="Financing cash flows from finance leases">(1,944</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--FinancingCashFlowsFromFinanceLeases_c20220101__20220331_z7busPQ1bBgg" style="border-bottom: Black 1pt solid; text-align: right">(1,809</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: white; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash paid for amounts included in the measurement of lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_ecustom--NetChangeInLeases_c20230101__20230331_zKyeA8UMEB54" style="border-bottom: Black 1pt solid; text-align: right" title="Net Change in leases">(88,597</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--NetChangeInLeases_c20220101__20220331_z9oDpginkHVh" style="border-bottom: Black 1pt solid; text-align: right">(65,521</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted average lease term – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WeightedAverageLeaseTermFinanceLeasesTerm_c20230101__20230331_zyidYqZlWLQ8">3 years and seven months</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--WeightedAverageLeaseTermFinanceLeasesTerm_c20220101__20220331_z2FKvjqtpc73">4 years and seven months</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average remaining lease term – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WeightedAverageRemainingLeaseTermOperatingLeases_c20230101__20230331_zmTBJ2n9n4Vk">3 years and 10 months</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--WeightedAverageRemainingLeaseTermOperatingLeases_c20220101__20220331_zBeS0jdHbIj8">4 years and 10 months</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--DiscountRateFinanceLeases_dp_uPure_c20230101__20230331_z7ijZColyMSl" style="text-align: right">6.60</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--DiscountRateFinanceLeases_dp_uPure_c20220101__20220331_zHGo2Ysazmu8" style="text-align: right">6.61</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--DiscountRateOperatingLeases_dp_uPure_c20230101__20230331_zqp4Fyut1Ik7" style="text-align: right">4.64</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--DiscountRateOperatingLeases_dp_uPure_c20220101__20220331_zVvpJqnmCcjg" style="text-align: right">4.64</td><td style="text-align: left">%</td></tr> </table> -526 -648 -86127 -63064 -1944 -1809 -88597 -65521 3 years and seven months 4 years and seven months 3 years and 10 months 4 years and 10 months 0.0660 0.0661 0.0464 0.0464 <p id="xdx_89F_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_z14iUNAOkZqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_zTlLiFcL7Rs" style="display: none">Schedule of Finance lease liability</span></p> <table cellpadding="0" cellspacing="0" id="xdx_30F_134_zvyHaXiDiGL7" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 3)"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_494_20230331_zQTCYBo6vjFj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amount</td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zQzs49Sw51E1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 70%; font-size: 10pt">Remainder of 2023</td><td style="width: 10%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 18%; font-size: 10pt; text-align: right">7,372</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_zdRFRSp88kXg" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2024</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">9,829</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_zE4KYdCI0k62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2025</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">9,829</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_z7SG9vp2Xy6h" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2026</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">6,195</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_zVBE9SuMTyU" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">2027</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,707</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--TotalUndiscountedMinimumFutureLeasePayment_iI_zqWFtdLBEsEa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">34,932</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--ImputedInterest_iI_zCBBl5Gzm9rk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Imputed interest</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,032</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--FinanceLeaseLiability_iI_zkcRBR2Wxptb" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total finance lease liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">30,900</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-size: 10pt; font-weight: bold">Disclosed as:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityCurrent_iI_zuUlIRxjvldj" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Current portion</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8,017</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zJZIT8Thznq8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Non-Current portion</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22,883</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinanceLeaseLiability_iI_z96iizSH3ofk" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; color: white; text-align: left; padding-bottom: 1pt">Lease liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">30,900</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> 7372 9829 9829 6195 1707 34932 -4032 30900 8017 22883 30900 <p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zryACe6RXWhk" style="margin: 0 0 0 22.5pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Schedule of Operating lease liability</span></p> <table cellpadding="0" cellspacing="0" id="xdx_303_134_zzhlqQhyCLzi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 4)"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_491_20230331_zxwbIODA5a75" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_400_eus-gaap--PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_iI_zoKbfeq6Tc49" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 70%">Remainder of 2023</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">262,549</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zK8MBOAS4NK6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">366,110</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zSd2n03zc6E9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">384,416</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zoxvmkn4wSS2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">403,637</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_zJPK3tNWg1Bl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">33,771</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--TotalUndiscountedMinimumFutureLeasePayments_iI_zh4JxsPWb1U" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total undiscounted minimum future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,450,483</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zKgIwO6bONLf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(25,465</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zEDX2y797WTh" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total operating lease liability</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,425,017</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; font-weight: bold">Disclosed as:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zfBKQikLSBa8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">299,027</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zMyMUiofplei" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Non-Current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,125,990</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zW9ZgxEX8Ws" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: #CCEEFF; text-align: left; padding-bottom: 1pt"> Lease liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,425,017</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 262549 366110 384416 403637 33771 1450483 25465 1425017 299027 1125990 1425017 89419 <p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_zclnY0srHb9d" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. <span style="background-color: white"><span id="xdx_828_z7u0ioM5K2fd">Short-term Convertible Notes</span></span></b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The short-term convertible notes consist of the following:</span></p> <p id="xdx_89F_eus-gaap--ScheduleOfShortTermDebtTextBlock_zzNYWdtIBDp4" style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">  <span id="xdx_8B8_zrgCHtet8Xvj" style="display: none">Schedule of short-term convertible notes</span></span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/></p> <table cellpadding="0" cellspacing="0" id="xdx_308_134_z3YuRVdyKdx3" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Short-term Convertible Notes (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Interest rate</b></span></td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Maturity Date</b></span></td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Principal</b></span></td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Interest</b></span></td> <td colspan="2"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>March 31, 2023</b></span></td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2022</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Leonite Capital, LLC</span></td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteCapitalLLCMember_zxcsHMrqaak5" style="text-align: right"><span style="font-size: 10pt">12.0</span></td> <td><span style="font-size: 10pt">%</span></td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteCapitalLLCMember_zl06PjTnmMyh" title="Maturity Date">On Demand</span></span></td> <td> </td> <td><span style="font-size: 10pt"> $</span></td> <td id="xdx_984_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteCapitalLLCMember_zPfVPNKWM8Aj" style="text-align: right" title="Principal amount"><span style="font-size: 10pt">129,379</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt"> $</span></td> <td id="xdx_98C_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteCapitalLLCMember_zSoofLzHOi0i" style="text-align: right"><span style="font-size: 10pt">59,198</span></td> <td> </td> <td> </td> <td colspan="2"><span style="font-size: 10pt"> $</span></td> <td id="xdx_983_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteCapitalLLCMember_zhabTkUMblC4" style="text-align: right"><span style="font-size: 10pt">188,577</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt"> $</span></td> <td id="xdx_988_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--LeoniteCapitalLLCMember_zdfovh2vJMtj" style="text-align: right" title="short-term convertible"><span style="font-size: 10pt">184,749</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Leonite Fund I, LP</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">Variable</span></td> <td> </td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteFundILPMember_zcmqe1Krga24">March 1, 2023</span></span></td> <td> </td> <td> </td> <td id="xdx_987_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteFundILPMember_zU0CEru6IoD2" style="text-align: right"><span style="font-size: 10pt">745,375</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteFundILPMember_zOaIl9PZKcS5" style="text-align: right"><span style="font-size: 10pt">19,738</span></td> <td> </td> <td> </td> <td colspan="2"> </td> <td id="xdx_983_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteFundILPMember_zzfu9uu6o8T2" style="text-align: right"><span style="font-size: 10pt">765,113</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98F_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--LeoniteFundILPMember_zmKYnFee9si5" style="text-align: right"><span style="font-size: 10pt">720,830</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Auctus Fund, LLC</span></td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--AuctusFundLLCMember_zfSfMziQEIsk" style="text-align: right"><span style="font-size: 10pt">0.0</span></td> <td><span style="font-size: 10pt">%</span></td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--AuctusFundLLCMember_zO6QOaljfWi4">On Demand</span></span></td> <td> </td> <td> </td> <td id="xdx_983_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--AuctusFundLLCMember_zbQFFDqG99Jk" style="text-align: right"><span style="font-size: 10pt">70,000</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_983_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--AuctusFundLLCMember_zbT5Pi44Riq9" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0772">—</span>  </span></td> <td> </td> <td> </td> <td colspan="2"> </td> <td id="xdx_980_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--AuctusFundLLCMember_zPvj62IhS5Sg" style="text-align: right"><span style="font-size: 10pt">70,000</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AuctusFundLLCMember_zG3IikIe0v55" style="text-align: right"><span style="font-size: 10pt">80,000</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Labrys Fund, LP</span></td> <td> </td> <td> </td> <td id="xdx_980_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LabrysFundLPMember_zKOcM5P63zX5" style="text-align: right"><span style="font-size: 10pt">12.0</span></td> <td><span style="font-size: 10pt">%</span></td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LabrysFundLPMember_zW3f1uejtA0h">On Demand</span></span></td> <td> </td> <td> </td> <td id="xdx_986_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LabrysFundLPMember_zzXHuSBRPDq1" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0777">—</span>  </span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LabrysFundLPMember_zOOKYZSMQU3e" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0778">—</span>  </span></td> <td> </td> <td> </td> <td colspan="2"> </td> <td id="xdx_986_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LabrysFundLPMember_zB6rL22C68Q1" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0779">—</span>  </span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_985_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--LabrysFundLPMember_zt3WYSW8GYK5" style="text-align: right"><span style="font-size: 10pt">8,826</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Ed Blasiak</span></td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--EdBlasiakMember_zcgyKh3oD096" style="text-align: right"><span style="font-size: 10pt">6.5</span></td> <td><span style="font-size: 10pt">%</span></td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--EdBlasiakMember_zGaBbyJGrJC2">On Demand</span></span></td> <td> </td> <td> </td> <td id="xdx_983_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--EdBlasiakMember_zpKfyKJoc8P3" style="text-align: right"><span style="font-size: 10pt">55,000</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98E_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--EdBlasiakMember_zKoEPf40awe" style="text-align: right"><span style="font-size: 10pt">9,216</span></td> <td> </td> <td> </td> <td colspan="2"> </td> <td id="xdx_98B_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--EdBlasiakMember_zbP7Wxi3iZTj" style="text-align: right"><span style="font-size: 10pt">64,216</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_989_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--EdBlasiakMember_zhzzpwMJjykc" style="text-align: right"><span style="font-size: 10pt">63,322</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Joshua Bauman</span></td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--JoshuaBaumanMember_zV6TQKe590Aa" style="text-align: right"><span style="font-size: 10pt">11.0</span></td> <td><span style="font-size: 10pt">%</span></td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--JoshuaBaumanMember_zhNmKVz9eI16">October 21, 2022</span></span></td> <td> </td> <td> </td> <td id="xdx_980_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--JoshuaBaumanMember_zboFCC0tmlh3" style="text-align: right"><span style="font-size: 10pt">150,000</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98A_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--JoshuaBaumanMember_zRm0bO5MuTF9" style="text-align: right"><span style="font-size: 10pt">23,778</span></td> <td> </td> <td> </td> <td colspan="2"> </td> <td id="xdx_98D_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--JoshuaBaumanMember_z3FtTj9tMfEl" style="text-align: right"><span style="font-size: 10pt">173,778</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98A_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--JoshuaBaumanMember_z3fIQ47gxPU5" style="text-align: right"><span style="font-size: 10pt">169,710</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Series N convertible notes</span></td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--SeriesNConvertibleNotesMember_ziAo4yUhJ5Bl" style="text-align: right"><span style="font-size: 10pt">6.0</span></td> <td><span style="font-size: 10pt">%</span></td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--SeriesNConvertibleMember_z0ki8R3jupf8">On Demand</span></span></td> <td> </td> <td> </td> <td id="xdx_98F_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--SeriesNConvertibleNotesMember_z8oin3RHC4Za" style="text-align: right"><span style="font-size: 10pt">3,229,000</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--SeriesNConvertibleNotesMember_zvZ0rRq4yDp8" style="text-align: right"><span style="font-size: 10pt">860,586</span></td> <td> </td> <td> </td> <td colspan="2"> </td> <td id="xdx_98B_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--SeriesNConvertibleNotesMember_z5y7oX7sfaXl" style="text-align: right"><span style="font-size: 10pt">4,089,586</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_987_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--SeriesNConvertibleNotesMember_zBLGWc8eNDs" style="text-align: right"><span style="font-size: 10pt">4,041,813</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt"><b> $</b></span></td> <td id="xdx_98C_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331_zvQJf8gaDVn4" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><b>4,378,754</b></span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt"><b> $</b></span></td> <td id="xdx_98B_eus-gaap--InterestCostsCapitalized_c20230101__20230331_zfuxfiRKLdC7" style="border-bottom: black 2.25pt double; text-align: right" title="Interest"><span style="font-size: 10pt"><b>972,516</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 2.25pt double"><span style="font-size: 10pt"><b>$</b></span></td> <td id="xdx_989_ecustom--ShorttermConvertible_c20230101__20230331_z5GmDycMx0y" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><b>5,351,270</b></span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt"><b>$</b></span></td> <td id="xdx_986_ecustom--ShorttermConvertible_c20220101__20221231_ztsIYf570tnb" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><b>5,269,250</b></span></td> <td> </td></tr> </table> <p id="xdx_8A7_znLakqVqG2g4" style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span><span style="background-color: white"> <b> </b> </span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Leonite Capital, LLC</b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On July 12, 2020, the Company entered into a Senior Secured Convertible Note agreement with Leonite for $440,000 with an original issue discount of $40,000 for gross proceeds of $400,000, the initial tranche advanced will be for cash of $200,000 plus the OID of $20,000, the remaining advances will be at the discretion of the Leonite. The loan bears interest at 6.5% per annum and matures on June 12, 2021. The Company is required to make monthly payments of the accrued interest on the advances made. The note is convertible into common shares at the option of the holder at $0.10 per share, or 80% multiplied by the price per share paid in subsequent financings or after a six month period from the effective date at 60% of the lowest trading price during the preceding 21 consecutive trading days. The note has both conversion price protection and anti-dilution protection provisions.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On February 28, 2022, in terms of a conversion notice, Leonite converted the principal sum of $149,250 of the Leonite Note into 150,000,000 shares of common stock at a conversion price of $0.0010 per share.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white">On March 1, 2023, the Company entered into a forbearance agreement with Leonite whereby the parties agreed to extend the maturity date of the note to June 8, 2023, the Company will continue to pay interest on the note, until repaid. The note has not been repaid as yet and the Company in continuing to negotiate the resolution of the note. </p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Leonite Fund I, LP</b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Effective June 1, 2022, The Company entered into a Note Exchange Agreement whereby the convertible promissory notes entered into with Labrys Fund LP on May 7, 2021, with. A principal outstanding of $341,000, and on June 2, 2021 with a principal outstanding of $230,000 and accrued interest thereon of $25,300, were exchanged for a new Senior Secured Convertible Promissory note in the principal amount of $745,375, including an OID of $149,075. The Note matured on March 1, 2023, and bore interest at the minimum of 10% per annum or the Wall Street Journal quoted prime rate plus 5.75%. The note is currently in default, although no default has been declared and management is negotiating with Leonite on a resolution.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Interest is payable monthly and the note may be prepaid with a prepayment penalty of 10%. The note is convertible into common stock at a fixed conversion price of $0.01 per share, subject to anti-dilution adjustments and a fundamental transaction clause allowing the note holder to receive the same consideration as common stockholders would receive.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The convertible note is secured by all of the assets of Ethema Health Corporation and Addiction Recovery Institute of America, LLC.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white">On March 1, 2023, the Company entered into a forbearance agreement with Leonite whereby the parties agreed to extend the maturity date of the note to June 8, 2023, the Company will continue to pay interest on the note, until repaid. The note has not been repaid as yet and the Company in continuing to negotiate the resolution of the note. </p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Auctus Fund, LLC</b></span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On August 7, 2019, the Company, entered into a Securities Purchase Agreement with Auctus Fund, LLC, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $225,000. The Note had a maturity date of May 7, 2020 and bore interest at the rate of ten percent per annum from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company had the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note is convertible at any time and from time to time at the election of Auctus Fund, LLC during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to 60% of the lowest closing bid price of the Company’s common stock for the thirty trading days prior to conversion.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On June 15, 2020, The Company entered into an amended agreement with Auctus whereby the Company agreed to discharge the principal amount of the note by nine equal monthly installments of $25,000 commencing in October 2020. During the year ended December 31, 2021, the Company repaid Auctus the principal sum of $50,000.</span></p> <p style="margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During March 2022, the Company paid $20,000 of principal on the convertible note, thereby reducing the principal outstanding to $80,000. The note matured May 7, 2020, Auctus Fund LLC has not declared a default and we are in constant discussion with the lender on settling the note.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During February 2023, the Company paid $10,000 of principal on the convertible note, thereby reducing the principal outstanding to $70,000. The note matured May 7, 2020, Auctus Fund LLC has not declared a default and we are in constant discussion with the lender on settling the note.</span><b> </b></p> <p style="margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><br/></b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>  </b></span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Ed Blasiak</b></span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On September 14, 2020, the Company entered into a Securities Purchase Agreement with Ed Blasiak (“Blasiak”), pursuant to which the Company issued a senior secured convertible promissory note in the aggregate principal amount of $55,000, including an original issue discount of $5,000. The note bears interest at 6.5% per annum and matures on September 14, 2021. The note is senior to any future borrowings and commencing on October 1, 2020 the Company will make monthly payments of the accrued interest under the note. The note may be prepaid at certain prepayment penalties and is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions; or 80% of the price per share of subsequent equity financings or; after six months 60% of the lowest trading price during the preceding six month period.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The note has matured and is in default, Ed Blasiak has not declared a default under the note and we are in communication with Mr. Blasiak on our ability to repay the note. </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Joshua Bauman</b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On September 14, 2020, the Company entered into a Securities Purchase Agreement with Bauman, pursuant to which the Company issued a senior secured convertible promissory note in the aggregate principal amount of $110,000, including an original issue discount of $10,000. The note bears interest at 6.5% per annum and matures on September 14, 2021. The note is senior to any future borrowings and commencing on October 1, 2020 the Company will make monthly payments of the accrued interest under the note. The note may be prepaid at certain prepayment penalties and is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions; or 80% of the price per share of subsequent equity financings or; after six months 60% of the lowest trading price during the preceding six month period.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On June 8, 2021, in terms of a conversion notice received by the Company, Bauman converted the aggregate principal sum of $100,000 including interest thereon of $5,563 into 106,313,288 shares of common stock.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On October 25, 2021, in terms of a conversion notice received by the Company, Bauman converted the aggregate principal sum of $37,500 including interest thereon of $1,155 into 39,405,310 shares of common stock, thereby extinguishing the note.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">  </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On October 21, 2021, the Company entered into a Securities Purchase Agreement with Bauman, pursuant to which the Company issued a senior secured convertible promissory note in the aggregate principal amount of $150,000, including an original issue discount of $16,250. The note bears interest at 11.0% per annum, which is guaranteed and earned in full on issue date and matured on October 21, 2022. The note is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The note has matured and is in default, Mr. Bauman has not declared a default under the note and we are in communication with Mr. Bauman on our ability to repay the note. </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Series N convertible notes</b></span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Between January 28, 2019 and June 11, 2020, the Company closed several tranches of Series N Convertible notes in which it raised $3,229,000 in principal from accredited investors through the issuance to the investors of the Company’s Series N convertible notes, in the total original principal amount of $3,229,000, which Notes are convertible into the Company’s common stock at a conversion price of $0.08 per share together with three year warrants to purchase up to a total of 52,237,500 shares of the Company’s common stock at an exercise price of $0.12 per share. Both the conversion price under the Notes and the exercise price under the warrants are subject to standard adjustment mechanisms. The notes matured one year from the date of issuance.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The series N convertible notes matured and are in default. The Company is considering its options to settle these notes.</span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfShortTermDebtTextBlock_zzNYWdtIBDp4" style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">  <span id="xdx_8B8_zrgCHtet8Xvj" style="display: none">Schedule of short-term convertible notes</span></span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/></p> <table cellpadding="0" cellspacing="0" id="xdx_308_134_z3YuRVdyKdx3" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Short-term Convertible Notes (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Interest rate</b></span></td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Maturity Date</b></span></td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Principal</b></span></td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Interest</b></span></td> <td colspan="2"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>March 31, 2023</b></span></td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2022</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Leonite Capital, LLC</span></td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteCapitalLLCMember_zxcsHMrqaak5" style="text-align: right"><span style="font-size: 10pt">12.0</span></td> <td><span style="font-size: 10pt">%</span></td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteCapitalLLCMember_zl06PjTnmMyh" title="Maturity Date">On Demand</span></span></td> <td> </td> <td><span style="font-size: 10pt"> $</span></td> <td id="xdx_984_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteCapitalLLCMember_zPfVPNKWM8Aj" style="text-align: right" title="Principal amount"><span style="font-size: 10pt">129,379</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt"> $</span></td> <td id="xdx_98C_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteCapitalLLCMember_zSoofLzHOi0i" style="text-align: right"><span style="font-size: 10pt">59,198</span></td> <td> </td> <td> </td> <td colspan="2"><span style="font-size: 10pt"> $</span></td> <td id="xdx_983_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteCapitalLLCMember_zhabTkUMblC4" style="text-align: right"><span style="font-size: 10pt">188,577</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt"> $</span></td> <td id="xdx_988_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--LeoniteCapitalLLCMember_zdfovh2vJMtj" style="text-align: right" title="short-term convertible"><span style="font-size: 10pt">184,749</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Leonite Fund I, LP</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">Variable</span></td> <td> </td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteFundILPMember_zcmqe1Krga24">March 1, 2023</span></span></td> <td> </td> <td> </td> <td id="xdx_987_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteFundILPMember_zU0CEru6IoD2" style="text-align: right"><span style="font-size: 10pt">745,375</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteFundILPMember_zOaIl9PZKcS5" style="text-align: right"><span style="font-size: 10pt">19,738</span></td> <td> </td> <td> </td> <td colspan="2"> </td> <td id="xdx_983_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LeoniteFundILPMember_zzfu9uu6o8T2" style="text-align: right"><span style="font-size: 10pt">765,113</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98F_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--LeoniteFundILPMember_zmKYnFee9si5" style="text-align: right"><span style="font-size: 10pt">720,830</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Auctus Fund, LLC</span></td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--AuctusFundLLCMember_zfSfMziQEIsk" style="text-align: right"><span style="font-size: 10pt">0.0</span></td> <td><span style="font-size: 10pt">%</span></td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--AuctusFundLLCMember_zO6QOaljfWi4">On Demand</span></span></td> <td> </td> <td> </td> <td id="xdx_983_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--AuctusFundLLCMember_zbQFFDqG99Jk" style="text-align: right"><span style="font-size: 10pt">70,000</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_983_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--AuctusFundLLCMember_zbT5Pi44Riq9" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0772">—</span>  </span></td> <td> </td> <td> </td> <td colspan="2"> </td> <td id="xdx_980_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--AuctusFundLLCMember_zPvj62IhS5Sg" style="text-align: right"><span style="font-size: 10pt">70,000</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--AuctusFundLLCMember_zG3IikIe0v55" style="text-align: right"><span style="font-size: 10pt">80,000</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Labrys Fund, LP</span></td> <td> </td> <td> </td> <td id="xdx_980_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LabrysFundLPMember_zKOcM5P63zX5" style="text-align: right"><span style="font-size: 10pt">12.0</span></td> <td><span style="font-size: 10pt">%</span></td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LabrysFundLPMember_zW3f1uejtA0h">On Demand</span></span></td> <td> </td> <td> </td> <td id="xdx_986_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LabrysFundLPMember_zzXHuSBRPDq1" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0777">—</span>  </span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LabrysFundLPMember_zOOKYZSMQU3e" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0778">—</span>  </span></td> <td> </td> <td> </td> <td colspan="2"> </td> <td id="xdx_986_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--LabrysFundLPMember_zB6rL22C68Q1" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0779">—</span>  </span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_985_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--LabrysFundLPMember_zt3WYSW8GYK5" style="text-align: right"><span style="font-size: 10pt">8,826</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Ed Blasiak</span></td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--EdBlasiakMember_zcgyKh3oD096" style="text-align: right"><span style="font-size: 10pt">6.5</span></td> <td><span style="font-size: 10pt">%</span></td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--EdBlasiakMember_zGaBbyJGrJC2">On Demand</span></span></td> <td> </td> <td> </td> <td id="xdx_983_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--EdBlasiakMember_zpKfyKJoc8P3" style="text-align: right"><span style="font-size: 10pt">55,000</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98E_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--EdBlasiakMember_zKoEPf40awe" style="text-align: right"><span style="font-size: 10pt">9,216</span></td> <td> </td> <td> </td> <td colspan="2"> </td> <td id="xdx_98B_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--EdBlasiakMember_zbP7Wxi3iZTj" style="text-align: right"><span style="font-size: 10pt">64,216</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_989_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--EdBlasiakMember_zhzzpwMJjykc" style="text-align: right"><span style="font-size: 10pt">63,322</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Joshua Bauman</span></td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--JoshuaBaumanMember_zV6TQKe590Aa" style="text-align: right"><span style="font-size: 10pt">11.0</span></td> <td><span style="font-size: 10pt">%</span></td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--JoshuaBaumanMember_zhNmKVz9eI16">October 21, 2022</span></span></td> <td> </td> <td> </td> <td id="xdx_980_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--JoshuaBaumanMember_zboFCC0tmlh3" style="text-align: right"><span style="font-size: 10pt">150,000</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98A_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--JoshuaBaumanMember_zRm0bO5MuTF9" style="text-align: right"><span style="font-size: 10pt">23,778</span></td> <td> </td> <td> </td> <td colspan="2"> </td> <td id="xdx_98D_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--JoshuaBaumanMember_z3FtTj9tMfEl" style="text-align: right"><span style="font-size: 10pt">173,778</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98A_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--JoshuaBaumanMember_z3fIQ47gxPU5" style="text-align: right"><span style="font-size: 10pt">169,710</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Series N convertible notes</span></td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--SeriesNConvertibleNotesMember_ziAo4yUhJ5Bl" style="text-align: right"><span style="font-size: 10pt">6.0</span></td> <td><span style="font-size: 10pt">%</span></td> <td> </td> <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--LongTermDebtMaturitiesRepaymentTerms_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--SeriesNConvertibleMember_z0ki8R3jupf8">On Demand</span></span></td> <td> </td> <td> </td> <td id="xdx_98F_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--SeriesNConvertibleNotesMember_z8oin3RHC4Za" style="text-align: right"><span style="font-size: 10pt">3,229,000</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--InterestCostsCapitalized_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--SeriesNConvertibleNotesMember_zvZ0rRq4yDp8" style="text-align: right"><span style="font-size: 10pt">860,586</span></td> <td> </td> <td> </td> <td colspan="2"> </td> <td id="xdx_98B_ecustom--ShorttermConvertible_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--SeriesNConvertibleNotesMember_z5y7oX7sfaXl" style="text-align: right"><span style="font-size: 10pt">4,089,586</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_987_ecustom--ShorttermConvertible_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--SeriesNConvertibleNotesMember_zBLGWc8eNDs" style="text-align: right"><span style="font-size: 10pt">4,041,813</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt"><b> $</b></span></td> <td id="xdx_98C_ecustom--DebtInstrumentOfPrincipalAmount_c20230101__20230331_zvQJf8gaDVn4" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><b>4,378,754</b></span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt"><b> $</b></span></td> <td id="xdx_98B_eus-gaap--InterestCostsCapitalized_c20230101__20230331_zfuxfiRKLdC7" style="border-bottom: black 2.25pt double; text-align: right" title="Interest"><span style="font-size: 10pt"><b>972,516</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 2.25pt double"><span style="font-size: 10pt"><b>$</b></span></td> <td id="xdx_989_ecustom--ShorttermConvertible_c20230101__20230331_z5GmDycMx0y" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><b>5,351,270</b></span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt"><b>$</b></span></td> <td id="xdx_986_ecustom--ShorttermConvertible_c20220101__20221231_ztsIYf570tnb" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><b>5,269,250</b></span></td> <td> </td></tr> </table> 0.120 On Demand 129379 59198 188577 184749 March 1, 2023 745375 19738 765113 720830 0.000 On Demand 70000 70000 80000 0.120 On Demand 8826 0.065 On Demand 55000 9216 64216 63322 0.110 October 21, 2022 150000 23778 173778 169710 0.060 On Demand 3229000 860586 4089586 4041813 4378754 972516 5351270 5269250 <p id="xdx_807_eus-gaap--ShortTermDebtTextBlock_zBN4NHs3lg95" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. <span style="background-color: white"><span id="xdx_82D_zrtu8Ij0M951">Short-term Notes</span></span></b></span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Leonite Capital, LLC</b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Secured Promissory Notes </i></b> </span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On March 1, 2022, the Company entered into a secured Promissory Note in the aggregate principal amount of $124,000 for net proceeds of $100,000 after an original issue discount of $24,000. Due to the failure to repay the note by due date, a penalty of $37,200 was added to the principal outstanding and the Company incurs a monthly monitoring fee of $2,000 per month. In addition the note earns interest at a default rate of 24% per annum on the total balance outstanding, including the monthly monitoring fee and accrued interest.</span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Note had a maturity date of April 1, 2022. This note has not been repaid at the date of this report. We are in negotiations with Leonite to settle the balance outstanding and no default has been declared.</span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The balance outstanding on the note, including default penalty, interest accrued and monthly monitoring fees is $231,481 as of March 31, 2023.</span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On May 3, 2022, the Company, entered into a secured Promissory Note in the aggregate principal amount of $76,250 for net proceeds of $61,000 after an original issue discount of $15,250. Due to the failure to repay the note by due date, a penalty of $22,875 was added to the principal outstanding and the Company incurs a monthly monitoring fee of $2,000 per month. In addition the note earns interest at a default rate of 24% per annum on the total balance outstanding, including the monthly monitoring fee and accrued interest.</span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Note had a maturity date of June 17, 2022. This note has not been repaid at the date of this report. We are in negotiations with Leonite to settle the balance outstanding and no default has been declared.</span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The balance outstanding on the note, including default penalty, interest accrued and monthly monitoring fees is $143,634 as of March 31, 2023.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>LXR Biotech</b></span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On April 12, 2019, the Company, entered into a secured Promissory Note in the aggregate principal amount of CDN$133,130. The Note had a maturity date of April 11, 2020 and bears interest at the rate of six percent per annum from the date on which the Note was issued.</span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 4.35pt 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">This note has not been repaid, is in default and remains outstanding. The balance outstanding at March 31, 2023 was $121,806.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80E_ecustom--MortgageLoansTextBlock_zOT3m725nap1" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. <span style="background-color: white"><span id="xdx_82D_zA2JjkzdmFTc">Mortgage loans</span></span></b></span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Mortgage loans is disclosed as follows:</span></p> <p id="xdx_890_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z9wflMFbzBP1" style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8BD_zFjD8pRHgcri" style="display: none">Schedule of mortgage loans</span> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_305_134_zCBnIxxIvRt4" style="width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Mortgage loans (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest </b><br/> <b>rate</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maturity date</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal </b><br/> <b>Outstanding</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued </b><br/> <b>interest</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b><br/> <b>2023</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b><br/> <b>2022</b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td colspan="7"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cranberry Cove Holdings, Ltd.</b> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pace Mortgage</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230331_zKb5FpCNxi9e" style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 19, 2022</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </span></td> <td id="xdx_986_eus-gaap--PrincipalAmountOutstandingOnLoansSecuritized_iI_c20230331_zwUbN9H2Ucpg" style="border-bottom: black 1pt solid; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,473,334</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20230331_zccgtn8lox7l" style="border-bottom: black 1pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,796</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--LoansPayable_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--CranberryCoveHoldingsLtdMember_zLWryQmXNiOc" style="border-bottom: black 1pt solid; width: 14%; text-align: right" title="Loans Payable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,478,130</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> $</span></td> <td id="xdx_984_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--CranberryCoveHoldingsLtdMember_zZHNBDIu9u38" style="border-bottom: black 1pt solid; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,504,605</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td colspan="4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosed as follows:</b> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term portion </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--LoansPayableCurrent_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--CranberryCoveHoldingsLtdMember_z1EPXde2HNZ1" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,478,130</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--LoansPayableCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--CranberryCoveHoldingsLtdMember_zeyeVy7XLXD2" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,504,605</span></td></tr> <tr> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AF_zygWYF352ML9" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Cranberry Cove Holdings, Ltd. (“CCH”)</i></b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><br/> On July 19, 2017, CCH, a wholly owned subsidiary, closed on a loan agreement in the principal amount of CDN$5,500,000. The loan is secured by a first mortgage on the premises owned by CCH located at 3571 Muskoka Road 169, Bala, Ontario.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The loan bears interest at the fixed rate of 4.2% with a 5-year primary term and a 25-year amortization. The Company has guaranteed the loan and the Company’s chief executive officer and controlling shareholder also has personally guaranteed the Loan. CCH and the Company have granted the Lender a general security interest in its assets to secure repayment of the Loan. The loan is amortized with monthly installments of CDN $29,531.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The loan matured on July 19, 2022, and negotiations with the lender continue, no new terms have been presented to the Company as yet. The Company has continued to make installments in terms of the original mortgage agreement.</span> </p> <p style="margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z9wflMFbzBP1" style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8BD_zFjD8pRHgcri" style="display: none">Schedule of mortgage loans</span> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_305_134_zCBnIxxIvRt4" style="width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Mortgage loans (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest </b><br/> <b>rate</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maturity date</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal </b><br/> <b>Outstanding</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued </b><br/> <b>interest</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b><br/> <b>2023</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b><br/> <b>2022</b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td colspan="7"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cranberry Cove Holdings, Ltd.</b> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pace Mortgage</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230331_zKb5FpCNxi9e" style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 19, 2022</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </span></td> <td id="xdx_986_eus-gaap--PrincipalAmountOutstandingOnLoansSecuritized_iI_c20230331_zwUbN9H2Ucpg" style="border-bottom: black 1pt solid; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,473,334</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20230331_zccgtn8lox7l" style="border-bottom: black 1pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,796</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--LoansPayable_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--CranberryCoveHoldingsLtdMember_zLWryQmXNiOc" style="border-bottom: black 1pt solid; width: 14%; text-align: right" title="Loans Payable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,478,130</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> $</span></td> <td id="xdx_984_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--CranberryCoveHoldingsLtdMember_zZHNBDIu9u38" style="border-bottom: black 1pt solid; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,504,605</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td colspan="4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosed as follows:</b> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term portion </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--LoansPayableCurrent_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--CranberryCoveHoldingsLtdMember_z1EPXde2HNZ1" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,478,130</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--LoansPayableCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--CranberryCoveHoldingsLtdMember_zeyeVy7XLXD2" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,504,605</span></td></tr> <tr> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 0.042 3473334 4796 3478130 3504605 3478130 3504605 <p id="xdx_801_ecustom--GovernmentAssistanceLoansTextBlock_zFiIJMNOxAKd" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. <span style="background-color: white"><span id="xdx_821_zzo8vfhTqEEf">Government assistance loans</span></span></b></span></p> <p style="margin: 0 0 0 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On December 1, 2020, CCH was granted a Covid-19 related government assistance loan in the aggregate principal amount of CDN$ 40,000 (Approximately $31,000). the grant is interest free and CDN$ 10,000 is forgivable if the loan is repaid in full by December 31, 2022. The maturity date of this loan was extended by an additional year to December 31, 2023.</span></p> <p style="margin: 0 0 0 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On January 12, 2021, CCH received a further CDN$ 20,000 Covid-19 related government assistance loan. The loan is interest free and if repaid by December 31, 2022, CDN$ 10,000 is forgivable.</span></p> <p style="margin: 0 0 0 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On May 3, 2021, ARIA was granted a government assistance loan in the aggregate principal amount of $157,367. The loan is forgivable if the Company demonstrates that the proceeds were used for expenses such as employee costs during the pandemic. Should the loan not be forgiven, interest is payable on the loan at the rate of 1% per annum and the principal is repayable and interest is payable over an 18 month period.</span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On September 21, 2022, ARIA received partial forgiveness of the government assistance loan of $104,368, the balance of the loan plus accrued interest is due and payable. On December 30, 2022, the Company sold ARIA to its Chairman and CEO and agreed to assume the repayment of the government assistance loan. As of March 31, 2023, the balance outstanding, including interest thereon was $44,336.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_800_ecustom--ReceivablesFundingTextBlock_z8l61lEaAsUb" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11. <span style="background-color: white"><span id="xdx_82C_z62ss6MBRStk">Receivables funding</span></span></b></span></p> <p style="margin: 0 0 0 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>September 26, 2022 Funding</i></b></span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> On September 26, 2022, the Company, through its 75% held subsidiary, Evernia Health Center, LLC, entered into a Receivables Sale Agreement with Itria Ventures LLC (“Itria”), whereby $310,000 of the Receivables of Evernia were sold to Itria, for gross proceeds of $250,000. The Company also incurred fees of $5,500, resulting in net proceeds of $244,500. The Company is obliged to pay 7.41% of the receivables until the amount of $310,000 is paid in full, with periodic repayments of $6,458 per week. The guarantor of the funding is a minority shareholder in ATHI.</span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company made weekly cash payments of $6,458 totaling $167,917 on the September 26, 2022 funding. The balance outstanding at March 31, 2023 was $147,083, less unamortized discount of $30,949.</span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>December 13, 2022 Funding</i></b><i> </i></span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On December 13, 2022, the Company, through its 75% held subsidiary, Evernia Health Center, LLC entered into a Receivables Sale Agreement with Itria Ventures LLC (“Itria”), whereby $305,000 of the Receivables of Evernia were sold to Itria, for gross proceeds of $250,000. The Company also incurred fees of $2,500, resulting in net proceeds of $247,500. The Company is obliged to pay 6.08% of the receivables until the amount of $305,000 is paid in full, with periodic repayments of $6,354 per week. The guarantor of the funding is a minority shareholder in ATHI.</span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company made weekly cash payments of $6,354 totaling $88,958 on the December 13, 2022 funding. The balance outstanding at March 31, 2023 was $211,042, less unamortized discount of $40,228.</span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>January 19, 2023 Funding</i></b></span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On January 19, 2023, the Company received funding from an agreement entered into on December 14, 2022 through its 75% held subsidiary, Evernia Health Center, LLC entered into a Receivables Sale Agreement with Bizfund.com (“Bizfund)”), whereby $132,000 of the Receivables of Evernia were sold to Bizfund, for gross proceeds of $100,000. The Company is obliged to pay 15.0% of the receivables until the amount of $132,000 is paid in full, with periodic repayments of $2,750 per week. The guarantor of the funding is a minority shareholder in ATHI.</span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company made weekly cash payments of $2,750 totaling $24,750 on the January 19, 2023 funding. The balance outstanding at March 31, 2023 was $107,250, less unamortized discount of $26,536.</span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>February 14, 2023 Funding</i></b> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On February 14, 2023, the Company, through its 75% held subsidiary, Evernia Health Center, LLC entered into a Receivables Sale Agreement with Fox Business Funding (“Fox”), whereby $118,800 of the Receivables of Evernia were sold to Fox, for gross proceeds of $90,000. The Company is obliged to pay 8.0% of the receivables until the amount of $118,800 is paid in full, with periodic repayments of $2,970 per week. The guarantor of the funding is a minority shareholder in ATHI.</span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"/> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company made weekly cash payments of $2,970 totaling $17,820 on the February 14, 2023 funding. The balance outstanding at March 31, 2023 was $100,980, less unamortized discount of $25,183.</span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> <br/> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80F_ecustom--ThirdPartyTransactionsDisclosureTextBlock_z6Ftflhuv0Re" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12. <span style="background-color: white"><span id="xdx_82C_zObuPChu0U42">Third Party loans</span></span></b></span></p> <p style="margin: 0 0 0 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On April 12, 2019, Eileen Greene, a related party assigned CDN$1,000,000 of the amount owed by the Company to her, to a third party. The loan bears interest at 12% per annum which the Company agreed to pay. As of March 31, 2023 the balance of principal and interest outstanding on third party loans was CDN$798,950 ($590,372).</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zbl0fVLrP7L4" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. <span style="background-color: white"><span id="xdx_82F_zXeFhNWqno4h">Related party transactions</span></span></b></span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Shawn E. Leon</i></b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of March 31, 2023 and December 31, 2022, the Company had a payable to Shawn Leon of $389,476 and $411,611, respectively. Mr. Leon is a director and CEO of the Company. The balances payable are non-interest bearing and has no fixed repayment terms.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On December 30, 2022, the Company sold its wholly owned subsidiaries, Greenestone Muskoka and ARIA, to Mr. Leon for gross proceeds of $0. The Company realized a gain on disposal of $628,567 which was recorded as an increase in Additional Paid in Capital due to the related party nature of the transaction.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Due to the current financial position of the Group, Mr. Leon forfeited the management fees due to him for the three months ended March 31, 2023 and the year ended December 31, 2022.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Leon Developments, Ltd.</i></b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of March 31, 2023 and December 31, 2022, the Company owed Leon Developments, Ltd., $851,672 and $850,607, respectively, for funds advanced to the Company.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Eileen Greene</i></b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of March 31, 2023 and December 31, 2022, the Company owed Eileen Greene, the spouse of our CEO, Shawn Leon, $1,414,828 and $1,451,610, respectively. The amount owed to Ms. Greene is non-interest bearing and has no fixed repayment terms.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">All related party transactions occur in the normal course of operations and in terms of agreements entered into between the parties.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">   </span></p> <p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z11xirKIcN1e" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14. <span style="background-color: white"><span id="xdx_82C_zOIcIIrL9Gyb">Stockholder’s deficit</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td> <td style="width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common shares</b></span></td></tr> </table> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Authorized and outstanding </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company has authorized 10,000,000,000 shares with a par value of $0.01 per share. The company has issued 3,729,053,805 shares of common stock at March 31, 2023 and December 31, 2022.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b)</b></span></td> <td style="width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A Preferred shares</b></span></td></tr> </table> <p style="margin: 0 0 0 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Authorized, issued and outstanding </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company has authorized 10,000,000 Series A preferred shares with a par value of $0.01 per share. The company has issued and outstanding 4,000,000 Series A Preferred shares at March 31, 2023 and December 31, 2022.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c)</b></span></td> <td style="width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B Preferred shares</b></span></td></tr> </table> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Authorized and outstanding </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company has authorized 400,000 Series B preferred shares with a par value of $1.00 per share. The company has issued and outstanding 400,000 Series B Preferred shares at March 31, 2023 and December 31, 2022.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="background-color: white">The Series B preferred shares are senior secured and were mandatorily redeemable by the Company on July 1, 2021, and were originally classified as mezzanine debt. These Series B preferred shares have been reclassified as current liabilities for the three months ended March 31, 2023 as they meet the definition of liabilities in terms of ASC 480- debt and are no longer contingently convertible, due to the fact that the redemption date has passed and the Company is currently negotiating with the preferred note holders to settle the total liabilities owing to them, including certain convertible notes. The Company continues to accrue dividends at the rate of 6% per annum.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d)</b></span></td> <td style="width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock options</b></span></td></tr> </table> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our board of directors adopted the Greenstone Healthcare Corporation 2013 Stock Option Plan (the “Plan”) to promote our long-term growth and profitability by (i) providing our key directors, officers and employees with incentives to improve stockholder value and contribute to our growth and financial success and (ii) enable us to attract, retain and reward the best available persons for positions of substantial responsibility. A total of 10,000,000 shares of our common stock have been reserved for issuance upon exercise of options granted pursuant to the Plan. The Plan allows us to grant options to our employees, officers and directors and those of our subsidiaries; provided that only our employees and those of our subsidiaries may receive incentive stock options under the Plan. We have no issued options at March 31, 2023 under the Plan.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 4%; text-indent: 19.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>e)</b></span></td> <td style="width: 93%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">All of the warrants have cashless exercise terms whereby in-the-money warrants may be exercised by reducing the number of shares issued in terms of the warrant exercise to offset the proceeds due on the exercise.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">All of the warrants have price protection features whereby any securities issued subsequent to the date of the warrant issuance date, were issued at a lower price, or have conversion features that are lower than the current exercise price, or were converted at a lower price, or are exercisable at a lower price, to the current warrant exercise price, will result in the exercise price of the warrant being set to the lower issue, conversion or exercise price.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">  </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A summary of the Company’s warrant activity during the period from January 1, 2022 to March 31, 2023 is as follows:</span></p> <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zFitLGxTLY4f" style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zhcXWyOhLJi1" style="display: none">Schedule of warrants outstanding</span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_302_134_z0L7Gw62XZj4" style="width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stockholders deficit (Details)"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No. of shares</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise price<br/> per share</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> average exercise<br/> price</b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding as of January 1, 2022</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_znPmKUOtEO1b" style="width: 17%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>623,777,506</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$0.000675 to $0.12</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zEfSpriz8T1h" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.0052875</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zZJzjvrnxmP" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0855">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zb8BdacYSvv3" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0856">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited/cancelled</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231_zvhMWourNMba" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,925,000</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.12</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_z29uxfhcZFA" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.12</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z3wM1P1xl9A2" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0859">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zPqScOVz15H3" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0860">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding as of December 31, 2022</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230331_zv2UkVuWLBf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>602,852,506</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$0.000675 to $0.00205</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230331_z6tem8tBL24b" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.001306</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230331_zeAsQAa8SBO5" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0863">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230331_zbj5mdEP4L2h" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0864">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited/cancelled</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20230331_zjLFeaYTD1tg" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0865">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230331_zzFx585v0Q3k" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0866">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230331_zNjHQeksGAMb" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0867">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230331_zqnadORrK5le" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0868">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding as of March 31, 2023</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230331_zhsODKB8PsEg" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>602,852,506</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$0.000675 to $0.00205</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230331_zhELGDNuHZl2" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.001306</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_zpQBdsJTAPfi" style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">   </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white">  </p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The following table summarizes information about warrants outstanding at March 31, 2023:</span></p> <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ztTd3YDFi7Df" style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> <span id="xdx_8B6_zOrMr5e3UTr7" style="display: none">Schedule of assumption</span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_30A_134_zegGBTzTDYF4" style="width: 100%; background-color: white; border-collapse: collapse" summary="xdx: Disclosure - Stockholders deficit (Details 1)"> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants outstanding</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants exercisable</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise price</b></span></td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No. of shares</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid"><p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average</b></span></p> <p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>remaining years</b></span></p></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid"><p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average</b></span></p> <p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No. of shares</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid"><p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average</b></span></p> <p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.000675</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_ecustom--WarrantsOutstanding_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Excercise1Member_zCScg9s4ZJbc" style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">326,286,847</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Excercise1Member_zpjFPyJbN5y1">2.28</span></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98A_ecustom--WarrantsExercisable_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Excercise1Member_z11F0cJxG8we" style="width: 14%; text-align: right" title="Warrants exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">326,286,847</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.002050</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_ecustom--WarrantsOutstanding_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Excercise2Member_zc2f7GfN27Q1" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">276,565,659</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Excercise2Member_z35kuexOVzge">2.77</span></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_ecustom--WarrantsExercisable_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--Excercise2Member_zwHhcgnTt4c2" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">276,565,659</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_ecustom--WarrantsOutstanding_c20230101__20230331_z52DzRiCkob7" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>602,852,506</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm_dtY_c20230101__20230331_zkCUlcbbL3Of">2.51</span></b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331_zlrSsOheXihf" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.001306</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_ecustom--WarrantsExercisable_c20230101__20230331_zxQ6zFbhY0Bk" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>602,852,506</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_984_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable_c20230101__20230331_ziaiwo4pLPoh" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.001306</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_zmOkrPhPBpy3" style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">All of the warrants outstanding at March 31, 2023 are vested. The warrants outstanding at March 31, 2023 have an intrinsic value of $0. </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zFitLGxTLY4f" style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zhcXWyOhLJi1" style="display: none">Schedule of warrants outstanding</span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_302_134_z0L7Gw62XZj4" style="width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stockholders deficit (Details)"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No. of shares</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise price<br/> per share</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> average exercise<br/> price</b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding as of January 1, 2022</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_znPmKUOtEO1b" style="width: 17%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>623,777,506</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$0.000675 to $0.12</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zEfSpriz8T1h" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.0052875</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zZJzjvrnxmP" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0855">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zb8BdacYSvv3" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0856">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited/cancelled</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231_zvhMWourNMba" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,925,000</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.12</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_z29uxfhcZFA" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.12</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z3wM1P1xl9A2" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0859">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zPqScOVz15H3" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0860">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding as of December 31, 2022</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230331_zv2UkVuWLBf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>602,852,506</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$0.000675 to $0.00205</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230331_z6tem8tBL24b" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.001306</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230331_zeAsQAa8SBO5" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0863">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230331_zbj5mdEP4L2h" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0864">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited/cancelled</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20230331_zjLFeaYTD1tg" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0865">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230331_zzFx585v0Q3k" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0866">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230331_zNjHQeksGAMb" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0867">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230331_zqnadORrK5le" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0868">—</span>  </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding as of March 31, 2023</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230331_zhsODKB8PsEg" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>602,852,506</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$0.000675 to $0.00205</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230331_zhELGDNuHZl2" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.001306</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 623777506 0.0052875 20925000 0.12 602852506 0.001306 602852506 0.001306 <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ztTd3YDFi7Df" style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> <span id="xdx_8B6_zOrMr5e3UTr7" style="display: none">Schedule of assumption</span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_30A_134_zegGBTzTDYF4" style="width: 100%; background-color: white; border-collapse: collapse" summary="xdx: Disclosure - Stockholders deficit (Details 1)"> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants outstanding</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants exercisable</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise price</b></span></td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No. of shares</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid"><p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average</b></span></p> <p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>remaining years</b></span></p></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid"><p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average</b></span></p> <p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No. of shares</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid"><p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average</b></span></p> <p style="margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.000675</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_ecustom--WarrantsOutstanding_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Excercise1Member_zCScg9s4ZJbc" style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">326,286,847</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Excercise1Member_zpjFPyJbN5y1">2.28</span></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98A_ecustom--WarrantsExercisable_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Excercise1Member_z11F0cJxG8we" style="width: 14%; text-align: right" title="Warrants exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">326,286,847</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.002050</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_ecustom--WarrantsOutstanding_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Excercise2Member_zc2f7GfN27Q1" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">276,565,659</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm_dtY_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Excercise2Member_z35kuexOVzge">2.77</span></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_ecustom--WarrantsExercisable_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--Excercise2Member_zwHhcgnTt4c2" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">276,565,659</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_ecustom--WarrantsOutstanding_c20230101__20230331_z52DzRiCkob7" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>602,852,506</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm_dtY_c20230101__20230331_zkCUlcbbL3Of">2.51</span></b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331_zlrSsOheXihf" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.001306</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_ecustom--WarrantsExercisable_c20230101__20230331_zxQ6zFbhY0Bk" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>602,852,506</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td id="xdx_984_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable_c20230101__20230331_ziaiwo4pLPoh" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.001306</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 326286847 P2Y3M10D 326286847 276565659 P2Y9M7D 276565659 602852506 P2Y6M3D 0.001306 602852506 0.001306 <p id="xdx_809_ecustom--SegmentInformationTextBlock_zgRd5gepueuj" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15. <span style="background-color: white"><span id="xdx_82C_zLZljImLUtqf">Segment information</span></span></b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company has two reportable operating segments:</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rental income from the property owned by CCH subsidiary located at 3571 Muskoka Road, #169, Bala, on which the operations of the Canadian Rehab Clinic were located prior to disposal on February 14, 2017 and subsequently leased to the purchasers of the business of the Canadian Rehab Clinic, for a period of 5 years renewable for a further three five-year periods and with an option to acquire the property at a fixed price.</span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Rehabilitation Services provided to customers, these services were provided to customers at our Evernia, Addiction Recovery Institute of America and Seastone of Delray operations.</span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The segment operating results of the reportable segments for the three months ended March 31, 2023 is disclosed as follows:</span></p> <p id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zxKHzhnD3U62" style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B2_zPJQOTZBro66" style="display: none">Schedule of segment information</span> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_304_134_zsET1WcPFUkl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20230101__20230331_zdrid6ildFUf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20230101__20230331__us-gaap--StatementBusinessSegmentsAxis__custom--InPatientServicesMember_zb7VbNp07VQ7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_49B_20230101__20230331__us-gaap--StatementBusinessSegmentsAxis__custom--TotalMember_zMGaTxh4GKg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rental<br/> Operations</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In-Patient<br/> services</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_403_ecustom--Revenues1_zNXqzcKrrNYa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; font-weight: bold">Revenue</td><td style="width: 5%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 11%; font-weight: bold; text-align: right">89,419</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 5%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 11%; font-weight: bold; text-align: right">1,210,627</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,300,046</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CostsAndExpenses_z6aShqMZ4pJa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,120</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,194,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,225,020</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--OperatingIncomeLoss1_zur9epLZF4Fh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,299</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,727</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,026</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_zfZVIWWF6mpf" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Other (expense) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InterestExpense_iN_di_zrdOcTjSyqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.8pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(47,733</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(109,363</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(157,096</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_za8Y9CIy69Y5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.8pt">Amortization of debt discount</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0914">—</span>  </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(76,921</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(76,921</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--ForeignExchangeMovementsOne_zwyYZ53brs18" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.8pt">Foreign exchange movements</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,035</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,920</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,955</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--OciBeforeReclassificationsNetOfTaxAttributableToParent_zDvy5L1ytgT5" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Net income (loss) before taxes</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">10,531</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(172,477</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(161,946</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--SegmentTax_zT14AabBND2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 5.8pt">Taxes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0926">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,771</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,771</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_ecustom--NetIncomeLossOne_zYnccQpEvLRc" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.8pt">Net income (loss)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">10,531</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(186,248</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(175,717</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The operating assets and liabilities of the reportable segments as of March 31, 2023 is as follows:</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20230331__us-gaap--StatementBusinessSegmentsAxis__custom--RentalOperationsMember_zbfEGrMJcKJe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_491_20230331__us-gaap--StatementBusinessSegmentsAxis__custom--InPatientServicesMember_zyFL79IzXef" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_49C_20230331_zuf2EIw9gagc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rental<br/> Operations</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In-Patient<br/> services</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_40C_ecustom--PurchaseOfFixedAssets1_iI_z4MWWQTggj21" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; font-weight: bold; text-align: left; padding-bottom: 1pt">Purchase of fixed assets</td><td style="width: 5%; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0934">—</span>  </td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="width: 5%; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; font-weight: bold; text-align: right">52,418</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="width: 5%; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; font-weight: bold; text-align: right">52,418</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsCurrent_iI_zxNfvIsVYTD3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">233</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">689,431</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">689,664</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsNoncurrent_iI_zUf5wzjbaQp1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,441,143</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,474,998</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,916,141</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--OperatingAssetsAndLiabilities_iI_zT1NfZW3dQuj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,985,120</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,083,220</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14,068,340</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--OtherLiabilitiesNoncurrent_iNI_di_zn7nRdnxc3bd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(619,856</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,350,792</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,970,648</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_ecustom--IntercompanyBalances_iI_zNPusPZ2vPDa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Intercompany balances</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,299,110</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,299,110</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0956">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--NetLiabilityAssetposition_iI_zAFejiYz7pd6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net liability position</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(4,462,710</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(4,970,473</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(9,433,183</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table> <p style="margin: 0 0 0 31.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The segment operating results of the reportable segments for the three months ended March 31, 2022 is disclosed as follows:</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49B_20220101__20220331__us-gaap--StatementBusinessSegmentsAxis__custom--RentalOperationsMember_zGuu94qCE223" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_490_20220101__20220331__us-gaap--StatementBusinessSegmentsAxis__custom--InPatientServicesMember_zLQFhmMGop7c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_49F_20220101__20220331__us-gaap--StatementBusinessSegmentsAxis__custom--TotalMember_zzzqFewELt2a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rental<br/> Operations</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In-Patient<br/> services</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_401_eus-gaap--Revenues_zDN9SkWCnrgi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Revenue</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">93,874</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">929,441</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,023,315</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CostsAndExpenses_zc3vjAEZkMth" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(33,316</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(915,059</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(948,375</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingIncomeLoss_zDCXIG4gOcV8" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Operating income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,558</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,382</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74,940</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherNoncashIncomeExpenseAbstract_iB_zz7z0ZT7b3Y7" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Other (expense) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.8pt">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,018</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,018</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InterestExpense_iN_di_zW1ZvdLFlQQh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.8pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(53,607</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(27,161</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(80,768</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_zwRaEphGm673" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.8pt">Amortization of debt discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0987">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(252,832</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(252,832</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncreaseDecreaseInDerivativeAssetsAndLiabilities_zBSsCW3SOxjc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.8pt">Derivative liability movement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,476</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.8pt">Foreign exchange movements</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(21,829</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(73,727</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(95,556</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--OciBeforeReclassificationsNetOfTaxAttributableToParent_z0CbtMHV986c" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Net loss before taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14,878</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(131,844</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(146,722</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--SegmentTax_zBPC00kThP8h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 5.8pt">Taxes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0999">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(18,263</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(18,263</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--NetIncomeLossOne_z1JvCLIEbx21" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.8pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(14,878</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(150,107</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(164,985</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The operating assets and liabilities of the reportable segments as of March 31, 2022 is as follows:</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20220331__us-gaap--StatementBusinessSegmentsAxis__custom--RentalOperationsMember_zRPkLwJXkEh1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_490_20220331__us-gaap--StatementBusinessSegmentsAxis__custom--InPatientServicesMember_zHJmaGrDjA91" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_490_20220331__us-gaap--StatementBusinessSegmentsAxis__custom--TotalMember_zP4JMkiF51Ng" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rental<br/> Operations</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In-Patient<br/> services</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_40C_ecustom--PurchaseOfFixedAssets1_iI_zyJ1gy3hd3Qk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-bottom: 1pt">Purchase of fixed assets</td><td style="width: 5%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">—</span>  </td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 5%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">72,858</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 5%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">72,858</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AssetsCurrent_iI_zyE5RZQxdw43" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">551</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">355,167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">355,718</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AssetsNoncurrent_iI_zkPxkS4JDFJ2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,773,914</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,426,324</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,200,238</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingAssetsAndLiabilities_iI_z89kGYB94O4a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,590,715</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(12,078,894</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(13,669,609</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OtherLiabilitiesNoncurrent_iI_zXAcnPHjTsQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(636,577</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,710,232</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,346,809</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--MandatoryRedeemablePreferredShares_iI_zVdpYjd3akhg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Mandatory redeemable preferred shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1027">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(400,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(400,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--IntercompanyBalances_iI_zNnMuptGT0Gl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Intercompany balances</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,238,399</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,238,399</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--NetLiabilityAssetposition_iI_zLEXVA4T7ZOc" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net liability position</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,785,572</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(11,646,034</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(9,860,462</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table> <p id="xdx_8A2_zFDGmQYHbbg6" style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zxKHzhnD3U62" style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B2_zPJQOTZBro66" style="display: none">Schedule of segment information</span> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_304_134_zsET1WcPFUkl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20230101__20230331_zdrid6ildFUf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20230101__20230331__us-gaap--StatementBusinessSegmentsAxis__custom--InPatientServicesMember_zb7VbNp07VQ7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_49B_20230101__20230331__us-gaap--StatementBusinessSegmentsAxis__custom--TotalMember_zMGaTxh4GKg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rental<br/> Operations</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In-Patient<br/> services</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_403_ecustom--Revenues1_zNXqzcKrrNYa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; font-weight: bold">Revenue</td><td style="width: 5%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 11%; font-weight: bold; text-align: right">89,419</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 5%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 11%; font-weight: bold; text-align: right">1,210,627</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,300,046</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CostsAndExpenses_z6aShqMZ4pJa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,120</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,194,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,225,020</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--OperatingIncomeLoss1_zur9epLZF4Fh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,299</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,727</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,026</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_zfZVIWWF6mpf" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Other (expense) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InterestExpense_iN_di_zrdOcTjSyqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.8pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(47,733</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(109,363</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(157,096</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_za8Y9CIy69Y5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.8pt">Amortization of debt discount</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0914">—</span>  </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(76,921</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(76,921</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--ForeignExchangeMovementsOne_zwyYZ53brs18" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.8pt">Foreign exchange movements</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,035</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,920</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,955</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--OciBeforeReclassificationsNetOfTaxAttributableToParent_zDvy5L1ytgT5" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Net income (loss) before taxes</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">10,531</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(172,477</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(161,946</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--SegmentTax_zT14AabBND2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 5.8pt">Taxes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0926">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,771</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,771</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_ecustom--NetIncomeLossOne_zYnccQpEvLRc" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.8pt">Net income (loss)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">10,531</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(186,248</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(175,717</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The operating assets and liabilities of the reportable segments as of March 31, 2023 is as follows:</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20230331__us-gaap--StatementBusinessSegmentsAxis__custom--RentalOperationsMember_zbfEGrMJcKJe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_491_20230331__us-gaap--StatementBusinessSegmentsAxis__custom--InPatientServicesMember_zyFL79IzXef" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_49C_20230331_zuf2EIw9gagc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rental<br/> Operations</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In-Patient<br/> services</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_40C_ecustom--PurchaseOfFixedAssets1_iI_z4MWWQTggj21" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; font-weight: bold; text-align: left; padding-bottom: 1pt">Purchase of fixed assets</td><td style="width: 5%; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0934">—</span>  </td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="width: 5%; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; font-weight: bold; text-align: right">52,418</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="width: 5%; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; font-weight: bold; text-align: right">52,418</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsCurrent_iI_zxNfvIsVYTD3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">233</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">689,431</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">689,664</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsNoncurrent_iI_zUf5wzjbaQp1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,441,143</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,474,998</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,916,141</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--OperatingAssetsAndLiabilities_iI_zT1NfZW3dQuj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,985,120</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,083,220</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14,068,340</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--OtherLiabilitiesNoncurrent_iNI_di_zn7nRdnxc3bd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(619,856</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,350,792</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,970,648</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_ecustom--IntercompanyBalances_iI_zNPusPZ2vPDa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Intercompany balances</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,299,110</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,299,110</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0956">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--NetLiabilityAssetposition_iI_zAFejiYz7pd6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net liability position</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(4,462,710</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(4,970,473</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(9,433,183</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table> <p style="margin: 0 0 0 31.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The segment operating results of the reportable segments for the three months ended March 31, 2022 is disclosed as follows:</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49B_20220101__20220331__us-gaap--StatementBusinessSegmentsAxis__custom--RentalOperationsMember_zGuu94qCE223" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_490_20220101__20220331__us-gaap--StatementBusinessSegmentsAxis__custom--InPatientServicesMember_zLQFhmMGop7c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_49F_20220101__20220331__us-gaap--StatementBusinessSegmentsAxis__custom--TotalMember_zzzqFewELt2a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rental<br/> Operations</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In-Patient<br/> services</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_401_eus-gaap--Revenues_zDN9SkWCnrgi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Revenue</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">93,874</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">929,441</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,023,315</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CostsAndExpenses_zc3vjAEZkMth" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(33,316</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(915,059</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(948,375</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingIncomeLoss_zDCXIG4gOcV8" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Operating income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,558</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,382</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74,940</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherNoncashIncomeExpenseAbstract_iB_zz7z0ZT7b3Y7" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Other (expense) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.8pt">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,018</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,018</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InterestExpense_iN_di_zW1ZvdLFlQQh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.8pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(53,607</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(27,161</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(80,768</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_zwRaEphGm673" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.8pt">Amortization of debt discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0987">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(252,832</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(252,832</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncreaseDecreaseInDerivativeAssetsAndLiabilities_zBSsCW3SOxjc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.8pt">Derivative liability movement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,476</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.8pt">Foreign exchange movements</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(21,829</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(73,727</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(95,556</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--OciBeforeReclassificationsNetOfTaxAttributableToParent_z0CbtMHV986c" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Net loss before taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14,878</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(131,844</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(146,722</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--SegmentTax_zBPC00kThP8h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 5.8pt">Taxes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0999">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(18,263</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(18,263</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--NetIncomeLossOne_z1JvCLIEbx21" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.8pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(14,878</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(150,107</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(164,985</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The operating assets and liabilities of the reportable segments as of March 31, 2022 is as follows:</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20220331__us-gaap--StatementBusinessSegmentsAxis__custom--RentalOperationsMember_zRPkLwJXkEh1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_490_20220331__us-gaap--StatementBusinessSegmentsAxis__custom--InPatientServicesMember_zHJmaGrDjA91" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_490_20220331__us-gaap--StatementBusinessSegmentsAxis__custom--TotalMember_zP4JMkiF51Ng" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rental<br/> Operations</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In-Patient<br/> services</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_40C_ecustom--PurchaseOfFixedAssets1_iI_zyJ1gy3hd3Qk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-bottom: 1pt">Purchase of fixed assets</td><td style="width: 5%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">—</span>  </td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 5%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">72,858</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 5%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">72,858</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AssetsCurrent_iI_zyE5RZQxdw43" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">551</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">355,167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">355,718</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AssetsNoncurrent_iI_zkPxkS4JDFJ2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,773,914</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,426,324</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,200,238</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingAssetsAndLiabilities_iI_z89kGYB94O4a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,590,715</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(12,078,894</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(13,669,609</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OtherLiabilitiesNoncurrent_iI_zXAcnPHjTsQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(636,577</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,710,232</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,346,809</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--MandatoryRedeemablePreferredShares_iI_zVdpYjd3akhg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Mandatory redeemable preferred shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1027">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(400,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(400,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--IntercompanyBalances_iI_zNnMuptGT0Gl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Intercompany balances</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,238,399</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,238,399</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--NetLiabilityAssetposition_iI_zLEXVA4T7ZOc" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net liability position</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,785,572</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(11,646,034</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(9,860,462</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr> </table> 89419 1210627 1300046 30120 1194900 1225020 59299 15727 75026 47733 109363 157096 -76921 -76921 -1035 -1920 -2955 10531 -172477 -161946 -13771 -13771 10531 -186248 -175717 52418 52418 233 689431 689664 2441143 3474998 5916141 -4985120 -9083220 -14068340 619856 1350792 1970648 -1299110 1299110 -4462710 -4970473 -9433183 93874 929441 1023315 -33316 -915059 -948375 60558 14382 74940 53607 27161 80768 -252832 -252832 197476 197476 -14878 -131844 -146722 -18263 -18263 -14878 -150107 -164985 72858 72858 551 355167 355718 2773914 3426324 6200238 -1590715 -12078894 -13669609 -636577 -1710232 -2346809 -400000 -400000 1238399 -1238399 1785572 -11646034 -9860462 <p id="xdx_808_eus-gaap--EarningsPerShareTextBlock_zzlUNYbdz0Ql" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16. <span style="background-color: white"><span id="xdx_82E_z4I3DJxVYYj9">Net income (loss) per common share</span></span></b></span></p> <p style="margin: 0 0 0 31.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For the three months ended March 31, 2023 and 2022, the following warrants and convertible securities were excluded from the computation of diluted net loss per share as the results would have been anti-dilutive.</span></p> <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zk71UicPCfod" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zv6bvxP5A658" style="display: none">Schedule of Antidilutive Securities</span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_30A_134_z8h5YgLqPlIe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net income (loss) per common share (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Three months ended<br/> March 31,<br/> 2023</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Three months ended<br/> March 31,<br/> 2022</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zCFg59qhc0Xc" style="width: 12%; text-align: right">602,852,506</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zrGpovkGS361" style="width: 12%; text-align: right">611,140,006</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zwCTFYZwC4Bb" style="border-bottom: Black 1pt solid; text-align: right">582,290,570</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zuLZDMu8sGpb" style="border-bottom: Black 1pt solid; text-align: right">458,435,448</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_zTzFij8kisAa" style="border-bottom: Black 1pt solid; text-align: right">1,185,143,076</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zM1nuqwCMLI9" style="border-bottom: Black 1pt solid; text-align: right">1,069,575,454</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/></p> <p id="xdx_8A6_zUyYbQVGONX4" style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zk71UicPCfod" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zv6bvxP5A658" style="display: none">Schedule of Antidilutive Securities</span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_30A_134_z8h5YgLqPlIe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net income (loss) per common share (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Three months ended<br/> March 31,<br/> 2023</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Three months ended<br/> March 31,<br/> 2022</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zCFg59qhc0Xc" style="width: 12%; text-align: right">602,852,506</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zrGpovkGS361" style="width: 12%; text-align: right">611,140,006</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zwCTFYZwC4Bb" style="border-bottom: Black 1pt solid; text-align: right">582,290,570</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNoteMember_zuLZDMu8sGpb" style="border-bottom: Black 1pt solid; text-align: right">458,435,448</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_zTzFij8kisAa" style="border-bottom: Black 1pt solid; text-align: right">1,185,143,076</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_zM1nuqwCMLI9" style="border-bottom: Black 1pt solid; text-align: right">1,069,575,454</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/></p> 602852506 611140006 582290570 458435448 1185143076 1069575454 <p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zIvcLmo8Z6c9" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17. <span style="background-color: white"><span id="xdx_82B_zBI08kQZZPf4">Commitments and contingencies</span></span></b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>a.</i></b></span></td> <td style="width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Options granted to purchase shares in ATHI</i></b></span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On July 12, 2020, the Company entered into a five year option agreement with Leonite Capital LLC (“Leonite”) and other investors (collectively the “Transferees”). The Company agreed to sell to Leonite a portion of the total outstanding shares of ATHI from the shares of ATHI held by the company. The Company provided Leonite an option to purchase 4,000,000 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $400), based on the advances that Leonite made to the Company totaling $396,000. Leonite shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Leonite to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.</span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On September 14, 2020, the Company entered into a five year option agreement with Ed Blasiak (“Blasiak”) whereby the Company agreed to sell to Blasiak a portion of the total outstanding shares of ATHI. The Company provided Blasiak an option to purchase 571,428 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $57), based on the advances that Blasiak made to the Company totaling $50,000. Blasiak shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Blasiak to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.</span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On October 29, 2020, the Company entered into a five year option agreement with First Fire whereby the Company agreed to sell to First Fire a portion of the total outstanding shares of ATHI. The Company provided First Fire an option to purchase 1,428,571 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $143), based on the advances that First Fire made to the Company totaling $120,000. First Fire shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by First Fire to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.</span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On October 29, 2020, the Company entered into a five year option agreement entered into with Bauman, so that the Company agreed to sell to Bauman a portion of the total outstanding shares of ATHI. The Company provided Bauman an option to purchase 1,428,571 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $143), based on the advances that Bauman made to the Company totaling $120,000. Bauman shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Bauman to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.</span></p> <p style="margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>b.</i></b></span></td> <td style="width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mortgage loans</i></b></span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The company has a mortgage loan as disclosed in note 9 above. The mortgage loan matured on July 19, 2022 and the Company currently owes $3,478,130. The terms of the loan are currently being negotiated.</span></p> <p style="margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>c.</i></b></span></td> <td style="width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other</i></b></span></td></tr> </table> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company has principal and interest payment commitments under the Convertible notes disclosed under Note 7 above. Conversion of these notes are at the option of the investor, if not converted these notes may need to be repaid.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">From time to time, the Company and its subsidiaries enter into legal disputes in the ordinary course of business. The Company believes there are no material legal or administrative matters pending that are likely to have, individually or in the aggregate, a material adverse effect on its business or results of operations.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">    </span></p> <p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zvWviKZ2zK28" style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.5pt; background-color: white"><b>18. </b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_829_zaoz8TnMUWOh">Subsequent events</span></span></b></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b> </b></span></p> <p style="margin: 0 0 0 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company has evaluated subsequent events through the date of the condensed consolidated financial statements were issued, we did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>  </b></span></p> <p style="margin: 0 0 0 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: yellow"><b><i/></b></span></p> EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 61 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 102 270 1 false 33 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://grst/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://grst/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Sheet http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT Sheet http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Sheet http://grst/role/CondensedConsolidatedStatementOfCashFlows CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Disclosure - Nature of business Sheet http://grst/role/NatureOfBusiness Nature of business Notes 7 false false R8.htm 00000008 - Disclosure - Summary of significant accounting policies Sheet http://grst/role/SummaryOfSignificantAccountingPolicies Summary of significant accounting policies Notes 8 false false R9.htm 00000009 - Disclosure - Going concern Sheet http://grst/role/GoingConcern Going concern Notes 9 false false R10.htm 00000010 - Disclosure - Property and equipment Sheet http://grst/role/PropertyAndEquipment Property and equipment Notes 10 false false R11.htm 00000011 - Disclosure - Intangibles Sheet http://grst/role/Intangibles Intangibles Notes 11 false false R12.htm 00000012 - Disclosure - Leases Sheet http://grst/role/Leases Leases Notes 12 false false R13.htm 00000013 - Disclosure - Short-term Convertible Notes Notes http://grst/role/Short-termConvertibleNotes Short-term Convertible Notes Notes 13 false false R14.htm 00000014 - Disclosure - Short-term Notes Notes http://grst/role/Short-termNotes Short-term Notes Notes 14 false false R15.htm 00000015 - Disclosure - Mortgage loans Sheet http://grst/role/MortgageLoans Mortgage loans Notes 15 false false R16.htm 00000016 - Disclosure - Government assistance loans Sheet http://grst/role/GovernmentAssistanceLoans Government assistance loans Notes 16 false false R17.htm 00000017 - Disclosure - Receivables funding Sheet http://grst/role/ReceivablesFunding Receivables funding Notes 17 false false R18.htm 00000018 - Disclosure - Third Party loans Sheet http://grst/role/ThirdPartyLoans Third Party loans Notes 18 false false R19.htm 00000019 - Disclosure - Related party transactions Sheet http://grst/role/RelatedPartyTransactions Related party transactions Notes 19 false false R20.htm 00000020 - Disclosure - Stockholder???s deficit Sheet http://grst/role/StockholdersDeficit Stockholder???s deficit Notes 20 false false R21.htm 00000021 - Disclosure - Segment information Sheet http://grst/role/SegmentInformation Segment information Notes 21 false false R22.htm 00000022 - Disclosure - Net income (loss) per common share Sheet http://grst/role/NetIncomeLossPerCommonShare Net income (loss) per common share Notes 22 false false R23.htm 00000023 - Disclosure - Commitments and contingencies Sheet http://grst/role/CommitmentsAndContingencies Commitments and contingencies Notes 23 false false R24.htm 00000024 - Disclosure - Subsequent events Sheet http://grst/role/SubsequentEvents Subsequent events Notes 24 false false R25.htm 00000025 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of significant accounting policies (Policies) Policies 25 false false R26.htm 00000026 - Disclosure - Property and equipment (Tables) Sheet http://grst/role/PropertyAndEquipmentTables Property and equipment (Tables) Tables http://grst/role/PropertyAndEquipment 26 false false R27.htm 00000027 - Disclosure - Intangibles (Tables) Sheet http://grst/role/IntangiblesTables Intangibles (Tables) Tables http://grst/role/Intangibles 27 false false R28.htm 00000028 - Disclosure - Leases (Tables) Sheet http://grst/role/LeasesTables Leases (Tables) Tables http://grst/role/Leases 28 false false R29.htm 00000029 - Disclosure - Short-term Convertible Notes (Tables) Notes http://grst/role/Short-termConvertibleNotesTables Short-term Convertible Notes (Tables) Tables http://grst/role/Short-termConvertibleNotes 29 false false R30.htm 00000030 - Disclosure - Mortgage loans (Tables) Sheet http://grst/role/MortgageLoansTables Mortgage loans (Tables) Tables http://grst/role/MortgageLoans 30 false false R31.htm 00000031 - Disclosure - Stockholder???s deficit (Tables) Sheet http://grst/role/StockholdersDeficitTables Stockholder???s deficit (Tables) Tables http://grst/role/StockholdersDeficit 31 false false R32.htm 00000032 - Disclosure - Segment information (Tables) Sheet http://grst/role/SegmentInformationTables Segment information (Tables) Tables http://grst/role/SegmentInformation 32 false false R33.htm 00000033 - Disclosure - Net income (loss) per common share (Tables) Sheet http://grst/role/NetIncomeLossPerCommonShareTables Net income (loss) per common share (Tables) Tables http://grst/role/NetIncomeLossPerCommonShare 33 false false R34.htm 00000034 - Disclosure - Summary of significant accounting policies (Details Narrative) Sheet http://grst/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of significant accounting policies (Details Narrative) Details http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies 34 false false R35.htm 00000035 - Disclosure - Property and equipment (Details) Sheet http://grst/role/PropertyAndEquipmentDetails Property and equipment (Details) Details http://grst/role/PropertyAndEquipmentTables 35 false false R36.htm 00000036 - Disclosure - Property and equipment (Details Narrative) Sheet http://grst/role/PropertyAndEquipmentDetailsNarrative Property and equipment (Details Narrative) Details http://grst/role/PropertyAndEquipmentTables 36 false false R37.htm 00000037 - Disclosure - Intangibles (Details) Sheet http://grst/role/IntangiblesDetails Intangibles (Details) Details http://grst/role/IntangiblesTables 37 false false R38.htm 00000038 - Disclosure - Intangibles (Details Narrative) Sheet http://grst/role/IntangiblesDetailsNarrative Intangibles (Details Narrative) Details http://grst/role/IntangiblesTables 38 false false R39.htm 00000039 - Disclosure - Leases (Details) Sheet http://grst/role/LeasesDetails Leases (Details) Details http://grst/role/LeasesTables 39 false false R40.htm 00000040 - Disclosure - Leases (Details 1) Sheet http://grst/role/LeasesDetails1 Leases (Details 1) Details http://grst/role/LeasesTables 40 false false R41.htm 00000041 - Disclosure - Leases (Details 2) Sheet http://grst/role/LeasesDetails2 Leases (Details 2) Details http://grst/role/LeasesTables 41 false false R42.htm 00000042 - Disclosure - Leases (Details 3) Sheet http://grst/role/LeasesDetails3 Leases (Details 3) Details http://grst/role/LeasesTables 42 false false R43.htm 00000043 - Disclosure - Leases (Details 4) Sheet http://grst/role/LeasesDetails4 Leases (Details 4) Details http://grst/role/LeasesTables 43 false false R44.htm 00000044 - Disclosure - Leases (Details Narrative) Sheet http://grst/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://grst/role/LeasesTables 44 false false R45.htm 00000045 - Disclosure - Short-term Convertible Notes (Details) Notes http://grst/role/Short-termConvertibleNotesDetails Short-term Convertible Notes (Details) Details http://grst/role/Short-termConvertibleNotesTables 45 false false R46.htm 00000046 - Disclosure - Mortgage loans (Details) Sheet http://grst/role/MortgageLoansDetails Mortgage loans (Details) Details http://grst/role/MortgageLoansTables 46 false false R47.htm 00000047 - Disclosure - Stockholders deficit (Details) Sheet http://grst/role/StockholdersDeficitDetails Stockholders deficit (Details) Details 47 false false R48.htm 00000048 - Disclosure - Stockholders deficit (Details 1) Sheet http://grst/role/StockholdersDeficitDetails1 Stockholders deficit (Details 1) Details 48 false false R49.htm 00000049 - Disclosure - Segment Information (Details) Sheet http://grst/role/SegmentInformationDetails Segment Information (Details) Details 49 false false R50.htm 00000050 - Disclosure - Net income (loss) per common share (Details) Sheet http://grst/role/NetIncomeLossPerCommonShareDetails Net income (loss) per common share (Details) Details http://grst/role/NetIncomeLossPerCommonShareTables 50 false false All Reports Book All Reports grst_10q.htm ex31_1.htm ex32_1.htm grst-20230331.xsd grst-20230331_cal.xml grst-20230331_def.xml grst-20230331_lab.xml grst-20230331_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "grst_10q.htm": { "axisCustom": 0, "axisStandard": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 492, "http://xbrl.sec.gov/dei/2022": 28 }, "contextCount": 102, "dts": { "calculationLink": { "local": [ "grst-20230331_cal.xml" ] }, "definitionLink": { "local": [ "grst-20230331_def.xml" ] }, "inline": { "local": [ "grst_10q.htm" ] }, "labelLink": { "local": [ "grst-20230331_lab.xml" ] }, "presentationLink": { "local": [ "grst-20230331_pre.xml" ] }, "schema": { "local": [ "grst-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 393, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 65, "http://grst/20230331": 13, "http://xbrl.sec.gov/dei/2022": 5, "total": 83 }, "keyCustom": 56, "keyStandard": 214, "memberCustom": 19, "memberStandard": 13, "nsprefix": "grst", "nsuri": "http://grst/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://grst/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Property and equipment", "menuCat": "Notes", "order": "10", "role": "http://grst/role/PropertyAndEquipment", "shortName": "Property and equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Intangibles", "menuCat": "Notes", "order": "11", "role": "http://grst/role/Intangibles", "shortName": "Intangibles", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Leases", "menuCat": "Notes", "order": "12", "role": "http://grst/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Short-term Convertible Notes", "menuCat": "Notes", "order": "13", "role": "http://grst/role/Short-termConvertibleNotes", "shortName": "Short-term Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Short-term Notes", "menuCat": "Notes", "order": "14", "role": "http://grst/role/Short-termNotes", "shortName": "Short-term Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "grst:MortgageLoansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Mortgage loans", "menuCat": "Notes", "order": "15", "role": "http://grst/role/MortgageLoans", "shortName": "Mortgage loans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "grst:MortgageLoansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "grst:GovernmentAssistanceLoansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Government assistance loans", "menuCat": "Notes", "order": "16", "role": "http://grst/role/GovernmentAssistanceLoans", "shortName": "Government assistance loans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "grst:GovernmentAssistanceLoansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "grst:ReceivablesFundingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Receivables funding", "menuCat": "Notes", "order": "17", "role": "http://grst/role/ReceivablesFunding", "shortName": "Receivables funding", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "grst:ReceivablesFundingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "grst:ThirdPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Third Party loans", "menuCat": "Notes", "order": "18", "role": "http://grst/role/ThirdPartyLoans", "shortName": "Third Party loans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "grst:ThirdPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Related party transactions", "menuCat": "Notes", "order": "19", "role": "http://grst/role/RelatedPartyTransactions", "shortName": "Related party transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://grst/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Stockholder\u2019s deficit", "menuCat": "Notes", "order": "20", "role": "http://grst/role/StockholdersDeficit", "shortName": "Stockholder\u2019s deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "grst:SegmentInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Segment information", "menuCat": "Notes", "order": "21", "role": "http://grst/role/SegmentInformation", "shortName": "Segment information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "grst:SegmentInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Net income (loss) per common share", "menuCat": "Notes", "order": "22", "role": "http://grst/role/NetIncomeLossPerCommonShare", "shortName": "Net income (loss) per common share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Commitments and contingencies", "menuCat": "Notes", "order": "23", "role": "http://grst/role/CommitmentsAndContingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Subsequent events", "menuCat": "Notes", "order": "24", "role": "http://grst/role/SubsequentEvents", "shortName": "Subsequent events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Summary of significant accounting policies (Policies)", "menuCat": "Policies", "order": "25", "role": "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Property and equipment (Tables)", "menuCat": "Tables", "order": "26", "role": "http://grst/role/PropertyAndEquipmentTables", "shortName": "Property and equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Intangibles (Tables)", "menuCat": "Tables", "order": "27", "role": "http://grst/role/IntangiblesTables", "shortName": "Intangibles (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "28", "role": "http://grst/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Short-term Convertible Notes (Tables)", "menuCat": "Tables", "order": "29", "role": "http://grst/role/Short-termConvertibleNotesTables", "shortName": "Short-term Convertible Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "grst:MortgageLoansTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Mortgage loans (Tables)", "menuCat": "Tables", "order": "30", "role": "http://grst/role/MortgageLoansTables", "shortName": "Mortgage loans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "grst:MortgageLoansTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Stockholder\u2019s deficit (Tables)", "menuCat": "Tables", "order": "31", "role": "http://grst/role/StockholdersDeficitTables", "shortName": "Stockholder\u2019s deficit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "grst:SegmentInformationTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Segment information (Tables)", "menuCat": "Tables", "order": "32", "role": "http://grst/role/SegmentInformationTables", "shortName": "Segment information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "grst:SegmentInformationTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Net income (loss) per common share (Tables)", "menuCat": "Tables", "order": "33", "role": "http://grst/role/NetIncomeLossPerCommonShareTables", "shortName": "Net income (loss) per common share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FDICIndemnificationAsset", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Summary of significant accounting policies (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://grst/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of significant accounting policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FDICIndemnificationAsset", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Property and equipment (Details)", "menuCat": "Details", "order": "35", "role": "http://grst/role/PropertyAndEquipmentDetails", "shortName": "Property and equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Property and equipment (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://grst/role/PropertyAndEquipmentDetailsNarrative", "shortName": "Property and equipment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "grst:FiniteLivedIntangibleAssetUsefulLifeOne", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Intangibles (Details)", "menuCat": "Details", "order": "37", "role": "http://grst/role/IntangiblesDetails", "shortName": "Intangibles (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "grst:FiniteLivedIntangibleAssetUsefulLifeOne", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Intangibles (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://grst/role/IntangiblesDetailsNarrative", "shortName": "Intangibles (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Leases (Details)", "menuCat": "Details", "order": "39", "role": "http://grst/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)", "menuCat": "Statements", "order": "4", "role": "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "grst:ScheduleoOfFinanceAndOperatingLeaseTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Leases (Details 1)", "menuCat": "Details", "order": "40", "role": "http://grst/role/LeasesDetails1", "shortName": "Leases (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "grst:ScheduleoOfFinanceAndOperatingLeaseTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "grst:OtherLeaseTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "grst:OperatingCashFlowsFromFinanceLeases", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Leases (Details 2)", "menuCat": "Details", "order": "41", "role": "http://grst/role/LeasesDetails2", "shortName": "Leases (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "grst:OtherLeaseTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "grst:OperatingCashFlowsFromFinanceLeases", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Leases (Details 3)", "menuCat": "Details", "order": "42", "role": "http://grst/role/LeasesDetails3", "shortName": "Leases (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Leases (Details 4)", "menuCat": "Details", "order": "43", "role": "http://grst/role/LeasesDetails4", "shortName": "Leases (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "grst:DerivedRentalIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Leases (Details Narrative)", "menuCat": "Details", "order": "44", "role": "http://grst/role/LeasesDetailsNarrative", "shortName": "Leases (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "grst:DerivedRentalIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "grst:DebtInstrumentOfPrincipalAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Short-term Convertible Notes (Details)", "menuCat": "Details", "order": "45", "role": "http://grst/role/Short-termConvertibleNotesDetails", "shortName": "Short-term Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "grst:DebtInstrumentOfPrincipalAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "grst:MortgageLoansTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Mortgage loans (Details)", "menuCat": "Details", "order": "46", "role": "http://grst/role/MortgageLoansDetails", "shortName": "Mortgage loans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "grst:MortgageLoansTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Stockholders deficit (Details)", "menuCat": "Details", "order": "47", "role": "http://grst/role/StockholdersDeficitDetails", "shortName": "Stockholders deficit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "grst:WarrantsOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Stockholders deficit (Details 1)", "menuCat": "Details", "order": "48", "role": "http://grst/role/StockholdersDeficitDetails1", "shortName": "Stockholders deficit (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "grst:WarrantsOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "grst:SegmentInformationTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "grst:Revenues1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Segment Information (Details)", "menuCat": "Details", "order": "49", "role": "http://grst/role/SegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "grst:SegmentInformationTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "grst:Revenues1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_PreferredClassAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT", "menuCat": "Statements", "order": "5", "role": "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_PreferredClassAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Net income (loss) per common share (Details)", "menuCat": "Details", "order": "50", "role": "http://grst/role/NetIncomeLossPerCommonShareDetails", "shortName": "Net income (loss) per common share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://grst/role/CondensedConsolidatedStatementOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Nature of business", "menuCat": "Notes", "order": "7", "role": "http://grst/role/NatureOfBusiness", "shortName": "Nature of business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Summary of significant accounting policies", "menuCat": "Notes", "order": "8", "role": "http://grst/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Going concern", "menuCat": "Notes", "order": "9", "role": "http://grst/role/GoingConcern", "shortName": "Going concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "grst_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 33, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r425", "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grst/role/Cover" ], "xbrltype": "booleanItemType" }, "grst_AllowanceForCreditLossesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Allowance for credit losses" } } }, "localname": "AllowanceForCreditLossesPolicyTextBlock", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "grst_AllowanceForDoubtfulAccountsContractualAndOtherDiscountsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Allowance for Doubtful Accounts, Contractual and Other Discounts" } } }, "localname": "AllowanceForDoubtfulAccountsContractualAndOtherDiscountsPolicyTextBlock", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "grst_AuctusFundLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Auctus Fund L L C [Member]" } } }, "localname": "AuctusFundLLCMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "grst_BasicAndDilutedLossPerCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted loss per common share" } } }, "localname": "BasicAndDilutedLossPerCommonShare", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "grst_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable]" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/StockholdersDeficitDetails1" ], "xbrltype": "perShareItemType" }, "grst_ConsolidatedNetLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Consolidated Net loss" } } }, "localname": "ConsolidatedNetLoss", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "grst_ConversionOfConvertibleNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "ConversionOfConvertibleNotes", "verboseLabel": "Conversion of convertible notes" } } }, "localname": "ConversionOfConvertibleNotes", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "grst_ConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note [Member]" } } }, "localname": "ConvertibleNoteMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "grst_CranberryCoveHoldingsLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cranberry Cove Holdings Ltd [Member]" } } }, "localname": "CranberryCoveHoldingsLtdMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/MortgageLoansDetails" ], "xbrltype": "domainItemType" }, "grst_DebtInstrumentOfPrincipalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Principal amount" } } }, "localname": "DebtInstrumentOfPrincipalAmount", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "grst_DeferredTaxationMovement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred taxation movement" } } }, "localname": "DeferredTaxationMovement", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "grst_DerivativeLiabilityMovements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Derivative liability movements" } } }, "localname": "DerivativeLiabilityMovements", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "grst_DerivedRentalIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Derived rental income" } } }, "localname": "DerivedRentalIncome", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "grst_DisclosureGovernmentAssistanceLoansAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Government Assistance Loans" } } }, "localname": "DisclosureGovernmentAssistanceLoansAbstract", "nsuri": "http://grst/20230331", "xbrltype": "stringItemType" }, "grst_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://grst/20230331", "xbrltype": "stringItemType" }, "grst_DisclosureMortgageLoansAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mortgage Loans" } } }, "localname": "DisclosureMortgageLoansAbstract", "nsuri": "http://grst/20230331", "xbrltype": "stringItemType" }, "grst_DisclosureReceivablesFundingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables Funding" } } }, "localname": "DisclosureReceivablesFundingAbstract", "nsuri": "http://grst/20230331", "xbrltype": "stringItemType" }, "grst_DisclosureSegmentInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Information" } } }, "localname": "DisclosureSegmentInformationAbstract", "nsuri": "http://grst/20230331", "xbrltype": "stringItemType" }, "grst_DisclosureThirdPartyLoansAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Third Party Loans" } } }, "localname": "DisclosureThirdPartyLoansAbstract", "nsuri": "http://grst/20230331", "xbrltype": "stringItemType" }, "grst_DiscountInParValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discount In Par Value [Member]" } } }, "localname": "DiscountInParValueMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "grst_DiscountRateFinanceLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:DiscountRateFinanceLeases]" } } }, "localname": "DiscountRateFinanceLeases", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetails2" ], "xbrltype": "percentItemType" }, "grst_DiscountRateOperatingLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:DiscountRateOperatingLeases]" } } }, "localname": "DiscountRateOperatingLeases", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetails2" ], "xbrltype": "percentItemType" }, "grst_EdBlasiakMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ed Blasiak [Member]" } } }, "localname": "EdBlasiakMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "grst_Excercise1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Excercise 1 [Member]" } } }, "localname": "Excercise1Member", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/StockholdersDeficitDetails1" ], "xbrltype": "domainItemType" }, "grst_Excercise2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Excercise 2 [Member]" } } }, "localname": "Excercise2Member", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/StockholdersDeficitDetails1" ], "xbrltype": "domainItemType" }, "grst_FinancialnstrumentsRisksPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial instruments risks" } } }, "localname": "FinancialnstrumentsRisksPolicyTextBlock", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "grst_FinancingCashFlowsFromFinanceLeases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Financing cash flows from finance leases" } } }, "localname": "FinancingCashFlowsFromFinanceLeases", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "grst_FiniteLivedIntangibleAssetUsefulLifeOne": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLifeOne", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/IntangiblesDetails" ], "xbrltype": "stringItemType" }, "grst_ForeignExchangeMovements": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Foreign exchange movements" } } }, "localname": "ForeignExchangeMovements", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "grst_ForeignExchangeMovementsOne": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "ForeignExchangeMovementsOne", "verboseLabel": "Foreign exchange movements" } } }, "localname": "ForeignExchangeMovementsOne", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "grst_GovernmentAssistanceLoansNonCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "GovernmentAssistanceLoansNonCurrent", "verboseLabel": "Government assistance loans" } } }, "localname": "GovernmentAssistanceLoansNonCurrent", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "grst_GovernmentAssistanceLoansTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GovernmentAssistanceLoansTextBlock", "verboseLabel": "Government assistance loans" } } }, "localname": "GovernmentAssistanceLoansTextBlock", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/GovernmentAssistanceLoans" ], "xbrltype": "textBlockItemType" }, "grst_ImputedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Imputed interest" } } }, "localname": "ImputedInterest", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetails3" ], "xbrltype": "monetaryItemType" }, "grst_InPatientServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "In Patient Services [Member]" } } }, "localname": "InPatientServicesMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "grst_IntercompanyBalances": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Intercompany balances" } } }, "localname": "IntercompanyBalances", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "grst_InterestExpenseOnFinanceLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest expense on finance lease liabilities" } } }, "localname": "InterestExpenseOnFinanceLeaseLiabilities", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "grst_JoshuaBaumanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Joshua Bauman [Member]" } } }, "localname": "JoshuaBaumanMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "grst_LabrysFundLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Labrys Fund L P [Member]" } } }, "localname": "LabrysFundLPMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "grst_LeoniteCapitalLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leonite Capital L L C [Member]" } } }, "localname": "LeoniteCapitalLLCMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "grst_LeoniteFundILPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leonite Fund I L P [Member]" } } }, "localname": "LeoniteFundILPMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "grst_MandatoryRedeemablePreferredShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Mandatory redeemable preferred shares" } } }, "localname": "MandatoryRedeemablePreferredShares", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "grst_MortgageLoansTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MortgageLoansTextBlock", "verboseLabel": "Mortgage loans" } } }, "localname": "MortgageLoansTextBlock", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/MortgageLoans" ], "xbrltype": "textBlockItemType" }, "grst_NetChangeInLeases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net Change in leases" } } }, "localname": "NetChangeInLeases", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "grst_NetIncomeLossOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "NetIncomeLossOne", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLossOne", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "grst_NetLiabilityAssetposition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net liability position" } } }, "localname": "NetLiabilityAssetposition", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "grst_OperatingAssetsAndLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "OperatingAssetsAndLiabilities", "verboseLabel": "Current liabilities" } } }, "localname": "OperatingAssetsAndLiabilities", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "grst_OperatingCashFlowsFromFinanceLeases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operating cash flows from finance leases" } } }, "localname": "OperatingCashFlowsFromFinanceLeases", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "grst_OperatingCashFlowsFromOperatingLeases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operating cash flows from operating leases" } } }, "localname": "OperatingCashFlowsFromOperatingLeases", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "grst_OperatingIncomeLoss1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Operating income" } } }, "localname": "OperatingIncomeLoss1", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "grst_OtherLeaseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Other lease" } } }, "localname": "OtherLeaseTableTextBlock", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "grst_PurchaseOfFixedAssets1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Purchase of fixed assets" } } }, "localname": "PurchaseOfFixedAssets1", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "grst_ReceivablesFundingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ReceivablesFundingTextBlock", "verboseLabel": "Receivables funding" } } }, "localname": "ReceivablesFundingTextBlock", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/ReceivablesFunding" ], "xbrltype": "textBlockItemType" }, "grst_RedeemableAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable A Preferred Stock [Member]" } } }, "localname": "RedeemableAPreferredStockMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "grst_RedeemableBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable B Preferred Stock [Member]" } } }, "localname": "RedeemableBPreferredStockMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "grst_RelatedPartiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related parties" } } }, "localname": "RelatedPartiesPolicyTextBlock", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "grst_RelatedPartyPayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Related party payables" } } }, "localname": "RelatedPartyPayables", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "grst_RentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Rent expense" } } }, "localname": "RentExpense", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "grst_RentalOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rental Operations [Member]" } } }, "localname": "RentalOperationsMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "grst_RepaymentOfGovernmentAssistanceLoans": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Repayment of government assistance loans" } } }, "localname": "RepaymentOfGovernmentAssistanceLoans", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "grst_RepaymentOfRelatedPartyNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Repayment of related party notes" } } }, "localname": "RepaymentOfRelatedPartyNotes", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "grst_Revenues1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Revenue" } } }, "localname": "Revenues1", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "grst_RightofuseAssetsOperatingLeasesNetOfAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Right-of-use assets - operating leases, net of amortization" } } }, "localname": "RightofuseAssetsOperatingLeasesNetOfAmortization", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "grst_ScheduleoOfFinanceAndOperatingLeaseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of finance and operating lease" } } }, "localname": "ScheduleoOfFinanceAndOperatingLeaseTableTextBlock", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "grst_SegmentInformationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment information" } } }, "localname": "SegmentInformationTextBlock", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "grst_SegmentTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Taxes" } } }, "localname": "SegmentTax", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "grst_SeriesNConvertibleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series N Convertible [Member]" } } }, "localname": "SeriesNConvertibleMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "grst_SeriesNConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series N Convertible Notes [Member]" } } }, "localname": "SeriesNConvertibleNotesMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "grst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/StockholdersDeficitDetails1" ], "xbrltype": "durationItemType" }, "grst_ShorttermConvertible": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "short-term convertible" } } }, "localname": "ShorttermConvertible", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "grst_StockholdersDeficitAttributableToEthemaHealthCorporationStockholders": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit attributable to Ethema Health Corporation stockholders\u2019" } } }, "localname": "StockholdersDeficitAttributableToEthemaHealthCorporationStockholders", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "grst_ThirdPartyLoans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Third party loans" } } }, "localname": "ThirdPartyLoans", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "grst_ThirdPartyTransactionsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Third Party loans" } } }, "localname": "ThirdPartyTransactionsDisclosureTextBlock", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/ThirdPartyLoans" ], "xbrltype": "textBlockItemType" }, "grst_TotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total [Member]" } } }, "localname": "TotalMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "grst_TotalUndiscountedMinimumFutureLeasePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "TotalUndiscountedMinimumFutureLeasePayment", "verboseLabel": "" } } }, "localname": "TotalUndiscountedMinimumFutureLeasePayment", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetails3" ], "xbrltype": "monetaryItemType" }, "grst_TotalUndiscountedMinimumFutureLeasePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total undiscounted minimum future lease payments" } } }, "localname": "TotalUndiscountedMinimumFutureLeasePayments", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetails4" ], "xbrltype": "monetaryItemType" }, "grst_WarrantsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercisable" } } }, "localname": "WarrantsExercisable", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/StockholdersDeficitDetails1" ], "xbrltype": "sharesItemType" }, "grst_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "grst_WarrantsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:WarrantsOutstanding]" } } }, "localname": "WarrantsOutstanding", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/StockholdersDeficitDetails1" ], "xbrltype": "sharesItemType" }, "grst_WeightedAverageCommonSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding \u2013 Basic and diluted" } } }, "localname": "WeightedAverageCommonSharesOutstandingBasicAndDiluted", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "sharesItemType" }, "grst_WeightedAverageLeaseTermFinanceLeasesTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:WeightedAverageLeaseTermFinanceLeasesTerm]" } } }, "localname": "WeightedAverageLeaseTermFinanceLeasesTerm", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetails2" ], "xbrltype": "stringItemType" }, "grst_WeightedAverageRemainingLeaseTermOperatingLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:WeightedAverageRemainingLeaseTermOperatingLeases]" } } }, "localname": "WeightedAverageRemainingLeaseTermOperatingLeases", "nsuri": "http://grst/20230331", "presentation": [ "http://grst/role/LeasesDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive (loss) income" } } }, "localname": "AOCIIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndNotesReceivableNet": { "auth_ref": [ "r239", "r384" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable.", "label": "Receivables" } } }, "localname": "AccountsAndNotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r239", "r240" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r7", "r116", "r128" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r74", "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r31", "r32", "r152", "r385", "r392", "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r29", "r32", "r99", "r367", "r388", "r389", "r436", "r437", "r438", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r14", "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r322", "r323", "r324", "r447", "r448", "r449", "r466" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustment to reconcile consolidated net loss to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForNotesAndLoansReceivableCurrent": { "auth_ref": [ "r153", "r241", "r244" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on financing receivable, classified as current.", "label": "Receivables funding" } } }, "localname": "AllowanceForNotesAndLoansReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r40", "r50", "r110", "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r296", "r354", "r410", "r411", "r443" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "verboseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r50", "r67", "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/IntangiblesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r114", "r127", "r148", "r176", "r223", "r228", "r234", "r242", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r337", "r339", "r344", "r413", "r459", "r460", "r472" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r142", "r156", "r176", "r242", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r337", "r339", "r344", "r413", "r459", "r460", "r472" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets", "verboseLabel": "Current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r176", "r242", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r337", "r339", "r344", "r459", "r460", "r472" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets", "verboseLabel": "Non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r52", "r144", "r399" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r46", "r52", "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Ending cash balance", "periodStartLabel": "Beginning cash balance" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r46", "r108" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r149", "r150", "r151", "r176", "r194", "r195", "r198", "r199", "r205", "r206", "r242", "r265", "r267", "r268", "r269", "r272", "r273", "r300", "r301", "r303", "r307", "r313", "r344", "r398", "r434", "r444", "r450" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Weighted average exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r77", "r263", "r264", "r394", "r458" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDiscountOnShares": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.", "label": "Common Stock, Discount on Shares", "negatedLabel": "Discount for shares issued below par value" } } }, "localname": "CommonStockDiscountOnShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r447", "r448", "r466" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13", "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock - $0.01\u00a0par value,\u00a010,000,000,000\u00a0shares authorized;\u00a0 3,729,053,805\u00a0shares issued and outstanding as of March 31, 2023 and December 31, 2022." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r33", "r158", "r160", "r167", "r381", "r386" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r6" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible notes, net of discounts" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "verboseLabel": "Operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r79", "r174", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r290", "r297", "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Short-term Convertible Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/Short-termConvertibleNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r6", "r7", "r8", "r115", "r118", "r126", "r179", "r274", "r275", "r276", "r277", "r278", "r280", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r355", "r407", "r408", "r409", "r410", "r411", "r445" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/MortgageLoansDetails", "http://grst/role/Short-termConvertibleNotesDetails", "http://grst/role/StockholdersDeficitDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r445" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/MortgageLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r24", "r275" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/MortgageLoansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r25", "r179", "r274", "r275", "r276", "r277", "r278", "r280", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r355", "r407", "r408", "r409", "r410", "r411", "r445" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/MortgageLoansDetails", "http://grst/role/Short-termConvertibleNotesDetails", "http://grst/role/StockholdersDeficitDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r10", "r11", "r117", "r124", "r330" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred taxation" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther": { "auth_ref": [ "r474", "r476" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred policy acquisition cost due to the effect of foreign currency translation gain (loss) and increase (decrease) classified as other.", "label": "Deferred Policy Acquisition Cost, Foreign Currency Translation Adjustment and Other", "negatedLabel": "Foreign currency translation adjustment" } } }, "localname": "DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositContractsAssets": { "auth_ref": [ "r247", "r248" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.", "label": "Deposits paid" } } }, "localname": "DepositContractsAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r50", "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r50", "r72" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r50", "r218" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r465" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedLabel": "Derivative liability movement" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r101", "r102", "r103", "r104", "r105", "r178" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued dividends" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r83", "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock", "negatedLabel": "Preferred stock dividend" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r57", "r58" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net income (loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r200", "r201", "r202", "r203" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Net income (loss) per common share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/NetIncomeLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r345" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r81", "r139", "r162", "r163", "r164", "r180", "r181", "r182", "r184", "r189", "r191", "r204", "r243", "r315", "r322", "r323", "r324", "r333", "r334", "r342", "r346", "r347", "r348", "r349", "r350", "r351", "r367", "r388", "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FDICIndemnificationAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of receivable assets originating from the indemnification agreement with the Federal Deposit Insurance Corporation (FDIC), in which the FDIC is to partially cover losses.", "label": "Federal Deposit Insurance" } } }, "localname": "FDICIndemnificationAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r106", "r107" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Financial instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r357", "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Lease liability" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r357" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance lease liability", "verboseLabel": "Current portion" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/LeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Schedule of Finance lease liability" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r357" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Non-Current portion", "verboseLabel": "Finance lease liability" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/LeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Remainder of 2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2027" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r359", "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r358", "r361", "r412" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r147", "r258" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Finite-Lived Intangible Assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/IntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r70", "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/IntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r70", "r379" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, net", "verboseLabel": "Finite-Lived Intangible Assets, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/IntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Principals of consolidation and foreign currency translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r38" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r177", "r190", "r191", "r221", "r327", "r335", "r336", "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Taxation" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r161", "r325", "r326", "r328", "r329", "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r47", "r54" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r49" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r49" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": { "auth_ref": [ "r442" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.", "label": "Increase (Decrease) in Accrued Taxes Payable", "verboseLabel": "Taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities": { "auth_ref": [ "r442" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the net carrying value of derivative instruments reported as assets and liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).", "label": "Derivative liability movement" } } }, "localname": "IncreaseDecreaseInDerivativeAssetsAndLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r442", "r469" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r442" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "verboseLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r49" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "verboseLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangibles" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/Intangibles" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r69", "r375", "r376", "r377", "r379", "r401" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestCostsCapitalized": { "auth_ref": [ "r109" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest capitalized during the period.", "label": "Interest" } } }, "localname": "InterestCostsCapitalized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r111", "r122", "r165", "r217", "r353" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r41", "r295", "r410", "r411" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r169", "r171", "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r364", "r412" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of Operating lease liability" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Total operating lease liability" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "verboseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r21", "r176", "r242", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r338", "r339", "r340", "r344", "r404", "r459", "r472", "r473" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r120", "r133", "r413", "r446", "r455", "r467" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Total liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r23", "r143", "r176", "r242", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r338", "r339", "r340", "r344", "r413", "r459", "r472", "r473" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r2", "r3", "r4", "r8", "r9", "r176", "r242", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r338", "r339", "r340", "r344", "r459", "r472", "r473" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansFromOtherFederalHomeLoanBanks": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Federal Home Loan Bank (FHLBank) loans from another FHLBank.", "label": "Government assistance loans" } } }, "localname": "LoansFromOtherFederalHomeLoanBanks", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r8", "r118", "r125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loans Payable" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/MortgageLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/MortgageLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentTerms": { "auth_ref": [ "r78", "r82" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of timing of required repayments, sinking fund requirements, and other redeemable securities at fixed or determinable prices and dates in the five years immediately following the date of the latest balance sheet presented in the financial statements, and the amount thereafter to fully repay the principal of long-term debt. These disclosures may be made either on an individual debt or security basis, by type of debt or security basis, or on a combined basis.", "label": "Maturity Date" } } }, "localname": "LongTermDebtMaturitiesRepaymentTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ManagementFeeExpense": { "auth_ref": [ "r112" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).", "label": "Management fees" } } }, "localname": "ManagementFeeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r28", "r119", "r132", "r176", "r242", "r265", "r267", "r268", "r269", "r272", "r273", "r344" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r207", "r212" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/NatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r170" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r170" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r46", "r48", "r51" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r35", "r51", "r121", "r135", "r141", "r157", "r159", "r164", "r176", "r183", "r185", "r186", "r187", "r188", "r190", "r191", "r196", "r223", "r227", "r233", "r235", "r242", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r343", "r344", "r405", "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "verboseLabel": "Consolidated net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows", "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r97", "r100", "r157", "r159", "r190", "r191", "r438" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net income attributable to non-controlling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r185", "r186", "r187", "r188", "r192", "r193", "r197", "r199", "r223", "r227", "r233", "r235", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net loss available to common shareholders of Ethema Health Corporation" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r94", "r315", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r32", "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "Net loss before taxes" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r223", "r227", "r233", "r235", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income", "verboseLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss", "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r362", "r412" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r357" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r357" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liability", "verboseLabel": "Current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/LeasesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r357" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-Current portion", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/LeasesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r356" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r443" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAmortizationOfDeferredCharges": { "auth_ref": [ "r37", "r50" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization of other deferred costs recognized in the income statement.", "label": "Amortization of Other Deferred Charges", "verboseLabel": "Amortization of debt discount" } } }, "localname": "OtherAmortizationOfDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r155", "r413" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r95", "r96", "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.", "label": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r32", "r163", "r346", "r348", "r351", "r436" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Loss before taxation" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r95", "r96", "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to noncontrolling interest.", "label": "Net loss attributable to Ethema Health Corporation Stockholders\u2019" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "negatedLabel": "Non-current liabilities", "verboseLabel": "Non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "verboseLabel": "Other (expense) income" } } }, "localname": "OtherNoncashIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss", "http://grst/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForDeposits": { "auth_ref": [ "r440", "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for deposits on goods and services during the period; excludes time deposits and deposits with other institutions, which pertain to financial service entities.", "label": "Payments for Deposits", "negatedLabel": "Deposits paid" } } }, "localname": "PaymentsForDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r168", "r462", "r463", "r464" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12", "r300" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12", "r300" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12", "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock - Series A; $0.01\u00a0par value,\u00a010,000,000 shares\u00a0authorized; 4,000,000 shares outstanding as of March 31, 2023 and December 31, 2022." } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r154", "r245", "r246", "r400" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrincipalAmountOutstandingOnLoansSecuritized": { "auth_ref": [ "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This is the principal amount outstanding for securitized loans only (across all types of loans).", "label": "Principal Amount Outstanding on Loans Securitized or Asset-Backed Financing Arrangement" } } }, "localname": "PrincipalAmountOutstandingOnLoansSecuritized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/MortgageLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from receivables funding" } } }, "localname": "ProceedsFromCollectionOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from related party notes" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromUnsecuredNotesPayable": { "auth_ref": [ "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is uncollateralized (where debt is not backed by the pledge of collateral).", "label": "Proceeds from promissory notes" } } }, "localname": "ProceedsFromUnsecuredNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r136", "r137" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r435", "r456", "r468" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Right-of-use assets \u2013 finance leases, net of depreciation, included in Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r76", "r395", "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r73", "r145" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r75", "r134", "r383", "r413" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment", "verboseLabel": "Property, Plant and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r75", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of sale of property" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.", "label": "Purchase Obligation, to be Paid, Remainder of Fiscal Year", "verboseLabel": "Remainder of 2023" } } }, "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r451", "r452", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Accounts receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RedeemablePreferredStockMember": { "auth_ref": [ "r1", "r80", "r176", "r242", "r265", "r267", "r268", "r269", "r272", "r273", "r344" ], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable preferred stock. For instance, cumulative preferred stock, noncumulative preferred stock, convertible or series.", "label": "Redeemable Preferred Stock [Member]" } } }, "localname": "RedeemablePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r368", "r369", "r370", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related party transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfAccountsReceivableSecuritization": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments of securitizations of receivables treated as collateralized borrowings, which are classified as financing transactions.", "label": "Repayments of Accounts Receivable Securitization", "negatedLabel": "Repayment of receivables funding" } } }, "localname": "RepaymentsOfAccountsReceivableSecuritization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt", "negatedLabel": "Repayment of convertible notes" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfFirstMortgageBond": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument issued, secured by a first mortgage deed of trust, containing a pledge of real property. The lender has the highest claim on the property in case of default.", "label": "Repayments of First Mortgage Bond", "negatedLabel": "Repayment of mortgage" } } }, "localname": "RepaymentsOfFirstMortgageBond", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.", "label": "Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security", "negatedLabel": "Repayment of finance leases" } } }, "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfOtherDebt": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other.", "label": "Repayments of Other Debt", "negatedLabel": "Repayment of third party loans" } } }, "localname": "RepaymentsOfOtherDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r83", "r131", "r391", "r393", "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r139", "r180", "r181", "r182", "r184", "r189", "r191", "r243", "r322", "r323", "r324", "r333", "r334", "r342", "r388", "r390" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r166", "r176", "r214", "r215", "r226", "r231", "r232", "r236", "r237", "r238", "r242", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r344", "r382", "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "verboseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss", "http://grst/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r439" ], "calculation": { "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salaries and wages" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of mortgage loans" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/MortgageLoansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/NetIncomeLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r68", "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/IntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock": { "auth_ref": [ "r138", "r457", "r471" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.", "label": "Schedule of Right of use assets" } } }, "localname": "ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r62", "r63", "r64", "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of segment information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of assumption" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/MortgageLoansDetails", "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of short-term convertible notes" } } }, "localname": "ScheduleOfShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/Short-termConvertibleNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r85", "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of warrants outstanding" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r8", "r118", "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Mortgage loans" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r238", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r261", "r262", "r406", "r475" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance", "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance", "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r86", "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Stock based compensation" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Shares, Outstanding, Ending Balance", "periodStartLabel": "Shares, Outstanding, Beginning Balance" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r5", "r115", "r129", "r413" ], "calculation": { "http://grst/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term notes" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtInterestRateIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument.", "label": "Short-Term Debt, Interest Rate Increase" } } }, "localname": "ShortTermDebtInterestRateIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/MortgageLoansDetails", "http://grst/role/Short-termConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for short-term debt.", "label": "Short-term Notes" } } }, "localname": "ShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/Short-termNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r56", "r173" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r140", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r238", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r260", "r261", "r262", "r406", "r475" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r149", "r150", "r151", "r176", "r194", "r195", "r198", "r199", "r205", "r206", "r242", "r265", "r267", "r268", "r269", "r272", "r273", "r300", "r301", "r303", "r307", "r313", "r344", "r398", "r434", "r444", "r450" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r27", "r81", "r139", "r162", "r163", "r164", "r180", "r181", "r182", "r184", "r189", "r191", "r204", "r243", "r315", "r322", "r323", "r324", "r333", "r334", "r342", "r346", "r347", "r348", "r349", "r350", "r351", "r367", "r388", "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit", "http://grst/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r180", "r181", "r182", "r204", "r378" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit", "http://grst/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r12", "r13", "r81", "r82", "r83" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Shares, Conversion of Units" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r12", "r13", "r81", "r83", "r319" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r27", "r81", "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Conversion of convertible notes" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan": { "auth_ref": [ "r81" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the holder of the stock to reinvest dividends paid to them by the entity on new issues of stock by the entity.", "label": "Stock Issued During Period, Value, Dividend Reinvestment Plan", "negatedLabel": "Dividends accrued" } } }, "localname": "StockIssuedDuringPeriodValueDividendReinvestmentPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r16", "r17", "r65", "r413", "r446", "r455", "r467" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Total stockholders\u2019 deficit", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedBalanceSheets", "http://grst/role/CondensedConsolidatedStatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r86", "r175", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r315", "r341" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholder\u2019s deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r59", "r60", "r61", "r208", "r209", "r210", "r211" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://grst/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=99383045&loc=d3e9351-108337", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=99397363&loc=d3e9420-108338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r414": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r415": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r416": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r417": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r418": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r419": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r421": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r422": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r423": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r424": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r425": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r426": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r427": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r428": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r429": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r431": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r432": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r433": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919398-209981", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-07)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187103-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 66 0001903596-23-000455-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001903596-23-000455-xbrl.zip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�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